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During B cell maturation within the germinal centers of lymph nodes, genetical alterations,
such as chromosomal translocations and mutations are introduced into the genome in order
to increase the B cell receptor (BCR) specificity. Errors occurring during these processes,
namely class switch recombination and somatic hypermutation, can affect the expression of
tumor suppressors and proto-oncogenes, resulting in lymphomagenesis. Two major subtypes
of germinal center derived aggressive Non-Hodgkin B cell lymphoma are Burkitt lymphoma
(BL) and Diffuse Large B Cell Lymphoma (DLBCL). The MIR23A cluster, coding for miR-23a,
miR-27a and miR-24-2 is induced during normal germinal center reaction. While the MIR23A
cluster expression is low in germinal center B cells, it is upregulated in mature memory B cells.
However, BL and DLBCL tumors have aberrantly high MIR23A expression levels compared
to healthy controls, indicating that the cluster is de-regulated during lymphomagenesis. This
study identified the BCR signaling, which plays a key role during germinal center reaction, as
a general mechanism responsible for the induction of the MIR23A cluster in BL and DLBCL
cell lines. MEK/ERK signaling was shown to be the major signaling cascade mediating this
effect. Downstream transcription factors ELK1 and c-MYC are not involved in activation of the
MIR23A cluster in DLBCL. Since the MIR23A cluster could not be induced by BCR signaling
in normal germinal center B cells, this study hypothesizes that aberrant BCR signaling in BL
and DLBCL is responsible for the increased MIR23A cluster levels. The MIR23A cluster is
involved in many different solid cancers as well as leukemia and lymphoma. Its cellular func-
tion is discussed controversially among the different cancer entities, indicating that it is cell
type and context specific. One study reported that DLBCL patients with high miR-23a levels
show worse overall survival rates, suggesting an onco-miR function for the MIR23A cluster
in DLBCL. However, the processes that are regulated by the MIR23A cluster in DLBCL re-
main unknown. In order to elucidate the biological function of the MIR23A cluster in the B cell
lymphoma context, the targetomes of miR-23a and miR-27a were identified via Ago2-RNA
immunoprecipitation in a DLBCL cell line stably overexpressing miR-23a, miR-27a or a non
silencing control. By this approach 46 novel direct miR-23a and miR-27a targets in DLBCL
were identified. LIMK1 and PUMA were validated as miR-27a targets on protein level. Fur-
thermore, functional analyses demonstrated that miR-23a and miR-27a attenuate the ability of
DLBCL cells to undergo apoptosis in response to DNA damage. This might be one plausible
explanation why DLBCL patients with high miR-23a expression levels have a worse overall




A eukaryotic cell encountersmany intra- and extracellular signals. These signals are integrated
by sophisticated signaling cascades, resulting in activation or inhibition of genes directing the
cell to grow, divide, rest or even to die. Normally, these processes are tightly controlled. If
errors occur, the cell either undergoes apoptosis or it is eliminated by the immune system.
However, in some cases mutations can lead to de-regulation of tumor suppressors or proto-
oncogenes, leading to uncontrolled growth and proliferation (Hanahan and Weinberg, 2011).
The resulting tumor mass is termed neoplasm. If the cells have the ability to invade the sur-
rounding tissue or to spread into other tissues it is considered as malignant, otherwise it is said
to be benign. A malignant neoplasm is also referred to as cancer. Cancer can affect any part of
the body and is classified by its origin. Carcinomas arise from epithelial cells, sarcomas from
connective tissue or muscle cells and leukemia and lymphoma from the hematopoietic sys-
tem. While leukemias develop from the bone marrow and spread into the blood, lymphomas
develop from the lymphatic system forming solid tumors in the lymph nodes, bone marrow,
spleen and other non-lymphatic organs. According to the classification of the WHO to date
101 subtypes of leukemias and lymphomas exist (Swerdlow et al., 2016). The classification
is based on morphology, immunology, genetic aberrations and clinical aspects. The two main
subgroups of lymphoma are Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL). HL
show big multi-nucleated Reed-Sternberg cells (Sternberg, 1897; Reed, 1902), which are lack-
ing in NHL. NHL can further be divided in B cell or T cell derived and aggressive or indolent
NHL (Armitage et al., 2009). This study focuses on the aggressive B cell NHL (B-NHL) sub-
type, which constitutes the biggest group of NHL with about 90% of NHL cases (Armitage
et al., 2009). In developed countries aggressive NHL is one of the tenth most frequent cancer
diagnosed (Torre et al., 2015). Due to improved living circumstances and prolonged life ex-
pectancies, cancer is one of the leading cause of death worldwide (Ferlay et al., 2013).
Although much progress has been made in the last decades of cancer research leading to a
better understanding of the underlying mechanisms of malignant transformation, more effort
must be put into the molecular characterization of each individual cancer entity in order to
develop specific and effective treatments.
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1.1. B cell development, maturation and malignant transformation
B lymphocytes (B cells) are part of the adaptive immune system and are essential for the
humoral immune response against foreign antigens. They generate high affinity antibodies
that are secreted to effectively inactivate the specific antigen. Antibodies are composed of four
immunoglobulins (Ig): two identical heavy chain immunoglobulins (IgH) and two identical light
chain immunoglobulins (IgL) linked by disulfide bonds. Each of these polypeptides consists of a
carboxyterminal constant region (C) and an aminoterminal variable (V) region. Each mature B
cell expresses a membrane bound antibody on its surface that is associated with cofactors (Igα
and Igβ). Together they form the B cell receptor (BCR). This receptor gains its high specificity
during B cell maturation where complex genomic modifications to the immunoglobulin genes
are introduced.
Early development of B cells is initiated in the fetal liver and subsequently relocated into
the bone marrow of the mammalian embryo (reviewed in (Melchers, 2015)). A multipotent
hematopoietic stem cell in the bone marrow gives rise to a lymphoid progenitor, which devel-
ops into a precursor B cell that subsequently undergoes complex rearrangements of the im-
munoglobulin heavy and light chain variable region genes (reviewed in (Seifert et al., 2013)).
This process is called V(D)J recombination, because the variable region of the heavy and light
chain immunoglobulin gene is encoded on different gene segments: variable (V), diversity (D)
and joining (J) segments. From each of these segments one is randomly selected and step
wise joined together with the other segments. This process leads to a high variability in newly
formed immunoglobulins. Cells that express a functional, but non-autoreactive B-cell receptor
survive the selection process and are released as naive B cells into the blood.
Upon encountering of a T cell dependent antigen these cells are activated, migrate into sec-
ondary lymphatic organs like the lymph nodes, tonsils, spleen, mucosa associated lymphoid
tissue (MALT) or Peyer’s patches, where they maturate their B-cell receptor, undergo clonal
expansion and further differentiate into antibody secreting plasma cells or long lived memory
cells (reviewed in (De Silva and Klein, 2015)).
One site of B cell maturation are the lymph nodes. They are characterized by follicles that
are build up from naive B cells which are separated from each other by an interfollicular re-
gion that is surrounded by a T cell zone. Within the follicular centers a network of follicular
dendritic cells (FDC) can be found. When a naive B cell encounters an antigen, it migrates to
the border of T cell and B cell zone and forms long-lived interactions with antigen-specific T
cells leading to full activation of the B cell. A subset of these B cells differentiate into short-
lived plasmablasts, which secrete low affinity antibodies. Another subset of these cells enter
the germinal center (GC) pathway, where the BCR is further refined. Activated T and B cells
migrate to the follicular center and interact with the dendritic cells. The T cells become T follic-
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ular helper cells (TFH ) thus they upregulate B cell lymphoma 6 (BCL6), the master regulator of
TFH and GC B cell development (Baumjohann et al., 2011). The B cells start to divide rapidly
and to populate the follicle displacing the naive B cells, which thereby form a so called “mantle
zone” around the newly formed germinal center. Within the germinal center two different zones
develop: a densely packed “dark zone” containing proliferating B cells (centroblasts) and retic-
ular cells and a “light zone” containing non-proliferating B cells (centrocytes), TFH cells, FDCs
and macrophages. The centroblasts in the dark zone undergo somatic hypermutation (SHM),
a process that further diversifies the rearranged IgV genes. SHM results in different B cell
clones with a broad range of affinities against the antigen. The clones expressing a high-
affinity antigen receptor are positively selected within the light zone. Effective antigen binding
leads to enriched antigen capture followed by strong BCR signaling (see section 1.2.1) and
longer interactions with FDCs and TFH cells (fig. 1.1). The bystander cells (FDCs and TFH
cells) provide CD40L and secrete interleukine-4 and -21 (IL-4 and Il-21) (Liu et al., 2015; Shul-
man et al., 2014). In sum, these stimulations provide a survival signal, promoting positive
selection. Cells expressing an auto-reactive or defective BCR undergo apoptosis. Induction
of MYC expression during the selection process induces recircularization of the positive se-
lected cells between dark and light zone resulting in further refinement of the antigen specificity
(Dominguez-Sola et al., 2012). CD40 stimulation leads to nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) mediated upregulation of Interferon Regulatory Factor
4 (IRF4) expression (Saito et al., 2007), which represses BCL6 thereby terminating the dark
zone program. Within the light zone the cells undergo class switch recombination (CSR) or
finally differentiate into plasmablasts or memory cells and leave the germinal center (reviewed
in (De Silva and Klein, 2015)). CSR is a process were the isotype of the immunoglobulin is
switched (from IgM or IgD) by a new combination of the variable hypermutated VDJ gene ele-
ments with genes encoding for a different heavy chain (IgA, IgE or IgG), rendering their effector
function.
Notably, most aggressive B cell lymphoma resemble germinal center B cells expressing mark-
ers that reflect their origin. The cells seem to be frozen at a particular differentiation step during
germinal center reaction (reviewed in (Küppers, 2005)). Notably, some GC derived lymphoma
still undergo SHM. Indeed, aberrant SHM and CSR can promote lymphomagensis (Lenz et al.,
2007; Pasqualucci et al., 2008). If errors occur during CSR, free DNA ends are produced that
can cause chromosomal translocations, a genetic hallmark of lymphoma. The translocations
of proto-oncogeneMYC and BCL6 to immunoglobulin promoters are characteristic for aggres-
sive B cell lymphoma. Moreover, constitutive expression of BCL6 maintains a pro-proliferative
and DNA-damage tolerant phenotype leading to additional mutations which might further pro-
mote lymphomagensis (Cattoretti et al., 2005). Enhanced expression of MYC results from the
translocation into the immunoglobulin heavy chain or light chain loci and is characteristic for
Burkitt lymphoma (BL) cells (section 1.3). Aberrant SHM acting in the 5´ regulatory or coding
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Figure 1.1.: Germinal center reaction
During germinal center reaction activated B cells generate due to genomic modification of the immunoglobulin
genes high affinity antibodies and differentiate into antibody secreting plasmablasts or memory cells. Upon antigen
binding, activated B cells differentiate into centroblasts that undergo clonal expansion and somatic hypermutation
(SHM). SHM introduces point mutations into the V(D)J region of already rearranged immunoglobulin variable region
(IgV) genes (red dots). These cells move into the light zone, were T follicular helper cells (TFH cells) and follicular
dendritic cells (FDCs) help to elect these cells, that generated an B cell receptor (BCR) with improved binding
specificity. Higher affinity leads to increased antigen capture and promotes TFH cell binding and CD40L signaling
resulting in a survival signal. Cells with low binding capacity to the antigen undergo apoptosis. A subset of positive
selected B cells recirculates into the dark zone to further refine the BCR, whereas another subgroup undergoes
class switch recombination (CSR). CD40L = CD40 ligand, TCR = T cell receptor, MHC = major histocompatibility
complex, BL = Burkitt Lymphoma, FL = Follicular Lymphoma, DLBCL = Diffuse Large B cell Lymphoma. (modified
from de Silva and Klein, 2015)
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regions of proto-oncogenes or tumor suppressors may cause deregulation of those genes.
In fact, aberrant SHM mutates the negative regulatory region of BCL6 in Diffuse large B cell
lymphoma (DLBCL, see section 1.3) preventing BCL6 downregulation and termination of GC
reaction (reviewed in (Klein and Dalla-Favera, 2008)).
In general, lymphomagensis is considered to be a multistep process. The gene arrangements
performed during GC reaction are mutagenic processes that strongly increase the risk of ma-
lignant transformation, but tumor progression is also dependent on survival signals. These
signals are provided by the microenvironment and dependent on the expression of a func-
tional receptor (e.g. BCR and CD40 receptor (see sections 1.2.1 and 1.2.2)).
1.2. Signaling pathways involved in B cell activation
During B cell maturation autocrine signaling of the BCR is crucial for B cell survival, prolifera-
tion and differentiation. Only cells that express a functional BCR activate downstream signaling
cascades including PI3K (phosphoinositol 3-kinase), MAPK (mitogen-activated protein kinase)
and NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling, which in
sum provide a survival signal (see section 1.2.1). This signal is enforced by co-stimulatory
factors provided by the microenvironment within the GCs. FDCs and TFH cells present impor-
tant survival signals to the maturating B cell (reviewed in (De Silva and Klein, 2015)). In detail,
the antigen activated B cell presents peptides of this antigen by the major histocompatibility
complex II (MHCII) on its cell surface. This is recognized by the TFH cells, which express
membrane bound CD40L. This ligand activates the CD40 receptor of the B cell, resulting in
CD40 mediated NFκB signaling (Basso et al., 2004). Besides, FDCs express soluble sonic
hedgehog (Shh) providing an additional survival signal during GC reaction (Sacedon et al.,
2005). Moreover, it was shown that IL-21 and BAFF promote B cell survival by the activation
of JAK/STAT and NFκB signaling (Konforte et al., 2009; Khan, 2009).
In summary, the B cell activation is dependent on complex mechanisms including cell-cell in-
teractions, paracrine and autocrine signaling, which activates different signaling pathways that
subsequently activate gene expression resulting in the induction of proliferation and differenti-
ation of the GC B cell.
1.2.1. B cell receptor signaling
Each B cell expresses a unique membrane bound antibody, namely the B cell receptor (BCR).
The BCR is a multimeric complex, consisting of two identical heavy chain immunoglobulins
(IgH) and two identical light chain immunoglobulins (IgL) linked by disulfide bonds. Each of
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these polypeptides consist of a carboxyterminal constant region (C) and an aminoterminal
variable (V) region. The V region mediates the antigen binding whereas the C region anchors
the antibody within the membrane (Janeway et al., 2001). The antibody itself lacks signaling
capacity, thus the transmembrane proteins CD79A (Igα) and CD79B (Igβ) are intracellular, but
non-covalent associated to the C terminus of the immunoglobulin heavy chain (fig. 1.2). Both
CD79 chains contain an immunoreceptor tyrosine based activation motif (ITAM) in their intra-
cellular part, which are able to transduce signals intracellularly (reviewed in (Bojarczuk et al.,
2015)). Antigen binding induces BCR cross-linking followed by Sarcoma-family (SRC) kinase
LYN (Lck/Yes novel tyrosine kinase) recruitment and phosphorylation of the ITAM. Phospho-
rylated ITAM recruits spleen tyrosine kinase (SYK), which is subsequently phosphorylated
by LYN. Phosphorylated SYK further propagates the signal via B cell linker protein (BLNK)
to Burton’s tyrosine kinase (BTK) and phospholipase Cγ2 (PLCγ2). PLCγ2 hydrolyses PIP2
(phosphatidyl inositol-4,5-bisphosphate) to IP3 (inositol-1,4,5-trisphosphate) and DAG (diacyl-
glycerol). Increasing IP3 levels lead to the release of Ca2+ from the endoplasmatic reticulum
and consequently to the activation of calcineurin and the transcription factor NFAT (nuclear
factor of activated T cells). DAG activates protein kinase C (PKC), which in turn phosphory-
lates the multiprotein complex CBM (consisting of CARD11, BCL-10 and MALT1), that acti-
vates IκBα kinase complex (IKK) thereby initiating NFκB signaling. Another function of PLCγ2
is to activate mitogen-activated protein kinase (MAPK) pathway, including c-junNH2-terminal
kinase (JNK), extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 (Hashimoto et al.,
1998). Besides, LYN activated phosphorylation of co-receptor CD19 leads to activation of PI3K
(phosphoinositol 3-kinase) which in turn activates AKT signaling.
The BCR signaling activates many different signaling pathways, which also show “cross-talk”
with each other and also other signaling cascades (e.g. chemokine receptors) further increas-
ing complexity (Seda and Mraz, 2015). These signaling cascades activate many different
transcription factors, which regulate the expression of a set of GC-specific genes.
Beside the antigen induced activation of BCR signaling, a second form called “tonic” BCR sig-
naling exists. The tonic signaling is found in mature B cells and ensures antigen-independent
B cell survival.
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Figure 1.2.: Signaling cascades activated upon BCR activation
This figure depicts a simplified scheme of BCR downstream signaling cascades. The BCR consists of a pairs of
immunoglobulin heavy (IgH) and light (IgL) chains, whose variable region allows the BCR to bind an antigen. It is
intracellularly coupled to the heterodimer CD79A and CD79B, which mediates signal transduction. The immunore-
ceptor tyrosine based activation motif (ITAM) is phosphorylated upon antigen binding by the SRC-familiy kinase
LYN, which initiates the recruitment and activation of several signaling proteins that spread the signal on different
downstream signaling cascades as depicted in the scheme (for detailed description refer to the main text). Acti-
vation of these signaling cascades leads to activation of transcription factors (ERK, NFAT, NFκB, MYC etc.) that
activate genes responsible for survival of the cell. Ras = rat sarcoma, RAF = rapidly accelerated fibrosarcoma,
MEK = MAPK/ERK Kinase, ERK = extracellular signal regulated kinase, MYC = v-myc avian myelocytomatosis
viral oncogene homolog, BTK = Burton’s tyrosine kinase, PLCγ2 = phospholipase Cγ2, PI3K = phosphoinositol
3-kinase, PIP2 = phosphatidyl inositol-4,5-bisphosphate, IP3 = inositol-1,4,5-trisphosphate, DAG = diacylglycerol,
PKC = protein kinase C, NFAT = nuclear factor of activated T-cells, PKC = protein kinase C, CBM = CARD11-
BCL10-MALT1 signalosome, IKK = IκB kinase komplex, NFκB = nuclear factor kappa-light-chain-enhancer of acti-
vated B cells, AKT = protein kinase B, mTORC2 = mammalian target of Rapamycin complex 2, GSK3 = Glycogen
synthase kinase 3, FOXO = forkhead box. (figure taken from Bojarczuk et al., 2015)
It is not surprising that lymphoma take advantage of the BCR signaling, thus it provides survival
signals. In Burkitt lymphoma (section 1.3), which is characterized by MYC translocations, it
was shown that tonic BCR signaling via PI3K allows the cell to tolerate the otherwise lethal
ectopic MYC expression in absence of growth factors (Evan et al., 1992). 70% of BL harbor
transcription factor 3 (TCF3) mutations, that prevent the inhibition of TCF3 by ID3. Moreover
frequent ID3 mutations have been reported in BL (Richter et al., 2012; Schmitz et al., 2013).
Hyperactive TCF3 leads to decreased SHP1 activity, a negative regulator of PI3K dependent
BCR signaling, which results in enhanced BCR signaling.
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Another lymphoma subtype, namely activated B cell like (ABC) DLBCL (see section 1.3) shows
chronic active BCR signaling. Many ABC DLBCL patients carry Caspase recruitment domain-
containing protein 11 (CARD11) mutations affecting the coiled-coil domain, causing it to form
spontaneous aggregates that recruit all downstream signaling components of the NFκB path-
way (Lenz et al., 2008). Moreover, the ITAM of CD79 were reported to bemutated leading to an
exchange of the tyrosine residue to another amino acid (Davis et al., 2010). These mutations
prevent endocytosis of the BCR and blunt the activity of LYN, a SRC-family tyrosine kinase
that delivers negative feedback signals that attenuate BCR activity. Another mechanism for
chronic active BCR signaling is the reactivity against self antigen (Young et al., 2015). The
presence of BCR clusters on the cell surface of ABC DLBCL, which resemble the clusters that
are formed after antigen encountering, support this observation (Rui et al., 2011).
The high complexity of BCR signaling, which is misused by lymphoma to survive and pro-
liferate, provides many possibilities to interfere with, using targeted therapy. Indeed, many
inhibitors were developed to target BCR downstream kinases, such as BTK, SYK, SRC family
and PI3K, are already used in the clinics or in clinical trials (Young and Staudt, 2013; Gayko
et al., 2015).
1.2.2. CD40 signaling
Cluster of differentiation 40 (CD40) is a co-stimulatory receptor expressed on the surface of
many cells, including B cells. It belongs to the tumor necrosis factor receptor (TNFR) superfam-
ily and is activated by the soluble or membrane bound ligand CD40L. This ligand is regarded
as the classical co-stimulatory signal presented by T helper cells during GC formation (section
1.1) and promotes GC formation, immunoglobulin isotype switching, somatic hypermutation
and differentiation of GC B cells (reviewed in (Bojarczuk et al., 2015)). Ligand binding to CD40
leads to the activation of downstreamNFκB andMAPK signaling (reviewed in (Elgueta, 2009)).
In detail, binding of CD40L to CD40 promotes CD40 clustering and recruits TNFR-associated
factors (TRAFs) to the cytoplasmatic domain of CD40. In vivo studies in mice showed that
TRAF 1, 2, 3 and 5 are recruited to CD40 upon CD40L binding in B cells. TRAF1 activates
canonical NFκB signaling, while TRAF 5 activates both canonical and non-canonical NFκB
signaling (Xie et al., 2006; Hauer et al., 2005; Nakano et al., 1999) (section 1.2.3). TRAF2 has
multiple functions, hence it was shown to activate canonical NFκB signaling, while repressing
non-canonical NFκB signaling and furthermore activating MAPK (including JNK and p38) sig-
naling. In contrast, TRAF3 represents only a negative NFκB signaling regulator. In conclusion,
CD40 signaling activates primarily TRAFmediated NFκB signaling with an autoregulatory loop,
resulting in the expression of anti-apoptotic factors (BCL-XL, A20, survivin, Bfl-1, and c-FLIP).
Studies with B-NHL cells showed that cells expressing low levels of CD40L are protected from
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apoptosis (Pham et al., 2002), while transient in vitro and in vivo activation of CD40L in BL,
multiple myeloma and high-grade B cell lymphoma inhibited cell proliferation (Funakoshi et al.,
1994), indicating that quantitative levels might play a role in cell fate decision.
1.2.3. NFκB signaling
NFκB is a pleiotropic transcription factor involved in many biological processes such as in-
flammation, immunity, differentiation, proliferation, apoptosis and tumorigenesis (reviewed by
(Vallabhapurapu and Karin, 2009)). Five different NFκB family members exist: NF-κB1 (p50
and its precursor p105), NF-κB2 (p52 and its precursor p100), p65 (RelA), c-Rel and RelB.
These NFκB family members form homo- or heterodimers that bind to DNA to regulate spe-
cific target genes. In the inactive state their nuclear translocation sequence is shielded by
the inhibitors IκBα, IκBβ and IκBε. The release from the IκBs is controlled by IκB kinases
(IKKα/IKK1, IKKβ/IKK2 and IKKγ/NEMO). After activation by a given stimulus the IKKs phos-
phorylate IκB, leading to proteasomal degradation of IκB and the nuclear translocation of the
NFκB dimer.
Many different stimuli can activate NFκB signaling (cytokines, chemokines and adhesion mole-
cules) (Lawrence, 2009). Two NFκB signaling pathways are described: the canonical and the
non-canonical pathway. They differ in the mode of activation and utilization of NFκB mem-
bers. In the canonical pathway (e.g. activated by tumor necrosis factor (TNF) alpha) the NFκB
dimers p65/p50 and c-Rel/p50 are activated by the proteasomal degradation of IκBs which is
induced by phosphorylation from the trimeric IKK complex. The non-canonical pathway is acti-
vated by TNF family members, including CD40L (Berberich et al., 1994). Subsequently NFκB
inducing kinase (NIK) phosphorylates IKK which leads to partial proteasomal degradation of
p100 precursor into p52 and subsequent activation of RelB/p52 dimers.
Deregulated NFκB signaling was shown to play an important role in B-NHL, thus hyperacti-
vation of canonical NFκB signaling is characteristic for ABC DLBCL ((Davis et al., 2001), see
section 1.3).
1.2.4. MAPK/ERK signaling
The mitogen-activated protein kinase (MAPK) cascade is a central pathway that transmits sig-
nals from extracellular stimuli (growth factors, hormones, neurotransmitters and others) to reg-
ulate a broad variety of cellular processes, such as proliferation, differentiation, apoptosis and
stress response (Plotnikov et al., 2011). Each MAPK cascade consists of three main kinases:
MAP3K, MAP2K and MAPK, which subsequently phosphorylate each other in response to a
stimulus (reviewed in (Plotnikov et al., 2011)). Four different MAPK cascades were identified:
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extracellular signal-regulated kinase 1 and 2 (ERK1/2), c-Jun N-terminal kinase (JNK), p38 and
ERK5. Each of this MAPKs is activated by different MAP2Ks (Raman et al., 2007), leading
to distinct responses to a specific stimulus. In the context of B cell activation ERK1/2 cas-
cade plays a central role. Upon activation of the BCR (section 1.2.1), protein kinase C (PKC)
activates rapidly accelerated fibrosarcoma 1 (RAF1) signaling dependent phosphorylation of
ERK1/2 (Hashimoto et al., 1998). Activated RAF1 (the MAPK3) phosphorylates MEK1/2 (the
MAP2K), which in turn activates ERK1/2 (Ueda et al., 1996). ERK1/2 are Ser/Thr kinases that
phosphorylate a large number of downstream substrates of different cellular compartments
(Plotnikov et al., 2011). Among these substrates are many transcription factors, such as ELK1,
c-MYC, c-Fos and Ets domain factors, but also dual-specificity MAPK phosphatases (MKPs
or DUSPs) (Yoon and Seger, 2006). DUSPs are key negative regulators of MAPK signaling,
which inactivate the MAPKs but can furthermore mediate crosstalk between different MAPK
cascades (Kidger and Keyse, 2016). One of the first described ERK1/2 substrates was ETS
domain-containing protein ELK1, a transcription factor responsible for the activation of imme-
diate early genes (Gille et al., 1995). In detail, it was shown in fibroblasts that ELK1 forms a
ternary complex by p62TCF with serum response factor (SRF) thereby binding to serum re-
sponse element (SRE) of the c-Fos promoter, which facilitates c-Fos transcription. Induction
of c-Fos is important for cell proliferation and differentiation (Hisanaga et al., 1990; Shaulian
and Karin, 2001). Interestingly, ERK1/2 phosphorylation of ELK1 induces binding of c-Fos to
c-Jun, which together form the transcriptionally active AP-1 complex (Whitmarsh and Davis,
1996). AP-1 activity is required for cyclin D1 induction and cell cycle progression (Shaulian
and Karin, 2001).
The MAPK/ERK pathway is a key signaling system for the decision of cell fate. It is frequently
overactivated in human cancer due to genetic aberrations and is therefore considered to be
a driver for cancer development (reviewed in (Fey et al., 2016)). For aggressive lymphoma
it was reported that the ERK substrate ELK1 binds to LMO2, which is overexpressed in GC
derived B cell lymphoma (Cubedo et al., 2012).
1.3. B cell non Hodgkin Lymphoma (B-NHL)
According to the WHO in 2012 the incidence for NHL was estimated with 93.4 cases per
100,000 people and a mortality of 37.9 cases per 100,000 people in male and female (Ferlay
et al., 2013). More than 85% of newly diagnosed NHL cases are from B-cell origin and affect
men more frequently than women (Armitage et al., 2009). Aggressive B-NHL includes diffuse
large B-cell lymphoma (DLBCL), mantle-cell lymphoma (MCL), Burkitt lymphoma (BL) and fol-
licular lymphoma (FL) (Maxwell and Mousavi-Fard, 2013). The most common subtype with
approximately 40% of all NHL cases is DLBCL (Küppers, 2005).
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DLBCL mostly affects patients with an average age of mid-60. Symptoms can be swollen
lymph nodes, sweating at night, fever and dramatic weight loss (CancerresearchUK, 2016).
DLBCL is clinically, morphologically and genetically a heterogeneous disease. Morphologi-
cally it is characterized by nuclei that have double or more than double times the size of a
macrophage nucleus and a diffuse growth pattern (Paepe and Wolf-Peeters, 2007; Armitage
et al., 2009). According to their origin, DLBCL can be further be subdivided by gene expression
profiling on molecular level in germinal center B-like (GCB) and activated B-like (ABC) DLBCL
(Alizadeh et al., 2000). Each subtype is characterized by specific chromosomal translocations
and gene expression patterns.
A common feature of GCB DLBCL is the overexpression of BCL6, the master regulator and
transcriptional repressor during germinal center formation. BCL6 overexpression is caused
by translocations of BCL6 to heterologous promoters or point mutations in negative regulatory
elements of BCL6 promoter, which leads to the survival of DLBCL cells (Iqbal et al., 2007;
Ci et al., 2008). These cells constantly undergo somatic hypermutations thereby accumulat-
ing further mutations (Shaffer III et al., 2011). 20-30% of DLBCL harbor t(14;18) translocation
leading to the juxtaposion of BCL2 to immunoglobulin heavy chain gene (IGH) enhancer re-
sulting in BCL2 protein overexpression and inhibition of apoptosis (Lu et al., 2015). In 5-10%
of the cases translocations that juxtapose MYC with the IGH, κ, and λ genes (t(8;14), t(2;8)
and t(8;22)) lead to an upregulation of MYC (Li et al., 2012). MYC and BCL2 or BCL6 dou-
ble hit lymphoma show highly aggressive behavior leading to extremely poor outcome (Caimi
et al., 2016). Furthermore, the amplification of MIHG1 region, containing miR-17-92 cluster
was observed in approximately 12% of the cases (De Jong and Balagué Ponz, 2011).
The second molecular subtype, ABC DLBCL, is characterized by a constitutive active NFκB
signaling (Davis et al., 2001). Several pathway components leading to NFκB activation have
been shown to be mutated. Deletions and mutations in A20, a negative regulator, were found
in 20% of ABC DLBCL cases (Compagno et al., 2010). In 10% of ABC DLBCL cases mis-
sense mutations in the coiled-coiled domain of CARD11, which mediates oligomerization and
is crucial for NFκB activation, occur (Lenz et al., 2008). Moreover, somatic mutations in the
ITAM tyrosine kinase motifs of BCR signaling proteins CD79A and CD79B were demonstrated
to produce a sustained pseudo-BCR signal (Davis et al., 2010), which leads to chronic BCR
signaling that is important for ABC DLBCL cell survival (Davis et al., 2001). The large num-
ber of NFκB targets contribute to poor prognosis of ABC DLBCL patients by the prevention
of apoptosis, which reduces the sensitivity of the cells to chemotherapy (Baldwin, 2001). In
general, the prognosis for GCB DLBCL is better than for ABC DLBCL patients (Paepe and
Wolf-Peeters, 2007).
Usually, DLBCL arises de novo, but it can also develop from an indolent lymphoma, such
as follicular lymphoma (Martinez-Climent et al., 2003), chronic lymphocytic leukemia (Rossi
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and Gaidano, 2009), marginal zone lymphoma or nodular lymphocytic predominant Hodgkin
lymphoma (Fanale and Younes, 2008).
Nowadays the standard therapy for aggressive B-NHL, independent of the molecular sub-
type, is R-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone and the mon-
oclonal antibody rituximab), a combination of cytostatic and immunosuppressive drugs with
a chimeric human/murine immunoglobulin G1 monoclonal antibody that specifically binds to
CD20, a surface antigen expressed on each B cell (Feugier, 2005). Crosslinking of CD20 in-
duces complement-mediated cell lysis, antibody dependent cellular cytotoxicity and antibody
dependent apoptosis (Shan et al., 2000). Although the response rates, event free survival and
overall survival significantly improved compared to CHOP therapy alone, there are still patients
that do not respond to treatment or suffer from relapse (30-40%) or refractory disease (10%)
(Coiffier et al., 2002; Kahl, 2008; Cultrera and Dalia, 2012; Raut and Chakrabarti, 2014).
Another type of aggressive B-NHL is Burkitt lymphoma (BL). It was first described by De-
nis Burkitt in 1958 as the most prevalent African childhood lymphoma which localizes to the
mandible and other extranodal sites (Burkitt, 1958). This type of BL is the endemic form of BL
which can be found in Equatorial Africa and is in 98% of the cases associated with Epstein-
Barr virus (EBV) infections (McNally and Parker, 2006). In contrast, the sporadic form of BL
occurs worldwide and accounts for 2% of lymphoma in adults and up to 40% of lymphoma in
children in Western countries (Ferry, 2006). A third subtype of BL is associated with immunod-
eficiency and affects HIV carriers (Franceschi et al., 1999; Ferry, 2006) and patients that were
treated with immunosuppressiva (Gong et al., 2003). Characteristic for all three BL subtypes
is the translocation of proto-oncogene MYC into one of the three immunoglobulin gene loci
(Hummel et al., 2006). These translocations are considered to be the central event in Burkitt
lymphomagensis
(Dalla-Favera et al., 1982). BL develops within the germinal centers of the lymph node, hence
they display germinal center like features: expression of CD10 and BCL6, but no expres-
sion of BCL2 or CD5 (Stein and Hummel, 2007). The prognosis of BL is favorable with cure
rates > 90% in low stage BL and 70% in high stage BL, if treated intensively with multi-agent
chemotherapy for at least 48-72h in order to target all tumor cells passing through mitosis (De
Jong and Balagué Ponz, 2011).
According to their gene expression profile BL and GCB DLBCL are thought to derive from
centroblasts of the dark zone of the germinal center, while ABC DLBCL are thought to derive
from terminal determined centroblasts that differentiate into plasmablasts of the light zone
(Tamaru et al., 1995; Rosenwald et al., 2002; Pasqualucci and Dalla-Favera, 2014; Sehn and
Gascoyne, 2015).
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One major challenge in the clinics is to discriminate BL from DLBCL. Two studies aimed to
distinguish them on molecular level using gene expression profiles and cytogenetic analyses
(Hummel et al., 2006; Dave et al., 2006). Hummel and colleagues developed a molecular
classifier that reliably distinguishes BL from other mature aggressive B cell lymphoma. Cases
with an index score (I) greater than 0.95 were classified as molecular BL (mBL) and cases
with a score lower than 0.05 as non-molecular Burkitt lymphoma (non-mBL). Cases in be-
tween were designated as intermediate group, resembling mostly DLBCL cases. While this
study used predominantly genes that are NFκB target genes for discrimination, Dave and col-
leagues applied a gene set composed of MYC target genes, several germinal center B cell
and major-histocompatibility-complex (MHC) class I genes (Dave et al., 2006). Although, the
classification of aggressive B cell lymphomas can be achieved using different gene sets, not
every subtype can be identified by this approach alone. Characterization is crucial to identify
the best treatment strategy for the patients.
1.4. MicroRNAs
MicroRNAs (miRNAs or miRs) are small, single stranded and non-protein coding RNAs (ca.
21 nt) that mediate post-transcriptional gene silencing. The first miRNA lin-4 was identified
in Caenorhabditis elegans in 1993 and reported to have antisense complementarity to lin-14
messenger RNA (mRNA) (Lee et al., 1993). With the discovery of let-7 (Reinhart et al., 2000)
and its high conservation amongmany vertebrates, including humans (Pasquinelli et al., 2000),
the miRNA field rapidly expanded. Since then thousands of miRNAs have been identified in
various species (Kozomara and Griffiths-Jones, 2011). The expression of miRNAs is tissue
and cell type specific. About 60% of human protein coding genes are thought to be targeted by
miRNAs, thus harboring conserved miRNA binding sites in their mRNA sequences (Friedman
et al., 2009). One miRNA can target multiple mRNAs thereby regulating different cellular pro-
cesses. However, it was shown that one miRNA can inhibit multiple targets of gene networks
thereby applying additional levels of regulation (Na and Kim, 2013). Furthermore, they can
also act at different genes within a linear pathway resulting in a potentiation of the inhibitory
effect. Vice versa, one mRNA can be targeted by several different miRNAs, suggesting that
different miRNAs might act in concert to effectively downregulate their target. Furthermore,
miRNAs are frequently found in feedforward or feedback loops that mediate the amplification
or downregulation of the respective signal. Nowadays the mechanisms of miRNA biogenesis
is mostly understood, while the exact mode of action is still being debated on (reviewed in
(Filipowicz et al., 2008; Ameres and Zamore, 2013)). However, it is clear that miRNAs are
involved in the regulation of many important cellular processes. Therefore, deregulation may
lead to severe defects and result in diseases and cancer.
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1.4.1. MicroRNA biogenesis
In vertebrates, miRNAs are transcribed by RNA polymerase II (Lee et al., 2004) from miRNA
genes, introns of other host genes or intergenic regions (van Rooij, 2011; Cai et al., 2004)
(fig. 1.3). Approximately one third of miRNAs derive from transcripts that code for several
miRNAs and are termed miRNA clusters (Farazi et al., 2013). MiRNA biogenesis can be
exerted in canonical or non-canonical manner (reviewed in (Rottiers and Näär, 2012)). In the
canonical pathway miRNAs are first transcribed into the primary transcript (pri-miRNA), which
has a 5’ cap and a 3’ poly-A tail and forms one or more stem loop structures (Lee et al., 2004).
These stem loop structures are recognized by the microprocessor complex, which consists of
DGCR8 (DiGeorge syndrome chromosomal region 8) and Dicer. During transcription of the
primary transcript, DGCR8 binds to the double stranded part of the stem loop in the nascent pri-
miRNA (Morlando et al., 2008). Finally, DGCR8 assists Drosha to cleave the bound stem loop
approximately 11 nt distant from the ssRNA to dsRNA junction thereby producing a ~70 bp long
transcript called precursor miRNA (pre-miRNA) (Han et al., 2006). In non-canonical miRNA
pathway, miRNAs are either directly transcribed as short hairpin RNAs (shRNAs) or derive
from spliced introns, that re-fold into hairpins (mirtrons). In both pathways the newly generated
pre-miRNAs are transported by Exportin 5 into the cytoplasm (Bohnsack et al., 2004). There
Dicer and transactivation response RNA binding protein (TRBP) RNase III complex recognize
the pre-miRNA and cleave off the loop generating a ~21 bp long miRNA dublex composed of
sense and anti-sense (guide and passenger strand or miRNA and miRNA*) mature miRNAs
(Hutvágner et al., 2001). TRBP furthermore facilitates the loading of mature miRNA duplex
into the RISC complex, consisting mainly of argonaute (Ago), Dicer and TRBP (Chendrimada
et al., 2005). The strand with the weaker base pairing at the 5’ terminus of the miRNA duplex
binds to Ago, the effector protein of the RNA-induced silencing complex (RISC) (Khvorova
et al., 2003). In most cases, the anti-sense strand is degraded (Matranga et al., 2005). Four
different Ago proteins are expressed in humans: Ago1-4. Ago proteins harbor three domains:
the PAZ domain recognizes the two nucleotides that overhang at the 3’ end of the miRNA,
the Mid domain recognizes the cap structure of mRNAs and the PIWI domain has RNase-H-
like features (Hutvagner and Simard, 2008). Several studies report a high overlap of miRNAs
loaded into the different Ago isoforms (Burroughs et al., 2011; Siomi and Siomi, 2008; Hafner
et al., 2010). Indeed, it was reported that all Ago isoforms repress miRNA-mRNA duplexes
(Janas et al., 2012). However, only Ago2 protein has endonuclease/slicer activity, mediating
mRNA cleavage (Liu, 2004).
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Figure 1.3.: MiRNA biogenesis pathway
In the canonical pathway RNA polymerase II (Pol II) transcribes miRNAs either from intergenic, intronic or poly-
cistronic genomic loci. Drosha and DGCR8 recognize the stem loop sequence within the primary transcript (pri-
miRNA) and trim it to produce the precursor transcript (pre-miRNA). In the non-canonical pathway pre-miRNAs are
generated by splicing of introns (mirtrons) or are directly transcribed by short hairpins (shRNA). The pre-miRNA
from both pathways is exported into the cytoplasm by exportin 5, where DICER and transactivation-response RNA-
binding protein (TRBP8) cleave of the loop structure and produce a mature miRNA duplex. The guide strand of
this duplex is incorporated into the AGO-containing RNA-induced silencing complex (RISC), which then mediates
translational repression, mRNA degradation or sequestration. (figure taken from Rottiers et al. 2012)
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Each of these biogenesis steps can be modulated. Drosha dependent cleavage of pri-miRNA
to pre-miRNA can bemodified by accessory proteins like hnRNPA1, KKSHP and SMAD (Mich-
lewski and Cáceres, 2010; Davis et al., 2008). Additionally, Drosha processing of pri-miRNAs
can be prevented by RNA editing of adenine deaminases (ADARs), which change specific
adenins into inosines (Siomi and Siomi, 2010; Iizasa et al., 2010). Moreover, it was shown,
that hyper-edited double stranded miRNAs are degraded within the RISC complex (Scadden,
2005). Besides RNA modification, the major factors of the miRNA biogenesis machinery can
be regulated by post-transcriptional modifications, such as phosphorylation, hydroxylation or
ubiquitination leading to alterations in their localization, activity and stability (reviewed in (Kim
et al., 2010)).
1.4.2. Mechanism of translational inhibition by microRNAs
Once the mature miRNA is incorporated into the RISC (miRISC), the miRNA guides the protein
complex via its seed sequence to target mRNAs, leading to their translational inhibition or
degradation (reviewed in (Filipowicz et al., 2008)). In contrast to plants, where miRNAs are
often fully complementary to their target mRNAs and induce mRNA cleavage and degradation,
metazoan miRNAs bind only with partial complementarity and inhibit translation (Bartel, 2004).
In mammalia, the miRNA recognizes its target by perfect base pairing of nucleotide 2-8 at the 5’
end (Lewis et al., 2003). This sequence is called “seed” sequence. Besides the seed pairing,
supplementary pairing of the 3’ part of the miRNA is supportive but plays a minor role in target
recognition (Grimson et al., 2007; Brennecke et al., 2005). In principle miRNA binding sites can
be recognized all over a mRNA (Lytle et al., 2007), but effective translational repression was
shown for mRNAs that harbor conserved miRNA binding sites within their 3’UTR (Kuersten
and Goodwin, 2003).
While total complementarity of miRNAs to their target mRNAs (plant miRNAs or siRNAs) in-
duces mRNA cleavage, the exact mechanism by which miRNA interfere with the translation
machinery in mammalia is not well understood. However, it is known that Ago2 can compete
with translation initiation factor eIF4E for the m7G cap of the mRNA, disrupting translation initi-
ation and mRNA circularization (Filipowicz et al., 2008). Additionally, a drop-off model in which
miRNAs render ribosomes prone to premature termination is discussed (Petersen et al., 2006).
Furthermore, translation inhibition can be mediated by mRNA deadenylation (Fabian et al.,
2009; Braun et al., 2011) or sequestration in processing bodies (P-bodies) (Rottiers and Näär,
2012). P-bodies are cytoplasmatic foci, where enzymes that are involved in mRNA decay and
translational repression (incl. GW182, Ago proteins and miRNAs) accumulate (Kulkarni et al.,
2010). The translational repression of mRNAs and their localization to P-bodies are shown to
1.4. MICRORNAS 17
be transient, thus they can be reactivated followed by ribosome recruitment and subsequent
translation (Bhattacharyya et al., 2006).
1.4.3. MiRNAs in tumorigenesis
MiRNAs regulate virtual all cellular processes, including genes that are associated with tu-
morigenesis: cell cycle regulation, differentiation, apoptosis, stress response, inflammation,
migration and invasion. Therefore, dysfunctional expression of miRNA is considered as a
hallmark of cancer (Lawrie, 2013). Alterations of miRNA expression is often observed due
to genetical alterations, such as amplification, deletion or translocation of genes. Indeed, ap-
proximately 50% of annotated human miRNAs are located in fragile sites and associated with
cancer (Esquela-Kerscher and Slack, 2006). MiRNAs function as tumor-suppressor miRNAs,
when targeting an oncogene, or as onco-miRNAs, when targeting a tumor suppressor. Dele-
tion of a tumor suppressive miRNA as well as amplification of an oncogenic-miRNA (onco-miR)
can consequently lead to tumorigenesis.
Several miRNAs are deregulated in B cell lymphoma (e.g. miR-155, miR-17-92 cluster, miR-21,
miR-34a, miR-125B etc., reviewed in (Lawrie, 2013)). These miRNAs were shown to play
crucial roles during B cell development (reviewed in (de Yébenes et al., 2013)). One well de-
scribed example is miR-155, which is overexpressed in DLBCL (Kluiver et al., 2005). MiR-155
is considered as a key regulator in immune function under normal physiological conditions,
thus it can contribute to tumorigenesis in many different ways. MiR-155 negatively regulates
somatic hypermutation by targeting AID (Teng et al., 2008) and class switch recombination
by targeting PU.1 (purine-rich DNA sequence (PU-box) binding protein) (Vigorito et al., 2007).
Furthermore, it was reported that miR-155 targets SMAD5, preventing the growth inhibitory
effect of TGFβ1 and BMP2/4 (Rai et al., 2010). Overexpression of miR-155 inhibits INPP5D
which leads to TNFα dependent growth of DLBCL cells (Pedersen et al., 2009). While miR-155
seems to have onco-miR function in DLBCL, it is downregulated in BL, indicating that it might
have a tumor suppressor function in BL (Kluiver et al., 2005, 2006). Therefore, the function of
a miRNA seems to be dependent on the cellular context.
In summary, miRNA deregulation contributes to tumorigenesis by various means. However,
the fact that miRNA levels are altered within lymphoma subtypes, can be used as markers for
diagnosis (Lenze et al., 2011; Roehle et al., 2008). Furthermore, it was shown that miRNAs
can have prognostic value (Goswami et al., 2013) and can be used as therapeutic targets
(reviewed in (Oom et al., 2014)).
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1.5. The MIR23A cluster
ThemiR-23a~27a~24-2 cluster (MIR23A) is a polycistronic cluster coding formiR-23a, miR-27a
and miR-24 (fig. 1.4). It is encoded in an intergenic region on chromosome 19p13, which is
conserved among vertebrates and harbors its own promoter region. In fact, the MIR23A cluster
was one of the first miRNAs that were described to be transcribed by RNA polymerase II into
a ~2.2 kb long pri-miR-23a~27a~24-2 transcript (pri-miR-23a) (Lee et al., 2004). The MIR23a
cluster promoter lacks common promoter elements, such as the TATA box, initiator element,
downstream promoter element (DPE), TFIIB recognition element (BRE), downstream core el-
ement (DCE) and MED-1 (multiple start site element). Reporter gene assays showed that the
region from -806 to -603 bp has negative regulatory function, while the region between -603
to +36 bp has the strongest positive function of all tested promoter sequences and strongly
induces pri-miR-23a expression. The promoter region from -74 to -42 bp was absolutely nec-
essary for transcription (Lee et al., 2004).
Figure 1.4.: MIR23A cluster
The polycistronic MIR23A cluster is localized on the reverse strand of chromosome 19 and codes for the 2.2 kb
long primary transcript miR~23a~27a~24-2, which is processed into ~ 70 bp precursor transcripts pre-miR-23a,
pre-miR-27a and pre-miR-24-2 and subsequently into mature miR-23a, miR-27a and miR-24.
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Although all three miRNAs of this cluster are transcribed in one polycistronic transcript (pri-
miRNA), it was observed that the mature miR-23a and miR-27a expression is inconsistent in
leukemic cell lines, while miR-24 is not expressed (Yu et al., 2006), indicating that regulation
of the single miRNAs might be independent from each other, a well documented phenomenon
for miRNAs (Buck et al., 2010; Filipowicz et al., 2008).
Inmammals the paralogous clustermiR-23b~27b~24-1 (MIR23B), coding formiR-23b, miR-27b
and miR-24, exists in an intronic region of a zinc-dependent metallopeptidase on chromosome
9q22. The sequences of miR-23a and miR-23b, miR-27a and miR-27b differ only in one base,
while mature miR-24 sequence is identical and can only be distinguished from each other
as precursor miRNAs. As the paralogous miRNAs harbor the same seed sequences, it has
been suggested, that both clusters target the same set of mRNAs and might therefore have
similar functions within the cell. However, the regulation of both clusters might be indepen-
dent, as differential expression was reported in several cancer entities (reviewed in (Chhabra
et al., 2010)). Notably, the paralogous cluster is not expressed in leukemic cell lines (Yu et al.,
2006).
Interestingly, Karposi’s sacroma-associated herpesvirus (KSHV) expresses a miR-23-Mimic
(miR-K3) with high 5’ sequence complementarity to miR-23a and miR-23b, harboring the iden-
tical seed-sequence as miR-23a and miR-23b thereby targeting the same mRNAs (Manzano
et al., 2013). Since KSHV infections are associated in tumorigenesis (Giffin and Damania,
2014), this might indicate a onco-miR function for miR-23a.
Various miRNA profiling studies have reported that all three members of the MIR23A clus-
ter are deregulated in several diseases including muscle diseases, neurologic disorders and
many different cancer entities (reviewed in (Chhabra et al., 2010)). In particular, deregulation
of MIR23A cluster was observed for acute promyelocytic leukemia (APL) caused by the fu-
sion gene PML-RARA (Saumet et al., 2009). Furthermore, the MIR23A cluster is differentially
expressed between acute lymphoblastic leukemia (ALL; down) and acute myeloid leukemia
(AML, up) (Mi et al., 2007) as well as between BL (down) and DLBCL (up) (Lenze et al., 2011;
Iqbal et al., 2015), indicating that aberrant factors or events during hematopoiesis might be
responsible for MIR23A deregulation. Indeed, the MIR23A cluster was shown to play a crucial
role during hematopoiesis, hence it is regulated by PU.1, a potent repressor of the lymphoid
line, thereby promoting the myeloid line (Kong et al., 2010). Very recently, it was reported
that MIR23A germline knockout mice show an increased number of B lymphocytes in bone
marrow and spleen and a decreased number of myeloid cells (Kurkewich et al., 2016). For
later steps of B cell development several groups showed by miRNA profiling (micro array, RNA
sequencing or qRT-PCR) that the MIR23A cluster expression is induced during GC reaction
in normal healthy B cells (Basso et al., 2009; Tan et al., 2009; Zhang et al., 2009; Malumbres
et al., 2009)
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(Iqbal et al., 2015). Although none of these groups investigated the MIR23A cluster in detail,
all show in principle the same expression pattern for the MIR23A cluster: naive B cells and
GCB cells have low MIR23A cluster expression, while mature memory B cells have upregu-
lated MIR23A cluster levels (Basso et al., 2009; Tan et al., 2009; Zhang et al., 2009; Malumbres
et al., 2009; Iqbal et al., 2015), indicating that a process within the GCmight induce theMIR23A
cluster. Notably, Iqbal et al. verified the MIR23A cluster data by qRT-PCR (Iqbal et al., 2015).
Only Thapa et al. show higher miR-23a levels in naive B cells, that are downregulated in GCBs
and again upregulated in memory B cells (Thapa et al., 2011). These differences might be ex-
plained by different cell surface markers used to sort distinct B cell subpopulations. However,
the function of MIR23A cluster in B cells still remains unknown. Moreover, the mechanism by
which it is induced under physiological conditions is still unclear. Considering the fact, that
MIR23A cluster is differentially expressed between BL and DLBCL, which both develop from
GCB cells (Tamaru et al., 1995; Rosenwald et al., 2002; Pasqualucci and Dalla-Favera, 2014;
Sehn and Gascoyne, 2015), it can be suggested that pathways activated during GC reaction
might be responsible for the regulation of MIR23A cluster expression. First indications sup-
porting this hypothesis came from an arbitrary cell system, which mimics BL (P493-6) and
demonstrated that MYC can repress MIR23A cluster expression (Gao et al., 2009). Addition-
ally, for non-small cell lung cancer cells the transcription factor ELK1, which acts downstream
from MEK/ERK cascade, was reported to activate the MIR23A cluster (Acunzo et al., 2013).
Furthermore, the NFκB member p65 induced the MIR23A cluster in human leukemic T cells
(Rathore et al., 2012). However, experimental data supporting this hypothesis for DLBCL are
still missing.
Recently, Wang and colleagues reported that tumor samples of DLBCL patients show aberrant
high miR-23a levels compared to reactive lymph nodes of healthy control patients. Further-
more, they showed that patients with higher miR-23a levels have a worse overall survival rate
than patients with lower levels, indicating an onco-miR function of MIR23A cluster in DLBCL
(Wang et al., 2014). In order to understand why miR-23a worsens prognosis, knowledge about
the targets of the MIR23A cluster would be needed to explain which cellular processes are af-
fected by the MIR23A cluster. Indeed, several targets were already described for all three
members of the MIR23A cluster for different malignancies, except for lymphoma, indicating
that this cluster acts in many different cellular processes and can have diverse functions.
In pancreatic cancermiR-27a is overexpressed and acts as an onco-miR by targeting Sprouty2,
a negative regulator of Ras/MEK signaling, thereby inducing growth, colony formation and mi-
gration of pancreatic cells (Ma et al., 2010). Similar results were gained in colon cancer, where
miR-23a was shown to promote migration and invasion by targeting metastasis suppressor 1
(MTSS1) (Jahid et al., 2012). Moreover, the same group showed that miR-27a promotes prolif-
eration. In breast cancer miR-27a overexpression leads to downregulation of transcription fac-
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tor FOXO1 and induced cell proliferation as well as survival (Guttilla andWhite, 2009). FOXO1
is a putative tumor suppressor, which is also activated upon BCR signaling (see section 1.2.1).
In contrast, miR-23a acts as a tumor suppressor miRNA in osteosarcoma, where ectopic over-
expression of miR-23a inhibited proliferation, migration and invasion by targeting RUNX2 and
CXCL12 (He et al., 2014). A tumor suppressor function was also reported for miR-27a in col-
orectal cells (Bao et al., 2014). This group demonstrated, that miR-27a inhibited proliferation,
promoted apoptosis and attenuated migration. Furthermore, miR-27a inhibited tumor growth
in vivo (Bao et al., 2014). Gao et al. showed that miR-23a levels are downregulated in BL
upon MYC expression (Gao et al., 2009). Low miR-23a levels lead to increased mitochondrial
glutaminase (GLS) levels promoting glutamine metabolism resulting in higher energy produc-
tion. In this example, the oncogene MYC abolishes the tumor suppressor function of miR-23a
in order to facilitate cancer metabolism.
Taken together, these current findings indicate that the MIR23A cluster is aberrantly regulated
in DLBCL and that the biological function of the MIR23A cluster is cell type and context specific.
A previous study suggests that theMIR23A cluster might act as an onco-miR in DLBCL patients
(Wang et al., 2014). However, neither the reason for MIR23A cluster deregulation, nor the
biological function of the MIR23A cluster in DLBCL are understood.
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1.6. Aims
TheMIR23A cluster was shown to be deregulated inmany different diseases, including leukemia
and lymphoma. BL and DLBCL, two aggressive B-NHL subtypes, are derived from GCB cells.
Gene expression profiles show, that naive B cells and normal GCBs have low MIR23A clus-
ter levels compared to increased levels in memory B cells. Due to complex interactions with
the microenvironment of the GC, many different signaling cascades are activated during GC
reaction modulating survival, proliferation and differentiation of GCB cells. However, DLBCL
patients show aberrant highMIR23A cluster levels compared to healthy controls, indicating that
signaling cascades deregulated during GC reaction might be responsible for MIR23A cluster
activation. However, experimental data for the factors responsible for aberrant MIR23A cluster
regulation in DLBCL are missing.
The function of MIR23A cluster is controversially discussed, since onco-miR as well as tu-
mor suppressive functions were reported for the MIR23A cluster in different cancer entities.
Because miRNA function is dependent on the mRNAs targeted by the miRNA, its function is
context and cell type specific. A previous study reported that DLBCL patients with increased
miR-23a levels have a worse overall survival rate than patients with lower miR-23a levels.
These observations indicate the MIR23A cluster to function as an onco-miR in DLBCL. How-
ever, the processes in which the MIR23A cluster is involved in DLBCL are unknown.
Consequently, this study aims to answer the following two questions:
1. Which signaling pathways are responsible for the aberrant regulation of the MIR23A cluster
in DLBCL?
2. What is the DLBCL specific targetome of the MIR23A cluster? In detail, which mRNAs are
targeted by miR-23a and miR-27a?
By the identification of the miR-23a and miR-27a targetomes the cellular function of MIR23A
cluster in DLBCL can be predicted. Furthermore, the onco-miR hypothesis can be tested.
In order to investigate the MIR23A cluster regulation, MIR23A cluster levels were analyzed
upon stimulation of B cell relevant signaling pathways with different factors from the GC mi-
croenvironment, followed by the inhibition of downstream factors within the respective signaling
cascades. The cellular function of the MIR23A cluster was investigated by the identification
of miR-23a and miR-27a targetomes in a DLBCL model cell line. Therefore, DLBCL cell lines
overexpressing the respective miRNA or control were generated. These cell lines were used
to establish an Ago2-RNA immunoprecipitation assay. By this in vitro approach several novel
mRNA targets of the MIR23A cluster were identified for a DLBCL model cell line and were
subjected to functional validation.
2. Materials and Methods
2.1. Biological Material
2.1.1. Primary Material and Data
Primary material of human pediatric tonsils was obtained with informed consent from the legal
guardians of the children and ethical approval (34/7/06 Ethic-Commission University Göttin-
gen). Tonsillectomies were performed in the University Medical Center Göttingen.
Patient RNA sequencing data were obtained from the data base of the International Cancer
Genome Consortium (ICGC) Project “Determining Molecular Mechanisms in Malignant Lym-
phoma by Sequencing” (ICGC-MMML-Seq, https://ddc.icgc.org/releases/current/Projects/MALY-
DE, release v22 24.08.2016, published in (Hezaveh et al., 2016)).
2.1.2. Cell Lines
Cell lines used in this study are listed in table 2.1.
Table 2.1.: Cell lines
Cell line Description Distributor Reference
BL-2 Burkitt Lymphoma Bornkamm, Munich (Bertrand et al., 1981)
HEK293T Embryonal kidney DSMZ, Brunswick (Rio et al., 2015)
OCI-LY3 Diffuse large B cell lymphoma
(ABC)
DSMZ, Brunswick (Tweeddale et al., 1987)
OCI-LY7 Diffuse large B cell lymphoma
(GCB)
DSMZ, Brunswick (Tweeddale et al., 1987)
P493-6 MYC transformed lymphoblas-
toid cell line
Bornkamm, Munich (Polack et al., 1996)
U2932 R1 Diffuse large B cell lymphoma DSMZ, Brunswick (Quentmeier et al., 2013)
U2932 R2 Diffuse large B cell lymphoma DSMZ, Brunswick (Quentmeier et al., 2013)
2.1.3. Bacteria
E.coli Subcloning Efficiency DH5α Competent Cells were used for subcloning and plasmid
DNA amplification (Thermo Fisher Scientific, Waltham, USA). Genotype: F- φ80lacZ∆M15
∆(lacZYA-argF)U169 recA1 endA1 hsdR17(rk
− , mk
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2.2. Chemicals, Buffers & Consumables
2.2.1. Chemicals
Chemicals used in thesis study are listed in table 2.2:
Table 2.2.: Chemicals and Solutions
Chemical or solution Manufacturer
30% Acrylamid/Bis Solution (37,5:1) Bio-Rad, California, USA
Adenosine 5’triphosphate, ATP Roth, Karlsruhe, Germany
Agarose Sigma-Aldrich, Steinheim, Germany
anti FITC microbeads Miltenyi Biotec, Bergisch Gladbach, Germany
auto MACS rinsing buffer Miltenyi Biotec, Bergisch Gladbach, Germany
β-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany
Bacillol Bode, Hamburg, Germany
Biocoll Lymphoprep Solution Biochrom, Berlin, Germany
Bovine Serum Albumin BSA Serva, Heidelber, Germany
Brilliant Blue G Sigma-Aldrich, Steinheim, Germany
Chloroform J. T. Baker, Deventer, Netherlands
Complete protease inhibitor, EDTA-free Roche, Mannheim, Germany
Coomassie Plus Thermo Scientific, Massachusetts, USA
Disodiumhydrogenphosphate Roth, Karlsruhe, Germany
Dithiothreitol (DTT) Sigma-Aldrich, Steinheim, Germany
DMSO Sigma-Aldrich, Steinheim, Germany
dNTPs Peqlab, Erlangen, Germany
Dynabeads Protein G Life Technologies AS, Oslo, Norway
EDTA Sigma-Aldrich, Steinheim, Germany
EGTA Sigma-Aldrich, Steinheim, Germany
Ethanol J. T. Baker, Deventer, Netherlands
Ethidiumbromide Sigma-Aldrich, Munich, Germany
FACS flow Becton Dickinson, Heidelberg, Germany
FCS Sigma-Aldrich, Steinheim, Germany
Formaldehyde Sigma-Aldrich, Munich, Germany
Formic acid Sigma-Aldrich, Steinheim, Germany
Glycerol Roth, Karlsruhe, Germany
Glycine Roth, Karlsruhe, Germany
IGEPAL CA-630 Sigma-Aldrich, St. Louis, USA
Methanol J. T. Baker, Deventer, Netherlands
Methanol J. T. Baker, Deventer, Netherlands
MTT (Thiazolyl Blue Tetrazolium Bromide) Sigma-Aldrich, Steinheim, Germany
Nonidet P-40 Fluka, Missouri, USA
NXA931 GE Healthcare (Little Chalfont, UK)
PBS Sigma-Aldrich, Steinheim, Germany
Penicillin/Strepomycin Gibco, Massachusetts, USA
PhosSTOP Roche, Mannheim, Germany
Ponceau S solution Sigma-Aldrich, Steinheim, Germany
Potassiumchloride Roth, Karlsruhe, Germany
Potassiumhydrogenphosphate Roth, Karlsruhe, Germany
2-Propanol J. T. Baker, Deventer, Netherlands
Propidiumiodid Sigma-Aldrich, Steinheim, Germany
Puromycin Invivogen, Toulouse, France
Continued on next page
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Chemical or solution Manufacturer
Random Primers Invitrogen, Karlsruhe, Germany
Re-Blot Plus Mild Solution (10x) Millipore, Massachusetts, USA
RNase away Molecular BioProducts, San Diego, USA
RNase free H2O Sigma-Aldrich, Steinheim, Germany
RNAse Out Invitrogen, Karlsruhe, Germany
RPMI1640 Gibco, Massachusetts, USA
Sigma-AldrichAST Protease Inhibitor Sigma-Aldrich, Steinheim, Germany
Sodiumchloride Roth, Karlsruhe, Germany
Sodiumdeoxycholat Roth, Karlsruhe, Germany
Sodiumfluoride Sigma-Aldrich, Steinheim, Germany
Sodiumhydroxid Roth, Karlsruhe, Germany
TEMED Bio-Rad, California, USA
Triton X-100 Serva, Heidelberg, Germany
Tris Base Sigma-Aldrich, Steinheim, Germany
Tris HCl Sigma-Aldrich, Steinheim, Germany
Trypanblaue 0.4% in PBS Sigma-Aldrich, Steinheim, Germany
Tween 20 Sigma-Aldrich, Steinheim, Germany
Western lightning Plus ECL Perkin Elmer, Waltham, USA
2.2.2. Buffers and Solutions
Buffers and solutions used in this study are listed in table 2.3:
Table 2.3.: Buffers
Buffer Recipe
Ago2-RIP lysis buffer 25 mM Tris HCl pH 7.5
150 mM KCl
2 mM EDTA
0.5% (v/v) IGEPAL CA-630
0.5 mM DTT
4U/mL Rnase Out
1x Protease Inhibitor Cocktail, EDTA free




0.1% (v/v) IGEPAL CA-630
4U/mL Rnase Out
1x Protease Inhibitor Cocktail, EDTA free





MTT Solution I 5 mg/mL MTT in PBS
MTT Solution II 33 % DMSO (v/v),
5 % (v/v) Formic acid
62 % (v/v) Isopropanol
Nucl. extraction buffer A 10 mM HEPES pH 7.9
10 mM KCl
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RIPA lysis buffer 100 mM NaCl
50 mM TrisHCl pH 7.4
0.1% SDS
1% (v/v) NP-40
1x Protease Inhibitor Cocktail
1x Phosphatase Inhibitor Cocktail
0.25% Sodium-deoxycholat
Running buffer (1x) 25 mM Tris-base
192 mM Glycin
34.67 mM SDS
Separation gel mix 250 mM Tris-base, pH 8.8
25% (v/v) Acrylamid/Bis solution (40 %)
0.0004% (w/v) APS
0.00125% (v/v) TEMED
Stacking gel mix 250 mM Tris Base pH 6.8
12.5% (v/v) Acrylamid/bis solution (40 %)
0.0004% (w/v) APS
0.00125% (v/v) TEMED
TBS (1x) 20 mM Tris-base
137 mM Sodium chloride
Adjusted to pH 7.6
TBS-T 0.1% (v/v) Tween-20




Inhibitors used in this study are listed in table 2.4:
Table 2.4.: Inhibitors
Inhibitor Final Concentration Manufacturer
BEZ235 200 nM Selleckchem, Munich, Germany
Cyclohexamide 100 μg/mL Sigma-Aldrich, Steinheim, Germany
Etoposide 100 μM Sigma-Aldrich, Steinheim, Germany
Ibrutinib 1 μM Selleckchem, Munich, Germany
MK2206 3 μM Selleckchem, Munich, Germany
Trametinib 125 nM Selleckchem, Munich, Germany
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2.2.4. Consumables
Consumables used in this study are listed in table 2.5:
Table 2.5.: Consumables
Consumable Manufacturer
96 well PCR plates Applied Biosystems, Foster City, California, USA
Agilent RNA 6000 Pico Kit Agilent Technologies, Waldbronn, Germany
Agilent Small RNA kit Agilent Technologies, Waldbronn, Germany
Cell culture flasks Nunclon, Rosklide, Denmark
Cryotubes Nunc, Wiesbaden, Germany
DNA loBind tubes 1,5 mL, safe lock PCR clean Eppendorf, Hamburg, Germany
FACs tubes Becton Dickinson, Franklin Lakes, USA
Falcon tubes 15 ml Falcon, Reynosa, Mexico
Falcon tubes 50 ml Greiner Bio-One, Kremsmuenster, Austria
MACS LS columns Miltenyi Biotec, Bergisch Gladbach, Germany
MACS pre separation filters Miltenyi Biotec, Bergisch Gladbach, Germany
Multiwell cell culture plates Nunclon, Rosklide, Denmark
Nucleofection cuvettes Amaxa-biosystems, Cologne, Germany
PVDF membrane Biorad, Hercules, USA
Reaction tubes (0.5, 1.5, 2.0 mL) Eppendorf, Hamburg, Germany
Siliconized Tubes, 1,7ml (25 Tubes) Active Motif, La Hulpe, Belgium
2.3. Equipment
Equipment used in this study is listed in table 2.6:
Table 2.6.: Equipment
Instrument Manufacturer
7500 Fast Real-Time PCR System Applied Biosytems, Foster City, California, USA
Advanced Fluorescence Imager Intas, Goettingen, Germany
Amaxa Nucleofector 4D Lonza, Basel, Switzerland
Bioanalyzer2100 Agilent Waldbronn, Germany
FACS Calibur, FACS Aria III Becton Dickinson, Franklin Lakes, USA
Heraeus Multifuge 3L Thermo, Waltham, USA
Microcentrifuge 5424 Eppendorf, Hamburg, Germany
Multiscan Ex Platereader Thermo, Waltham, USA
NanoDrop1000 Thermo, Waltham, USA
Neubauer Counting Chamber Improved Lo Labor Optik, Friedrichsdorf, Germany
Thermocycler T3000 Biometra, Goettingen, Germany
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2.4. Stimulants
Stimulants used in this study are listed in table 2.7:
Table 2.7.: Stimulants
Description Final conc. Manufacturer
F(ab’)2 Fragment Goat α-human IgG 13 μg/mL Jackson ImmunoResearch, Suffolk, UK
F(ab’)2 Fragment Goat α-human IgM 13 μg/mL Jackson ImmunoResearch, Suffolk, UK
sCD40L 200 ng/mL Autogen bioclear, Wiltshire, UK
LPS 1 μg/mL Sigma-Aldrich, Steinheim, Germany
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2.5. Antibodies
Antibodies used for immunoblotting, FACS and Ago2-RIP are listed in table 2.8.
Table 2.8.: Antibodies
Antibody Species Order no. Working solution Manufacturer
Ago2 clone 11A9 rat SAB4200085 1:1,000 5% BSA TBS-T SIGMA, St. Louis, USA
3.6 μg per 4.5 μg beads
P-AKT (Ser473) rabbit 4060P 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
AKT (67E7) rabbit 4691P 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
BCL-6 rabbit 5650 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
BTK (D3H5) rabbit 8547 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
P-BTK (Tyr223) rabbit 5082 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
CD77 mouse 551353 50 μL per 1x108 cells Beckton Dickinson, New Jersey,
USA
c-MYC rabbit ab32072 1:5,000 5% BSA TBS-T Abcam, Cambridge, UK
ELK-1 rabbit 9182 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
P-ELK1 (Ser383) rabbit 9180 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
ERK rabbit sc-94 1:1,000 5% BSA TBS-T Santa Cruz, Dallas, US
P-ERK (Tyr204) mouse sc-7383 1:1,000 5% BSA TBS-T Santa Cruz, Dallas, US
GAPDH mouse ab8245 1:10,000 5% BSA TBS-T Abcam, Cambridge, UK
LIMK1 rabbit 3842 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
p53 rabbit 9282 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
PCNA rabbit ab19167 1:1,000 5% BSA TBS-T Abcam, Cambridge, UK
PUMA rabbit 12450 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
VRK3 rabbit 3260 1:1,000 5% BSA TBS-T Cell Signalling Technology, Dan-
vers, USA
IgG2a (aRTK2758) rat ab18450 3.6 μg per 4.5 μg beads Abcam, Cambridge, UK
(iso type ctrl)
mouse IgG HRP sheep NXA931 1:10,000 5% BSA TBS-T GE Healthcare Chicago, USA
rabbit IgG HRP donkey NA934V 1:10,000 5% BSA TBS-T GE Healthcare Chicago, USA
rat IgG HRP goat sc-2032 1:10,000 5% BSA TBS-T Santa Cruz, Dallas, USA
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2.6. Oligonucleotides
2.6.1. Primer
MiRNAs were detected using miScript Precursor Assays. Used primers are listed in table
2.9:
Table 2.9.: miScript primer
Order No primer description
MP00001645 Hs_mir-23a_PR_1 pre-miR-23a primer
MP00001701 Hs_mir-27a_PR_1 pre-miR-27a primer
MP00001666 Hs_miR-24-2_PR_1 pre-miR-24-2 primer
MS00031633 Hs_miR-23a_2 miR-23a-3p primer
MS00003241 Hs_miR-27a_1 miR-27a-3p primer
MS00006552 HS_miR-24_1 miR-24-3p primer
MS00007511 SNORD48_11 SNORD48 primer













miR-23a XhoI fw CTCGAGTGCTCTCTCTCTCTTTCTCC
miR-23a MluI rev ACGCGTACAGGCTTCGGGGCCTCT
miR-27a XhoI fw CTCGAGTTCCAACCGACCCTGAGC
miR-27a MluI rev ACGCGTTAGGCACGGGAGGCAGAGC
pri-miR-23a fw CCAGGGATTTCCAACCGACC
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2.6.2. siRNAs
SiRNAs used in this study are listed in table 2.11:
Table 2.11.: siRNAs
siRNA Cat. No. Manufacturer
MYC_5 SI00300902 Qiagen, Hilden, Germany
ELK1_7 SI02662506 Qiagen, Hilden, Germany
all stars negative SI03650318 Qiagen, Hilden, Germany
2.7. Ready to use reaction systems
Annexin V Apoptosis Detection kit PE (ebioscience, San Diego, USA), miRNeasy kit (Qiagen,
Hilden, Germany), SsoFast EvaGreen Supermix with Low Rox (Biorad, California, USA), miS-
cript SYBR Green PCR Kit (Qiagen, Hilden, Germany), miScript II RT Kit (Qiagen, Hilden, Ger-
many), RNA 6000 Pico Kit (Agilent Technologies, Waldbronn, Germany), Small RNA kit (Ag-
ilent Technologies, Waldbronn, Germany), QiaEx DNA fragment isolation kit, Machery-Nagel
Plasmid isolation kit. innuPREP Plasmid Mini Kit (Analytic Jena, Germany), NucleoBond®
Xtra Midi EF (Machery-Nagel, Düren, Germany).
2.8. Software
The following software products were used: the present thesis was written with LyX and Bib-
TeX. Literature-management and bibliography were generated using Mendeley Desktop Ver-
sion 1.16.1. Graphs were created using Microsoft Excel 2010. Figures were assembled using
GIMP and Microsoft Office PowerPoint 2010. Densidometry analyses were performed with Im-
ageJ 1.49v. qRT-PCR analysis was performed using SDS 2.4 and RQ Manager 1.2.1 (Applied
Biosystems). Bioanalyzer measurements were performed with Agilent Bioanalyzer expert
B.02.08.SI648 software. Western Blot chemoluminescence was detected by Intas Chemostar
Imager V 0.3.12.
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2.9. Eukaryotic expression vectors
Figure 2.1.: Lentiviral vector pGIPZ
ns ctrl hairpin sequence: 5´TGCTGTTGACAGTGAGCGATCTCGCTTGGGCGAGAGTAAG-
TAGTGAAGCCACAGATGTACTTACTCTCGCCCAAGCGAGAGTGCCTACTGCCTCGGA3´
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Figure 2.2.: MiR-23a pGIPZ
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Figure 2.3.: MiR-27a pGIPZ
2.9. EUKARYOTIC EXPRESSION VECTORS 35
Figure 2.4.: Topo TA cloning vector pCR2.1
Figure 2.5.: Transient expression vector pSG5
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Figure 2.6.: MiR-23a in transient expression vector pSG5
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Figure 2.7.: MiR-27a in transient expression vector pSG5
2.10. Cell Biology
2.10.1. Cell culture
All cells were maintained at 37°C in 5 % CO2 and subcultivated every second day. The BL
cell line BL-2 was cultured in RPMI-1640 with 10% fetal calf serum (FCS), 200 U/mL Penicilin
and 200 μg/mL Streptomycin. The DLBCL cell lines U2932 R1, U2932 R2 and OCI-LY3 were
cultured in cell culture medium RPMI-1640 with 20% FCS, 200 U/mL Penicilin and 200 μg/mL
Streptomycin and the DLBCL cell line OCI-LY7 was cultured in IMDM with 20% FCS, 200
U/mL Penicilin and 200 μg/mL Streptomycin. The BL cells were seeded at a density of 3 x 105
cells/mL the day before the experiment while DLBCL cell lines were seeded at a density of 5 x
105 cells/mL. HEK293T cells have been cultured in DMEM with 10% FCS. Approximately 2-3
x 106 cells/80 cm2 have been seeded and subcultivated (ratio: 1:4 to 1:5) every three days.
For cell number measurement cells were mixed in an equal ratio with 0.4 % Trypan blue and
counted using the Neubauer counting chamber.
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All cell lines have been tested regularly for mycoplasma contamination. Cells were no longer
than four weeks continuously cultivated. For cell freezing 4-5 x 106 cells were centrifuged for
5 min at 120xg at RT and resuspended in 1 mL freezing medium (normal culture medium sup-
plemented with 10% DMSO). For the freezing process cryo boxes which contain isopropanol
were used to ensure a constant cooling of approximately 1°C/min. Cryo boxes were stored im-
mediately at -80°C for 16-24 hours before they were transferred to liquid nitrogen for long-term
storage. For thawing, cells were washed with their corresponding culture medium, counted
and seeded in new culture medium (DLBCLs: 5 x 105 cells/mL; BLs: 3 x 105 cells/mL).
2.10.2. Isolation of CD77+ GCB cells from primary pediatric tonsills
Isolation of tonsillar mononuclear cells
Primary tonsillar tissue was kept on ice after tonsillectomy. The tonsillar cells were extracted by
mincing the tonsil in a petri dish with cold RPMI1640 plus P/S. To obtain tonsillar mononuclear
cells (TMCs), the cell solution was overlaid with Lymphoprep™ solution and separated by
density gradient centrifugation (400 x g, 30min at RTwithout break). The interphase containing
the TMCs was collected, washed once with cold RPMI1640 plus P/S and a second time with
cold autoMACS™ buffer plus.
Enrichment of CD77+ GC B cells
Cell enrichment was performed by an indirect labeling of the GC B cell marker CD77 on the
cell surface with an antibody coupled to magnetic beads (MACS™ MicroBeads). The mag-
netic sorting was performed usingMACS™ columns placed in a precooled MACS™Separator,
a strong permanent magnet. Thereby the MACS™ Column provides a magnetic field which
retains labeled cells. Elution was achieved by removing the column from the magnet and rins-
ing the column with buffer. TMCs were counted and resuspended in autoMACS™ buffer plus
(1x108 cells/250 μL). Cells were stained with anti CD77-FITC antibody (50 μL per 1x108 cells)
for 10 min at 4°C in the dark. Cells were washed once with 50 mL autoMACS™ buffer plus P/S
(centrifugation 300xg, 10 min, 4°C) and afterwards adjusted to a concentration of 40 μL/1x107
cells in autoMACS™buffer plus P/S. 10 μL anti-FITCmicrobeads per 1x107 TMCs were added
and incubated for 20 min at 4°C. Cells were washed with 50x volume of autoMACS™ buffer
plus P/S and resuspended in autoMACS™ buffer plus P/S. CD77+ cells were enriched using
LS MACS™ separation columns topped with pre-separation filters (500 μL with 1x108 CD77
cells per column). After the equilibration of the columns and filters with 500 μL autoMACS™
buffer plus P/S in the magnetic field, 1x108 cells in 500 μL autoMACS™ buffer plus P/S were
given onto each column. The columns were washed three times with 3 mL autoMACS™ buffer
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plus P/S. The first washing step was executed through a pre-separation filter. Elution was per-
formed with 5 mL autoMACS™ buffer plus P/S. An aliquot of CD77+ enriched cells was stored
at 4°C for cell characterisation by flow cytometry.
2.10.3. Nucleofection of cells
Small-interfering RNA (siRNA) against the indicated target genes or scrambled control were
transfected into the cells using Lonza Amaxa Nucleofection Kit (SF Cell Line 4D-Nucleofector®
X Kit L) and the Lonza Amaxa Nucleofector 4D device (100 pmol siRNA or 5 μg plasmid per
five million cells) according to the manufacturer’s instructions (program: Primary cell P3, CD
137 for U2932 R1). After the nucleofection process, cells were incubated in pre-warmed RPMI
1640 supplemented with 20 % FCS for 24/48 hours at 37°C in 5 % CO2. Knockdown quality
was verified with qRT-PCR and immunoblotting.
2.10.4. Inhibitor treatment
Cells were seeded in fresh cell culture medium at a density of 1 x 106 cells/mL and treated for
the indicated time span with the respective inhibitor (table 2.4). When performing combined
inhibitor and stimulation experiment, cells were pretreated 1-2 h before stimulation. Depending
on the experimental question, the cells were harvested for RNA isolation and/or for Western
blot analysis.
2.10.5. MTT Assay
For cell viability tests, the cell lines were treated with the inhibitor or solvent only as a control in
a cell density of 5 x 105 cells/mL for 24 h and 48 h at 37°C in 5 % CO2 . After X-4 h incubation
100 μL cell suspension was seeded into a 96 well plate and 10 μL MTT I solution was added
following an incubation for four hours at 37°C in 5 % CO2. Afterwards the cells were pelleted
for 10 min at 1200 rpm. The supernatant was discarded and the cell pellet was resuspended
in acidic MTT II solution. Optical density was afterwards determined at 560 nm and 750 nm
as reference wavelength using Thermo Multiscan Ex Platereader.
2.10.6. Stimulation of cells
One day prior to the experiment, cells were seeded at a cell density of 5 x 105 cells/mL in
the corresponding medium. At the day of the experiment cells were seeded at a density of
1 x 106 cells/mL in fresh medium without Penicillin and Streptomycin. The stimulant and the
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corresponding solvent as control (table 2.7) were added to the cells and resuspended before
incubation for the indicated time span at 37°C and 5% CO2. For harvesting, cells were cen-
trifuged 5 min at 210 x g and washed once with PBS. When analyzing phosphoproteins, cells
were harvested in a pre-cooled centrifuge, washed once with cold PBS and handled on ice
prior to cell lysis.
2.10.7. Generation of stable transduced U2932 R1 cells
Lentivirus production
For lentivirus production 5 x 106 HEK293T cells have been seeded per 10 cm2 cell culture
dish and grown to 80 % confluence in DMEM +10% FCS. Two hours prior to the experiment
HEK293T medium has been renewed without disturbing cell confluence.
Expression vector (pGIPZ LEF1 shRNA or pGIPZ non-silencing control), packaging plasmid
(pCMV delta R8.2) and envelope plasmid (pMD.2G) have been mixed in a ratio of 3:2:1. Cal-
cium chloride solution has been added to a final concentration of 0.5 M. While the calcium
chloride-plasmid mixture has been mixed thoroughly the same volume of 2x Hepes-buffered
NaCl solution has been added drop by drop. The final mixtures have been incubated for 3 min
at room temperature, mixed again and then carefully been added drop by drop to the HEK293T
cells. The next day cell supernatant has been removed and 5 ml fresh culture medium was
added carefully to each dish. HEK293T cells have been incubated for 24 hours at 37°C in 5 %
CO2 before the first virus harvest was performed. For that purpose HEK293T cell supernatant
was removed, stored at 4°C and HEK293T cells were covered for a second time with 5 ml of
cell culture medium per dish. After another day of incubation the second supernatants was
removed and mixed with the respective first supernatant. The resulting virus solutions were
centrifuged at 2,000 x g for 10 min at 4°C. To remove residual cell debris supernatants have
been transferred to new tubes and sterile filtered (0.45 μm pores). Virus solution has either
been used immediately for transduction or stored in liquid nitrogen.
Lentiviral transduction and selection of U2932 R1 pGIPZ
U2932 R1 cell concentration was adjusted to 1 x 106 cells/mL in RPMI1640 medium supple-
mented with 20 % FCS, 200 U/ml penicillin, 200 μg/ml streptomycin and 10 μg/mL protamin-
sulfate. Equal volume of virus solution (concentrated, 1:2 or 1:3) was added to the cell sus-
pension, mixed and centrifuged at 300 x g for 90 min at 37°C. 7 hours after transduction fresh
Medium without protaminsulfate was added to the cells. If green fluorescing cells could be ob-
served, 48h hours after transduction the selection process was started by addition of puromycin
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to a final concentration of 1.5 μg/mL to the cells. To control the selection process untransduced
cells were also treated with puromycin. Lentiviral transduced U2932 R1 cells have been ex-
panded, checked for GFP expression and frozen for long-term storage as described in section
2.10.1. MiRNA overexpression was regularly confirmed using qRT-PCR.
Figure 2.8.: Experimental outline for the generation of stable overexpressing clones
Pre-miR-23a, pre-miR-27a and non silencing control sequences were cloned into the stable transduction vector
pGIPZ. Triple tansfection of HEK293T cells with envelope vector pMD2.G, packaging vector pCMV∆R8.2 and
miRNA encoding vector pGIPZ in a ratio of 1:2:3 and lead to the secretion of lentiviruses coding for the respective
miRNA or non silencing control. The virus containing supernatant of HEK293T cells was subsequently used to
infect the DLBCL cell line U2932 R1. Positive clones were selected by puromycin and GFP expression.
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2.10.8. Flow cytometry
FACS (fluorescence activated cell sorting) analysis was performed with the BD FACS Calibur
and FACS Aria III flow cytometer and the BD FACS DIVA software. To analyze the cells, 1 x
106 cells were harvested, washed once with PBS and resuspended in 500 μL PBS. Cells were
either stained with antibody according to the manufacturer’s instructions or directly supple-
mented with propidiumiodide in an end concentration of 0.004 mg/mL before measurement.
Cells were gated to living PI negative population. For AnnexinV/7AAD staining, cells were not
gated.
2.11. Protein biochemistry
2.11.1. Whole cell lysates and cell fractionation
Whole cell lysates
Cells were harvested by centrifugation at 178 x g for 5 min at 4°C, washed once with PBS
and centrifuged for 4 min at 300 x g at 4°C. For whole cell lysates, cell pellets of 1 x 106 to
2 x 106cells were resuspended in 50 μL RIPA lysis buffer (supplemented with Protease and
Phosphatase Inhibitor) respectively and incubated on ice for 25 min. Subsequently, residual
cell debris was lost by centrifuging cell suspensions at 20,000 x g for 15 min at 4°C. Super-
natants were transferred to new reaction tubes and total protein amount was measured using
Bradford Assay.
Cell fractionation
Cell fractionation has been performed as described by (Schreiber et al., 1989). In short, cell
pellets of 5 x 106 cells were resuspended in 400 μl Nuclear Extract Buffer A and incubated
on ice for 13 min. Afterwards 25 μL 10 % NP-40 solution was added to each tube, mixed
thoroughly for 5 seconds and immediately centrifuged at 15.800 x g for 5 min at 4°C. The
supernatant containing the cytosolic fraction was transferred to a new tube. The pellets were
resuspended in 50 μl Nuclear Extract Buffer B and shaken thoroughly for 1-4 h at 4°C. After
centrifugation at 15.800 x g for 5 min at 4°C the supernatant, containing the nuclear fraction,
was transferred to a new tube and protein amount of both fractions was measured using Brad-
ford assay.
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2.11.2. Determination of protein concentration by Bradford assay
Determination of protein concentration was carried out by photometrical analysis using a mod-
ified Bradford assay (Bradford, 1976). A BSA standard curve was prepared and protein sam-
ples were diluted 1:200. 100 μL of Bradford solution was added to 50 μL diluted samples
and BSA standards and incubated for 10 min at RT. Measurement was performed at 620 nm
with Thermo Multiscan Ex Platereader. Protein concentration was calculated, adjusted with
RIPA to 1 μg/μL and boiled for 5 min at 95°C in 6x Laemmli Buffer. Samples were stored at
-20°C.
2.11.3. SDS PAGE and Western Blotting
SDS PAGE
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) was used for sep-
aration of proteins according to molecular weight (Laemmli, 1970). Modified buffers listed in
table 2.3 were used to prepare a gel composed of a 5% stacking and a 10-15% separation gel.
15 -25 μg total protein per sample was loaded onto the gel and electrophoresis was performed
in 1x Running buffer at constant 15 mA per gel for the stacking gel and 30 mA per gel for the
separation gel.
Western blotting and immunodetection
Separated proteins were transferred from SDS gel onto a hydrophobic PVDF membrane using
wet tank sandwich method (Renart et al., 1979; Towbin et al., 1979). The membrane was
activated for 30 sec in 100% MeOH, rehydrated in H2O for 2 min and equilibrated in transfer
buffer prior to use. Membrane and gel were stacked between filter papers into a wet tank
chamber filled with ice cold transfer buffer. Protein transfer was performed at 4°C and 100V for
1 h. Effective transfer of proteins was visualized by ponceau S staining and unspecific binding
sites were blocked using 5% BSA-TBS-T for 1 h at RT. After blocking, antibody solutions listed
in table 2.8 were added over night at 4°C. Next day, blots were washed four times 5 min with 1x
TBS-T. The secondary HRP coupled antibody against the species of origin of the first antibody
was added in a dilution of 1:10,000 in 5%BSA-TBS-T for 1 h at RT. Themembrane was washed
four times for 5 min with TBS-T, before detection of bound antibody using Western lightning
Plus ECL Solution and Western Lightning Image Reader. For reblotting, the membrane was
stripped of bound antibody for 20 min with 1x ReBlot mild buffer, blocked in 5% BSA-TBS-T for
60 min at RT and another primary antibody was added over night as described before.
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2.11.4. Ago2-RNA immunoprecipitation
The protocol for Ago2-RNA Immunoprecipitation (Ago2-RIP) used in this thesis was based
on the paper “Systematic Analysis of Viral and Cellular MicroRNA Targets in Cells Latently In-
fected with Human γ-Herpesvirus by RISC Immunoprecipitation Assay” (Dölken et al., 2010).
1.5 x 108 cells per replicate were harvested and washed twice in cold PBS before lysis in 4.2
mL Ago2-RIP lysis buffer in DNAlo bind reaction tubes. DTT, protease inhibitors and RNase-
Out were prepared freshly and added immediately before use. Lysates were incubated for
20 min on ice, frozen at -80°C for 10 min and thawed for 8 min at 30°C and 300 rpm. Cell
lysates were cleared by centrifugation at 15,000 x g for 30 min at 4°C. An aliquot was taken
as input control for Western blotting. Supernatants were supplemented with 4.5 mg mag-
netic beads that were coupled to 3.6 μg rat anti human Ago2 antibody or isotype control over
night at 4°C and washed once with Ago2-RIP wash buffer supplemented with protease and
RNase inhibitors. After incubation for 2.5 h rotating at 4°C, an aliquot from the supernatant
was taken as depletion control for Western blotting and the beads were washed 5 times with
ice cold Ago2-RIP wash buffer supplemented with protease and RNase inhibitors followed by
two wash steps with ice cold PBS supplemented with RNase inhibitor. An aliquot of beads was
taken for Western blotting output control. RNA was recovered from the remaining beads by
adding 1 mL Qiazol. Total RNA was prepared using the miRNeasy kit (QIAGEN) following the
manufacturer’s instructions including DNase digestion.
CDNA library preparation and Next Generation Sequencing were performed at the GMAK, HZI
Brunswick using Illumina kits and technology. For mRNA sequencing, poly A enrichment was
applied (ScriptSeq™v2RNA-Seq Library Preparation kit, Illumina). For small RNA sequencing
no enrichment was performed (TruSeq Small RNA Library Preparation kit). For sequencing
library pool of 12 pM was multiplexed on a single lane. Cluster generation was performed with
cBot (Illumina) using TruSeq SR Cluster Kit v3–cBot-HS (Illumina). Samples were sequenced
(50 bp single-end) on the Illumina High Seq 2500 using TruSeq SBS Kit v3 - HS (Illumina) for
50 cycles.
RNA sequencing reads were pre-processed including trimming of reads (fastq-mcf, ea-utils)
and quality control (FastQC) ensuring high quality reads and removal of adapter sequences.
Trimmed reads were mapped to the human genome (hg38) by STAR (Dobin et al., 2013) and
counted by HTseq (Anders et al., 2015). Further analysis was performed using the software
environment R/Bioconductor and the respective software packages. Normalization was per-
formed according to total number of reads within a sample and between samples (Anders et al.,
2010). Thresholds for differentially expressed genes were set to at least 2-fold enrichment and
a Benjamini-Hochberg adjusted p-value lower than 0.05.
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For gene ontology analyses of differentially expressed genes sets, the R-packages goseq and
Go.db were used (Young et al., 2010).
2.12. Molecular Biology
2.12.1. Total RNA isolation
Total RNA of cell pellets (1-5 x 106 cells, beads from Ago2-RIP assay) was isolated using the
miRNeasy kit (QIAGEN) t according to the manufacturer’s instructions. Total RNA was eluted
in 40 μl RNAse free water and the corresponding concentration has been determined using
the NanoDrop2000.
2.12.2. Reverse transcription
The Superscript II first-strand synthesis kit (Invitrogen) and random hexamer primers have
been used for the reverse transcription of mRNA to cDNA. For the cDNA synthesis 1 - 2 μg
total RNA were mixed with RNAse free water to a final volume of 10 μL. 2 μL random hexamer
primers (100 μM) were added, mixed and incubated at 70°C for 10 min in a thermocycler.
Subsequently, the tubes were cooled on ice before adding 8 μL master mix. The mixture was
incubated for 10 min at RT, before incubation in a thermocycler with the program shown in
table 2.12.
Master mix Thermocycler program
4 μL 5x First Strand Buffer 60 min 42°C
2 μL 0.1 M DTT 10 min 65°C
1 μL dNTPs (10 mM each ) constant 4°C
1 μL SuperScript RT II
Table 2.12.: Master mix and thermocycler program for reverse transcription of mRNAs
For miRNA detection, the miScript cDNA kit (Qiagen) was used. 1 μg total RNA (isolated with
the miRNeasy kit, Qiagen) was adjusted to a volume of 10 μL with RNase free water. 10
μL RT-Mastermix (see table 2.13) was added. High Flex buffer was used for parallel reverse
transcription of miRNA, mRNA and pre-miRNA. For reverse transcription of mature miRNAs
only, the High Spec buffer was used. The RNA-Mastermix solution was incubated for 1-2 min
at ice before starting the reverse transcription using the following protocol:
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Master mix Thermocycler program
4 μL 5x miScript Buffer 60 min 37°C
2 μL miScript Nucleics Mix 5 min 95°C
1 μL miScript II RT Mix constant 4°C
Table 2.13.: Master mix and thermocycler program for reverse transcription of mRNAs, pre-
miRNAs and miRNAs
2.12.3. Quantitative real-time polymerase chain reaction (qRT-PCR)
For relative transcript quantification, the fluorescent DNA binding dye SYBR Green was used.
If SYBR Green binds double-stranded DNA, this complex of DNA and the SYBR Green dye
will absorb blue light (λmax = 488 nm) and emit green light (λmax = 522 nm). Therefore, the
increasing fluorescence is used to quantify the amount of transcripts, which corresponds to
the number of PCR cycles with an exponential increase of fluorescence (cycle threshold =
CT -value). For the PCR reaction and the simultaneous fluorescence detection, the Applied
Biosytems 7500 Fast Real-Time PCR System was used.
For detection of mRNAs each reaction contained 10 μL SsoFast™ EvaGreen® Supermix (Bio-
rad), 10 pmol of each primer and 2-25 ng cDNA mRNA and had a final volume of 20 μl. For
detection of miRNAs or pre-miRNAs each reaction contained 10 μL 2 x QuantiTect SYBR Mix,
2 μL 10 x Universal Primer and 2 μL 10 xmiScript Primer (for pre miRNA detection no Universal
primer was added) and 2 -10 ng miScript cDNA in an final volume of 20 μL.
Each analysis has been performed in technical triplicates. The corresponding qRT-PCR pro-
grams are shown in table 2.14. A melt curve was performed after each PCR run to identify
unspecific PCR products.
Gene expression was evaluated relative to a house keeper using the SDS 2.4 and RQManager
1.2.1 (Applied Biosystems). Target gene transcript abundance was calculated using theΔΔCT
method. Therefore, the actual CT -values of genes of interest have been normalized to the CT -
values of the house keeper:
ΔCT = CT geneofinterest - CT housekeeper
The changes between a treated sample and untreated controls is formed as follows:
ΔΔCT = ΔCT treatment - ΔCT control
The number of cycles exponentially correlates with the amount of detected DNA in the sample,
thus relative n-fold changes can be calculated as:
RQ = 2−∆∆CT
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For mRNA detection CT values in this study were normalized to GAPDH. For miRNA or pre-
miRNA detection CT values were normalized to SNORD48.
miScript PCR SSoFast mix PCR
95°C 15 min 95°C 2 min
94°C 15 s 95°C 3 s
55°C 30 s 40x 40x
70°C 34 s 60°C 25 s
Table 2.14.: qRT-PCR programs
2.12.4. Conventional PCR
Polymerase chain reaction (PCR; (Mullis et al., 1986)) was used for amplification of DNA-
fragments and addition of restriction sites for cloning purposes. A typical PCR reaction, was
performed according to following protocol:
component amount thermocycling conditions:
template 1 colony/100 ng DNA
reaction buffer 1x initial denaturation 5 min 95°C
primer fw 20 pmol denaturation 30 s 95°C
primer rev 20 pmol annealing 30 s Tmelting 25x
dNTP mix 4 mmol elongation 1 min/kb 72°C
polymerase 1 U final elongation 5 min 72°C
total volume 15 μL
Table 2.15.: conventional PCR
2.12.5. DNA restriction digestion
For sequence specific hydrolysis of plasmid DNA, restriction endonucleases and the corre-
sponding buffers from Thermo Scientific were used. For hydrolysis of plasmid DNA with two
different restriction endonucleases the following protocol was used:
analytical preparative
1 μg plasmid DNA 3 μg plasmid DNA
3 U restriction endonuclease 1 10 U restriction endonuclease 1
3 U restriction endonuclease 2 10 U restriction endonuclease 2
2 μL 10 x reaction buffer 5 μL 10 x reaction buffer
x dd H2O x dd H2O
20 μL final volume 50 μL final volume
Table 2.16.: DNA restriction digestion
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Analytical samples were incubated for 1 h and preparative samples over night at 37°C. Tem-
peratures and buffers were chosen according to the manufacturer’s instructions.
2.12.6. Agarose gel electrophoresis
The negative charged DNA fragments can be separated according to their molecular weight
within an electrical field. Therefore, the DNA was mixed with 6 x loading dye (50% (v/v) glyc-
erol, 0.21% (w/v) bromphenole blue, 0.1% (w/v) xylene blue, 0.2 M EDTA pH 8.0 ) and loaded
onto a TAE-agarose gel (1-2 % (w/v) agarose in TAE buffer containing 0.5 μg/mL EtBr). The
percentage depended on the expected fragment size. Horizontal agarose gel electrophoresis
was performed for 30-60 min at 100-120 V in TAE buffer (40 mM Tris-HCL, pH 7.5, 1 mM Na2-
EDTA, pH 8.0, 0.2% (v/v) CH3COOH). Due to the intercalation of EtBr into double stranded
DNA, the DNA fragments could be visualized by exposure to UV-light.
2.12.7. DNA fragment extraction
DNA fragments were extracted from the agarose gel using QIAquick gel extraction kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
2.12.8. Determination of DNA and RNA concentration
DNA and RNA concentration was photometrically determined using NanoDrop2000 (Thermo
Scientific, St.Leon-Rot, Germany). DNA was measured at 360 nm and 280 nm. The ratio of
extinction at 260 nm to 280 nm should be ~1.8 for high quality DNA. RNA was measured at
260 nm and 230 nm. The ratio of extinction at 260 nm to 230 nm should be ~2.0 for high
quality RNA.
Before RNA sequencing, the RNA concentration and quality was assessed using Agilent RNA
6000 Pico Kit and Agilent Small RNA kit according to themanufacturer’s instructions. RNAwas
measured at Bioanalyzer2100 and quantified using Agilent Bioanalyzer expert B.02.08.SI648
software. High quality RNA has a RIN value of 8-10.
2.12.9. Ligation of DNA fragments
To mediate covalent linking of DNA fragments, 50 ng of dephosphorylated vector was mixed
with the insert in a molecular ratio of 5:1 (sticky end ligation) and incubated with T4DNA ligase
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(Thermo Scientific, St.Leon-Rot, Germany) over night at 16°C. Following standard protocol
was used:
amount component
50 ng linearized vector
x ng insert
2 Weiss U T4DNA ligase
1 μL 10 x T4DNA ligase buffer
x dd H2O
10 μL final volume
Table 2.17.: Ligation of DNA fragments
5 μL of the ligation mix was used for transformation into E.coli DH5 α.
2.12.10. Transformation
Transformation of E.coli DH5 α was performed by heat shock procedure: an aliquot with 50 μL
of chemical competent bacteria were thawed for several minutes on ice before gently mixing
with low amounts of plasmid DNA or 1-5 μL of ligation mix. After an incubation of 30 min on ice,
heat shock was performed for 90 s at 42°C. The cells were cooled down on ice immediately
and afterwards incubated with 200 μL LB-medium for 45 min at 37°C under constant shaking.
Finally, the cells were plated onto LB-Agar plates or pipetted into 200 mL fluid LB-medium
containing appropriate antibiotics for selection. Flasks or plates were incubated for 16 h at
37°C.
2.12.11. Cultivation of Bacteria
Escherichia coli (E.coli) bacteria were cultured in Luria-Bertani medium (LB medium) at 37°C.
For selection of transformed bacteria, media were supplemented with the corresponding an-
tibiotics (final concentration of ampicillin 100 μg/mL).
2.12.12. Plasmid Isolation
Plasmid DNA was isolated using innuPREP Plasmid Mini Kit (Analytic Jena) for cloning ap-
proaches or NucleoBond® Xtra Midi Plus EF kit (Machery-Nagel) for transfections in cell




3.1. Identification of signaling pathways regulating the MIR23A cluster
One aim of this thesis was to identify the signaling pathways responsible for MIR23A regulation
in DLBCL. Since the MIR23A cluster expression is induced during normal GC reaction, factors
present in the microenvironment of the GC were used to stimulate the cells and tested whether
MIR23A cluster expression can be induced.
3.1.1. CD40L signaling does not change MIR23A cluster expression in B-NHL
Signaling via the CD40 receptor plays an important role during B cell maturation (see section
1.2.2). The CD40 receptor activates a cascade of signaling molecules including PI3K and
MAPK signaling (JNK, p38 and ERK), resulting in the activation of many transcription factors
(Basso et al., 2004). Many described CD40 effects are NFκB dependent, hence it can be
considered asmain downstream effector (Berberich et al., 1994). Previous data from our group
already confirmed for BL that CD40L stimulation changes global gene expression (Dissertation
Alexandra Schrader 2011, published in (Schrader et al., 2012)).
To test whether CD40 signaling regulates the MIR23A cluster in GC derived lymphoma, a BL
and a DLBCL cell line were treated with sCD40L and analyzed for MIR23A expression by
qRT-PCR.
In order to detect only miR-24 levels that originate from MIR23A cluster and not from MIR23B
cluster, the pre-miR-24-2 levels were detected, because the mature miR-24 sequences are
identical and cannot be distinguished from each other.
The relative expression levels of mature miR-23a, miR-27a and pre-miR-24-2 do not change
upon stimulation with sCD40L, neither in BL-2 nor in U2932 R1 within the tested time period
(fig. 3.1). Only in U2932 R1, the pre-miR-23a and pre-miR-27a levels slightly increase after
4 hours of treatment. But this does not affect mature miR-23a and miR-27a levels. Both cell
lines respond on CD40L treatment with an increase in ICAM1 expression levels (Schrader
et al., 2012), indicating, that the stimulation was successful.
Lymphoma cells are transformed cells with altered signaling characteristics. Therefore, CD77
germinal center B-cells, which represent the precursor cells of GC derived B cell lymphoma
(centroblasts) (Pascual et al., 1994; Klein et al., 2003), were isolated from human pediatric
tonsils by MACs technology and treated for 10 h with 200 ng/mL sCD40L. In contrast to the
BL and DLBCL cell lines, primary CD77 GCBs respond to sCD40L treatment with a 2-fold
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induction of miR-23a and a slight induction of miR-27a (fig. 3.2). Successful CD40L stimulation
was verified by the induction of ICAM1.
These data indicate that CD40 signaling is not responsible for regulation of the MIR23A in BL
and DLBCL.
Figure 3.1.: CD40L does not change MIR23A cluster expression in B-NHL cell lines
(a) BL cell line BL-2 and (b) DLBCL cell line U2932 R1 were treated for the indicated time points with 200 ng/μL
sCD40L. RelativeMIR23A and ICAM1 levels were detected by qRT-PCRanalyses. Meanwith 95%CI, endogenous
control: SNORD48 for miRNA, GAPDH for mRNA.
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Figure 3.2.: CD40L induces MIR23A cluster expression in primary CD77 GCBs
Primary CD77 positive germinal center B-cells were isolated by MACS technology from human pediatric tonsils
and treated for 10h with 200 ng/μL sCD40L. Relative MIR23A levels were detected by qRT-PCR analyses. ICAM1
served as control for successful CD40L stimulation. One of two experiments is shown. Mean with 95% CI, en-
dogenous control: SNORD48 for miRNAs, GAPDH for ICAM1.
3.1.2. LPS does not change MIR23A cluster expression
Bacterial lipopolysaccharide (LPS) is a component of the cell wall of gram negative bacteria.
As an T cell independent antigen LPS activates Toll-like receptor 4 (TLR4). TLR4 signaling
was shown to activate GC response, resulting in the production of high affinity class switched
antibodies of plasma cells (reviewed in (Defranco et al., 2012)).
Activation of TLR4 recruits MyD88 and activates via TRAF6 and TAK1 the MAPK (JNK and
p38) and NFκB signaling (reviewed in (Doyle and O’Neill, 2006)). One LPS responsive target
gene isCD58, which served in this experiment as a control for successful stimulation (Schrader
et al., 2012).
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Figure 3.3.: LPS does not change MIR23A expression in DLBCL cell lines U2932 R1 and R2
U2932 R1 (a and b) and U2932 R2 (c and d) were stimulated for 16h with 1 μg/mL LPS. (a and c) relative pre-miR-
23a, miR-23a and miR-27a expression levels measured by qRT-PCR. (b) and (d) relative CD58 levels measured
by qRT-PCR. This experiment was performed once. Mean with 95% CI, house keeper: GAPDH for CD58 and
SNORD48 for pre-miR23a and miR-23a/27a.
The U2932 R2 clone responds to LPS stimulation with an increase of 50% ofCD58 expression,
but the MIR23A levels are not affected (fig. 3.3 c and d). Although, the U2932 R1 clone
responds stronger to LPS treatment with an upregulation of nearly 2.5-fold ofCD58 expression,
LPS treatment does not change pre-miR-23a, miR-23a or miR-27a levels.
In summary, together with the previous experiments (section 3.1.1) these data indicate, that
downstream NFκB signaling is not central for the regulation of the MIR23A cluster in BL and
DLBCL cell lines.
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3.1.3. BCR signaling activates the MIR23A cluster in BL and DLBCL
3.1.3.1. BCR signaling activates the MIR23A cluster in BL cell line BL-2
Previous data from our group revealed a large set of transcripts that is altered upon stimulation
of the B-cell receptor in the human BL cell line BL-2 (Schrader et al., 2012; Pirkl et al., 2015).
The gene expression micro array used in the latter publication to detect transcript expression in
this cell line covers the whole human transcriptome including non-coding RNAs and is therefore
able to detect precursor transcripts of miRNAs (dissertation Elisabeth Hand 2013, published
in (Pirkl et al., 2015)). Hence, this micro array data set was used in this study to analyze
MIR23A and paralogous MIR23B cluster expression patterns upon BCR stimulation during a
time course in BL-2 (fig. 3.4). An increase of pre-miR-24-2 transcript 60 min upon anti-IgM
F(ab)2-fragment stimulation, followed by pre-miR-23a after 210 min, but no induction of pre-
miR-27a in the examined time span of stimulation was observed (fig. 3.4 a). Since all pre-miRs
of the MIR23A cluster are processed from a single polycistronic transcript one would expect,
that all pre-miRs are induced. Moreover, one could speculate that the time order in which the
pre-miRs are induced may correlate with the position at which they are encoded on the primary
transcript.
The paralogous MIR23B cluster is also induced upon anti-IgM F(ab)2-fragment stimulation as
pre-miR-27b expression increases 180 min after stimulation (fig. 3.4 b). Instead, pre-miR-23b
and pre-miR-24-1 levels are not affected. These observations raise the question, whether the
DNA probes of the micro array correctly detect the small precursor transcripts.
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Figure 3.4.: Induction of MIR23A cluster in BL cell line BL-2 upon BCR stimulation
(a) and (b) Micro array gene expression analyses of MIR23A cluster (a) and MIR23B cluster (b) in BL cell line
BL-2 upon stimulation with 13 μg/mL anti-IgM F(ab)2-fragment for a 480 min time course. The mean of three
experiments is shown. Microarray gene expression dataset taken from the dissertation of Elisabeth Hand in 2013,
published in (Pirkl et al., 2015). (c) and (d) qRT-PCR gene expression analyses of relative (c) pri-miR-23a/b and
(d) miR-23a, miR-27a and pre-miR-24-2 expression in BL-2 upon 13 μg/mL anti-IgM F(ab)2-fragment stimulation
in a time course experiment. Mean with 95% CI, endogenous controls: c) GAPDH d) SNORD48. One out of two
representative experiments is shown.
Therefore, the micro array data were validated by quantitative real time PCR analyses (see fig.
3.4 c an d). According to the micro array data both MIR23 clusters are activated upon BCR
stimulation. Interestingly, the qRT-PCR data show, that the primary transcript of the MIR23A
cluster is clearly induced, while the primary transcript of the MIR23B cluster shows only minor
expression changes (fig. 3.4 c). Next the expression of the mature miRNAs was analyzed
by qRT-PCR (fig. 3.4 d). Because the mature miR-24 sequence is identical disregarding from
which locus it is transcribed, the precursor transcript pre-miR-24-2, which can be clearly distin-
guished from the pre-miR-24-1 transcript, was analyzed. As expected the pre-miR24-2 tran-
script is induced first followed by an induction of mature miR-23a and miR-27a after 120 min.
While the expression of the mature miRNAs constantly increases, the pre-miR-24-2 transcript
reaches its maximum of 2-fold induction after two hours followed by a decrease.
In summary, these data show for the first time that BCR signaling is responsible for the activa-
tion of the MIR23A cluster in BL.
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3.1.3.2. BCR signaling activates the MIR23A cluster in DLBCL cell line U2932 R1
Since BCR signaling was demonstrated to activate the MIR23A cluster in BL-2 cell line (see
section 3.1.3.1), it was questioned whether a DLBCL cell line, which develops from later stages
in GC reaction can also activate the MIR23A cluster expression in response to BCR signaling.
Therefore, the DLBCL cell line U2932 R1 was chosen as a model cell line (Quentmeier et al.,
2013). This cell line is on the one hand well characterized and shows on the other hand
relatively low levels of MIR23A cluster, making it favorable for induction and overexpression
experiments. Indeed, the MIR23A levels are induced upon BCR cross-link in DLBCL cell line
U2932 R1 (fig. 3.5 a).
Figure 3.5.: Induction of the MIR23A cluster in DLBCL cell line U2932 R1 upon BCR stimulation
The DLBCL cell line U2932 R1 was treated with 13 μg/mL anti-IgM F(ab)2-fragment . Relative MIR23A expression
was measured after 1, 2, 4, 8, 16 and 24 hours of stimulation by qRT-PCR. (a) primary transcript expression of
MIR23A and paralogous MIR23B cluster. (b) pri-/pre- and mature miR-23a expression. (c) pri-miR-23a, pre-miR-
27a and mature miR-27a expression. (d) pri-miR-23a, pre-miR-24-2 and mature miR-24 expression. Mean with
95% CI, endogenous control: GAPDH for pri-miRs and SNORD48 for mature and pre-miRs, one representative
experiment out of two is shown.
The primary miR-23a transcript is induced already after 60 min of BCR stimulation reaching its
maximum of 4.5-fold induction after 2 hours followed by a slow decrease. Instead, the primary
transcript of the paralogous cluster (pri-miR-23b) is only induced 1.5-fold after 60 min, stays
constant before it starts to decrease after 8 hours (fig. 3.5 a). Because the induction of the
paralogous cluster is weak compared to the MIR23A cluster all following analyses focus on
the MIR23A cluster.
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Interestingly, the kinetics of miRNA processing are fast, since the precursor transcripts of all
three miRNAs (blue lines in fig. 3.5 b, c and d) are induced already within 60 min, at the same
time as the primary transcript does. All precursor transcripts reach their maximum between
8 and 16 hours and decrease afterwards very slowly. With a short time delay after precursor
induction the mature miRNAs (green lines fig. 3.5 b, c and d) levels increase. The miR-23a
expression is induced after 5-8 hours followed by a slight induction of miR-27a after 8 hours
of stimulation, while miR-24 is not induced.
These data together with data from section 3.1.3.1 demonstrate that BCR signaling is respon-
sible for the MIR23A cluster activation in BL and in DLBCL cell lines.
3.1.3.3. BCR dependent MIR23A activation is a general mechanism in DLBCL, but not
in healthy germinal center B cells
BCR signaling induced the MIR23A cluster expression in a BL and a DLBCL cell line (section
3.1.3.1 and 3.1.3.2). The focus of this study was to elucidate the regulation of MIR23A cluster
in DLBCL. To analyze whether the activation of the MIR23A cluster is a general mechanism
in DLBCL, the DLBCL cell lines U2932 R2 (sister clone of U2932 R1, “ABC-like” DLBCL),
OCI-LY3 (ABC-DLBCL) and OCI-LY7 (GCB-DLBCL) were stimulated with anti-IgM F(ab)2-
fragment or anti-IgG F(ab)2-fragment, respectively. Furthermore, primary non transformed
CD77 positive germinal center B cells (CD77 GCBs) (Pascual et al., 1994; Klein et al., 2003)
were isolated from human pediatric tonsils and treated in the same manner as the DLBCL
cell lines in order to analyze whether the induction of MIR23A cluster by BCR signaling is a
physiological or an aberrant process.
All tested DLBCL cell lines respond with an induction of MIR23A cluster expression upon BCR
stimulation. In general, the miR-23a induction is stronger than the miR-27a induction, except
for OCI-LY3, where both were induced 2-fold. In contrast, primary non-transformed CD77
GCBs do not respond with an increase of miR-23a or miR-27a upon BCR cross-link, although
the BCR signaling is clearly activated since one BCR target gene SLAMF7 (Schrader et al.,
2012) is induced (fig. 3.6 b).
These data strongly indicate that BCR mediated MIR23A cluster activation is a general mech-
anism in BL and DLBCL. Although GCBs show active BCR signaling upon stimulation, they
do not upregulate the MIR23A cluster upon activation. This indicates that BCR signaling is
aberrantly modified in BL and DLBCL.
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Figure 3.6.: BCR signaling activates MIR23A cluster in different DLBCL cell lines, but not in
healthy control cells
The BCR was cross linked in different DLBCL cell lines for 16 hours with 13 μg/mL anti-IgM F(ab)2- or anti-IgG
F(ab)2-fragment and in primary CD77 germinal center cells for 10 hours with 13 μg/mL anti-IgM F(ab)2-fragment.
(a) miR-23a, miR-27a and (b) SLAMF7 expression were detected by qRT-PCR. Mean with 95% CI, endogenous
control: GAPDH for SLAMF7 and SNORD48 for miRNAs. One representative experiment of three for the cell lines
and two for GCBs is shown.
3.1.3.4. Inhibition of protein de-novo synthesis does not affect the MIR23A activation
upon BCR stimulation
To test whether the MIR23A cluster is induced by direct downstream signaling, the U2932
R1 cells were treated with cyclohexamide (CHX) simultaneously to BCR stimulation. CHX
inhibits protein de-novo synthesis by blocking translation elongation of the ribosome. Under
this conditions only transcription factors, that were activated by direct upstream signaling, but
not by secondary effects, are translocated into the nucleus and can induce MIR23A cluster
expression. In order to control effective CHX treatment, the c-MYC protein levels were an-
alyzed. C-MYC has a high protein turnover rate, being rapidly degraded by the proteasome
(Gregory and Hann, 2000). Thus, it functions perfectly as an indicator for effective ribosomal
inhibition.
As depicted in fig. 3.7 a) the MIR23A levels (pri-miR-23a, pre-miR-23a and pre-miR-27a) can
still be activated upon BCR stimulation with anti-IgM F(ab)2-fragment, when protein de-novo
synthesis is effectively blocked by CHX treatment. Notably, c-MYC accumulates upon BCR
stimulation in U2932 R1 fig. 3.7 b), hence it was further analyzed as a potential transcription
factor responsible for MIR23A regulation in section 3.1.3.6.
In summary, no protein de-novo synthesis is required for BCR dependent activation of the
MIR23A cluster, indicating a direct activation of MIR23A promoter.
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Figure 3.7.: Inhibition of protein de-novo synthesis does not interfere with MIR23A activation
upon BCR cross-link
U2932 R1 was pre-treated for 1 h with 100 μg/mL cyclohexamide (CHX) before stimulation with 13 μg/mL anti-IgM
F(ab)2-fragment for 2 h. (a) qRT-PCR analyses of pri-miR-23a, pre-miR-23a and pre-miR-27a (b) Western blot
analyses of c-MYC. GAPDH served as loading control. Mean with 95% CI, endogenous control: SNORD48 for
pre-miRNAs and GAPDH for pri-miR, one representative experiment of three is shown.
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3.1.3.5. BTK/MEK/ERK signaling activates the MIR23A cluster
In order to narrow down which signaling cascade downstream of the BCR is responsible for
activation of the MIR23A cluster in U2932 R1, the key enzymes BTK, MEK, PI3K and AKT,
which mediate the downstream effects of BCR (section 1.2.1), were systematically inhibited
by treatment with chemical inhibitors. These pre-treated cells were then stimulated with anti-
IgM F(ab)2-fragment followed by MIR23A cluster expression analyses. NFκB signaling was
excluded, because previous experiments showed no effect on MIR23A cluster expression
when stimulating this pathway in BL (BL-2) or DLBCL (U2932 R1) cell lines (fig. 3.1.1 and
3.1.2).
Ibrutinib irreversibly inhibits the Burton tyrosine kinase (BTK) by covalent binding to Cys-481 in
the ATP binding domain (Davids and Brown, 2014). BTK is one of the first proteins that is phos-
phorylated upon antigen binding. Importantly, BTK plays a key role in BCR signaling, because
it spreads the message by phosphorylation of PLCγ2 onto different downstream cascades: the
ERK, NFκB and PI3/AKT signaling. As a consequence, BTK inhibition should impair all sig-
naling cascades downstream of the B cell receptor. As a proof of principle it should no longer
be possible to activate the MIR23A cluster, when treating the cells with Ibrutinib and anti-IgM
F(ab)2-fragment simultaneously. This is exactly what could be observed when performing this
experiment with U2932 R1 (fig. 3.8 a): The pre-miR-23a and pre-miR-27a levels are acti-
vated upon anti-IgM F(ab)2-fragment stimulation as already previously observed. Treatment
with Ibrutinib alone does not alter pre-miR-23a and pre-miR-27a expression levels. Further-
more, the used ibrutinib concentration was not toxic to the cells, as shown in MTT assays (fig.
A.3). As expected, the MIR23A cluster is not activated upon double treatment with Ibrutinib
and anti-IgM F(ab)2-fragment. As shown in fig. 3.8 b) and 3.9 b) Ibrutinib effectively inhibited
phosphorylation of BTK and further downstream of P-ERK.
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Figure 3.8.: MIR23A cluster expression upon inhibition of key enzymes of BCR signaling
U2932 R1 was pre-treated for 2 hours with the respective inhibitor (1 μM Ibrutinib, 200 nM BEZ235, 3 μM MK2206)
before simultaneous stimulation with 13 μg/mL anti-IgM F(ab)2-fragment for 2h. Relative expression levels of
(a) pre-miR-23a and pre-miR-27a were detected by qRT-PCR analyses. (Mean with 95% CI, endogenous control:
SNORD48) (b-c) Western blot analyses of BCR downstream kinases P-ERK/ERK and P-AKT/AKT. GAPDH served
as loading control. One representative experiments of three is shown.
BEZ235 is an ATP-competitive PI3-kinase (p110α/γ/δ/β) and mTOR (p70S6K) inhibitor. PI3K
phosphorylates PIP2 to make PIP3, which recruits PDK1 and AKT to the cell membrane, where
AKT is activated by phosphorylation of mTORC2 and PDK1. Treatment with BEZ235 inhibits
therefore effectively the PI3K/mTOR/AKT signaling (Barrett et al., 2012). Indeed, Western blot
analyses show effective inhibition of P-AKT in U2932 R1 (fig. 3.8 c). The pre-miR-23a and
pre-miR-27a levels are slightly increased upon treatment of U2932 R1 with BEZ235 alone, but
can not be further increased when treated together with anti-IgM F(ab)2-fragment (fig. 3.8 a).
However, the error bars are high, making interpretations difficult. In order to interpret these data
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correctly, in a next experiment the cells were treated with an additional inhibitor specific for AKT:
MK2206. MK2206 allosterically inhibits auto-phosphorylation of T308 and S473 of AKT1, 2 and
3. It thereby prevents the AKT-dependent phosphorylation of numerous downstream targets.
Indeed, the control Western blot shows an effective inhibition of AKT phosphorylation (fig. 3.8
c). In contrast to BEZ235, MK2206 itself does not increase the pre-miR-23a or pre-miR-27a
levels (fig. 3.8 a). However, double treatment with MK2206 and anti-IgM F(ab)2-fragment lead
to an activation of the MIR23A cluster. Therefore, AKT signaling is not responsible for MIR23A
cluster activation upon BCR stimulation in U2932 R1.
Next, the MAPK/ERK signaling was studied by inhibition of MEK1/2 with Trametinib in U2932
R1. Trametinib is a high specific inhibitor acting allosterically and reversible (Lugowska et al.,
2015). Non-toxic concentrations of trametinib were used for the following experiments (see
MTT assays fig. A.3) Interestingly, Trametinib alone slightly downregulated pri-miR-23a, pre-
miR-23a and pre-miR-27a levels (fig. 3.9 a). Furthermore, cells that were pre-treated with
Trametinib were not able to activate the MIR23A cluster when simultaneously stimulated with
anti-IgM F(ab)2-fragment. As a control, Western blot analyses (fig. 3.9 b) show that Trametinib
effectively inhibited downstream ERK phosphorylation.
These observations indicate that BTK/MEK/ERK signaling is the BCR downstream cascade
that is predominantly responsible for the MIR23A cluster activation in DLBCL model cell line
U2932 R1.
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Figure 3.9.: Inhibition of BTK and MEK1/2 prevents MIR23A activation upon BCR stimulation in
U2932 R1
DLBCL cell line U2932 R1 was pretreated with Ibrutinib (1 μM) and Trametinib (125 nM) for 2 hours, before BCR
stimulation by 13 μg/mL anti-IgM F(ab)2-fragment. Protein samples were taken after 30 min and RNA samples
after 2 h of stimulation. (a) qRT-PCR analyses of pri-miR-23a, pre-miR-23a and pre-miR-27a expression upon
inhibitor/anti-IgM F(ab)2-fragment double treatment. (Mean with 95% CI, endogenous control: SNORD48 for miR-
NAs, GAPDH for pri-miR-23a) (b and c) Western blot analyses verifying effective inhibition of P-BTK by Ibrutinib
and P-ERK by Trametinib. GAPDH served as loading control. (Ibrutinib n=3, Trametinib n=2)
3.1.3.6. c-MYC as a potential activator of MIR23A cluster in DLBCL
The proto-oncogene c-MYC (MYC) plays an important role in early B-cell development where it
induces proliferation and contributes to lymphomagenesis (section 1.1). Previous experiments
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(fig. 3.7) indicated that MYC is activated upon BCR signaling in U2932 R1. Indeed, it was
already reported that MEK/ERK and PI3K signaling phosphorylate MYC, which leads to an
extended half life and accumulation of MYC protein (Sears et al., 2000), exactly as observed
for U2932 R1 (fig. 3.7).
Additionally, the sister clones of U2932 (subclones U2932 R1 and U2932 R2) differ in MYC
expression (Quentmeier et al., 2013). The subclone U2932 R1 expresses low MYC levels,
while the subclone U2932 R2 expresses high MYC levels (fig. 3.11). Interestingly, the MYC
low subclone U2932 R1 shows also low MIR23A levels, while the MYC high subclone U2932
R2 exhibits higher MIR23A levels. Furthermore, gene expression analyses showed that MYC
and pri-miR-23a are induced simultaneously upon BCR stimulation, indicating that MYC might
be a target gene of BCR signaling and might activate the MIR23A cluster in U2932 R1 (fig.
3.10). Moreover, previous studies showed that MYC can either activate (Li et al., 2013b) or
repress the MIR23A cluster (Gao et al., 2009), depending on the cellular context.
Figure 3.10.: c-MYC and pri-miR-23a are simultaneously induced upon BCR cross-link
Relative expression levels of pri-miR23a and c-MYC upon 13 μg/mL anti-IgM F(ab)2-fragment treatment in U2932
R1. Endogenous control: GAPDH, mean with 95% CI, one representative experiment of two is shown.
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Figure 3.11.: U2932 subclones R1 and R2 differ in c-MYC and MIR23A cluster expression
(a) qRT-PCR analysis of relative miR-23a/-27a, pre-miR-24-2 and c-MYC levels in U2932 subclones R1 and R2.
(Mean with 95% CI, endogenous control: SNORD48 or GAPDH) (b) Western blot analysis of MYC protein levels
in U2932 subclones R1 and R2. GAPDH served as loading control. One representative experiment out of three is
shown.
Taken together these positive correlations led to the hypothesis that MYC might be a good
candidate transcription factor for regulation of the MIR23A cluster. This hypothesis is further
supported by Gao and colleagues, who showed that c-MYC binds to the paralogous MIR23B
promoter by chromatin immunoprecipitation (ChIP) assay in P493-6 B cells (Gao et al., 2009).
Whether MYC can bind to the MIR23A promoter is not known. Controversial to the hypothesis
in this thesis, MYC inhibited miR-23a and the miR-23b levels in P493-6 B cells. The P493-6
cell line contains a tetracycline inducible c-MYC expression cassette (Tet-off system) by which
MYC levels can be regulated.
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Figure 3.12.: c-MYC inhibits MIR23A in P493-6
P493-6 cells were treated for the indicated time points with 1 ng/mL doxycycline to downregulate c-MYC protein
levels. a) qRT-PCR analysis of MIR23A cluster expression with and without doxycycline. (Mean with 95% CI,
endogenous control: SNORD48) b) control Western Blot showing efficient downregulation of c-MYC protein levels
upon doxycycline treatment. Dox = doxycycline. This experiment was performed once, samples were kindly
provided by Maren Schmidt.
To confirm the observations from Gao et al. 2009, the P493-6 cell line was treated for 4,
8, 12, and 24 hours with doxycycline to efficiently downregulate c-MYC levels (samples were
kindly provided by Maren Schmidt). These MYC low samples where then analyzed for MIR23A
cluster expression by qRT-PCR. Indeed, miR-23a is activated upon withdrawal of MYC (fig.
3.12), exactly as shown by Gao et al. in 2009. Additionally, the miR-27a and pre-miR-24-2
levels increase, indicating that the whole MIR23A cluster and not only miR-23a or miR-23b is
inhibited by MYC in P493-6.
However, the P493-6 is a model cell line for BL. In order to answer the question whether
MYC is the transcription factor, which activates the MIR23A cluster in DLBCL, classical ectopic
overexpression experiments were performed in U2932 R1. 24 hours after nucleofection of
the eukaryotic c-MYC expression vector, cells were analyzed for primary miR-23a transcript
expression via qRT-PCR. MYC overexpression was analyzed by Western blotting. Although,
MYC was strongly overexpressed (fig. 3.13 b), the relative expression levels of pri-miR-23a
were not altered.
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Figure 3.13.: Overexpression and knockdown of c-MYC do not alter pri-miR-23a levels in U2932
R1
5 μg plasmid per 5x10
6
cells was transfected by nucleofection in U2932 R1 (a and b). For MYC knock down
100 pmol siRNA per 5x10
6
cells was transfected (c and d). 24h after nucleofection pri-miR-23a expression levels
were detected by qRT-PCR (a and c). Mean with 95% CI, endogenous control: GAPDH. MYC protein levels were
detected by Western blotting (b and d). GAPDH served as loading control. One representative experiment of three
is shown.
The interpretation of ectopic overexpression experiments can be problematic in some cases,
because many proteins act in complexes. When their binding partners are not available in
excess, overexpression of the target protein might not exert any effect. Therefore, in a second
approach c-MYC was knocked down in the same cell line by a specific siRNA against c-MYC.
24h after nucleofection the pri-miR-23a levels and the MYC protein levels were analyzed (fig.
3.13 c and d). Although, the MYC protein levels were clearly reduced, the primary miR-23a
transcript levels were not significantly altered.
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This data are supported by another experiment, where MIR23A levels can be induced upon
BCR signaling although c-MYCprotein levels were abolished byCHX treatment (section 3.1.3.4,
fig. 3.7).
In conclusion, the hypothesis that c-MYC is responsible for activation of the MIR23A cluster in
response to BCR signaling, was refused for DLBCL cell line U2932 R1.
3.1.3.7. ELK1 as a potential activator of MIR23A in response to BCR
One transcription factor acting downstream of MEK/ERK signaling, is the E26-like kinase 1
(ELK1). ELK1 is a member of the ternary complex factor (TCF) subfamily of ETS-domain
transcription factors and is phosphorylated by ERK2 (MAPK1). Acunzo et al. showed by
chromatin immunoprecipitation, that ELK1 binds to the MIR23A promoter in lung cancer cells,
and that knockdown of ELK1 leads to a decrease in pri-miR-23a expression (Acunzo et al.,
2013). To check whether ELK1might be a potential candidate to activate the MIR23A cluster in
DLBCL, U2932 R1 cells were stimulated with anti-IgM F(ab)2-fragment and/or treated with the
MEK1/2 inhibitor Trametinib using non-toxic concentrations (see MTT assays fig. A.3).
Figure 3.14.: ELK1 phosphorylation is MEK1/2 dependent
Western blot analyses of nuclear extracts of DLBCL cell line U2932 R1 treated with 125 nM Trametinib and/or
13 μg/mL anti-IgM F(ab)2-fragment. PCNA serves as loading control. One of three independent experiments is
shown.
Western blot analyses of nuclear extracts show that P-ELK1 is induced within 15 min of BCR
stimulation (fig. 3.14). The P-ELK1 signal rapidly vanishes within one hour after stimulation.
In contrast, cells stimulated with anti-IgM F(ab)2-fragment and simultaneously treated with
Trametinib show no phosphorylation of ELK1. ELK1 protein levels are not affected by the
treatments. Consequently, ELK1 is activated by MEK/ERK pathway in U2932 R1. These
observation together with the Chip data from Acunzo et al. 2013 lead to the hypothesis that
ELK1 might be the MEK/ERK downstream transcription factor responsible for the activation of
the MIR23A cluster in response to B-cell receptor stimulation in U2932 R1.
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Figure 3.15.: Overexpression and knockdown of ELK1 does not alter pri-miR-23a levels
5 μg plasmid (pCMV or pCMV_ELK1) per 5x10
6
cells was transfected by nucleofection in U2932 R1 (a and b).
For ELK1 knock down 100 pmol siRNA (si ctrl or si ELK1) per 5x10
6
cells was transfected (c and d). 24h after
nucleofection pri-miR-23a expression levels were detected by qRT-PCR (a and c). Mean with 95% CI, endogenous
control: GAPDH. ELK1 protein levels were detected by Western blotting. GAPDH served as loading control (b and
d). One representative experiment of three is shown.
In order to test this hypothesis, ectopic overexpression experiments were performed in U2932
R1 cells. An eukaryotic expression plasmid coding for ELK1 was transfected by nucleofection
in U2932 R1. 24h after transfection, cells were harvested and analyzed for MIR23A expres-
sion by qRT-PCR and ELK1 protein overexpression by Western blotting. Although the ELK1
protein is markedly overexpressed, the pri-miR-23a levels are not affected (fig. 3.15 a and b).
Vice versa, knocking ELK1 down by siRNA has the same effect: the pri-miR-23a levels stay
constant while ELK1 is clearly down regulated (fig. 3.15 c and d).
These classical overexpression and knock down experiments are critical, because on the one
hand simple overexpression does not necessarily mean, that more ELK1 is phosphorylated.
Only the phosphorylated form acts as a transcription factor. On the other hand, it is very dif-
ficult to detect pri-miR-23a, because it is already very low expressed in U2932 R1. Knocking
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ELK1 down should lead to further decreased pri-miR-23a levels. Therefore, one additional ex-
periment was performed to prove that ELK1 does not activate the MIR23A cluster: ELK1 was
overexpressed in U2932 R1 and 24 h post transfection the overexpressing cells were stimu-
lated with anti-IgM F(ab)2-fragment. By this approach, the overexpressed ELK1 is activated by
phosphorylation and transported into the nucleus where it can bind to its target genes.
Figure 3.16.: Overexpression and activation of ELK1 in U2932 R1
5 μg plasmid (pCMV or pCMV_ELK1) per 5x10
6
cells was transfected by nucleofection in U2932 R1. 24 h post
transfection cells were stimulated with 13 μg/mL anti-IgM F(ab)2-fragment for 15 min. (a) ELK1 and P-ELK1 levels
were detected by Western blotting. GAPDH served as loading control. (b) Relative pre-miR-23a and pre-miR-27a
expression levels by qRT-PCR analyses. Endogenous control: SNORD48. One of two independent experiments
is shown.
Figure 3.16 a shows that cells transfected with ELK1 express enhanced ELK1 protein levels.
Additionally, BCR stimulation leads to an induction of P-ELK1 in the nuclear fractions. As
expected, cells that overexpress ELK1 and are subsequently stimulated with anti-IgM F(ab)2-
fragment (aIgM) show higher P-ELK levels as control transfected cells. However, higher nu-
clear P-ELK1 levels did not enhance the pri-miR-23a levels compared to cells that were trans-
fected with control vector and simultaneously stimulated with anti-IgM F(ab)2-fragment (fig.
3.16 a and b). Although high P-ELK1 levels are present in the nucleus, the induction of the
MIR23A cluster is not stronger than normal BCR stimulation.
Taken together, these knockdown and overexpression results show that, although MEK/ERK
signaling is active upon BCR stimulation leading to phosphorylation of ELK1, P-ELK1 is not
the downstream transcription factor responsible for induction of the MIR23A cluster.
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3.2. Identification of the MIR23A targetome
3.2.1. Experimental setup for MIR23A targetome identification
In order to analyze the biological function of the MIR23A cluster in DLBCL, the targetomes of
miR-23a and miR-27a were identified for the DLBCL model cell line U2932 R1. This approach
was achieved by an Ago2-RNA immunoprecipitation (Ago2-RIP), followed by high-throughput
RNA-Sequencing (fig. 3.17). Ago2 protein mediates the interaction of miRNA and mRNA
within the RISC. Hence, Ago2 immunoprecipitation captures miRNAs and RISC associated
mRNAs. These were compared between a miRNA overexpressing cell line to a non-silencing
control cell line. Under the assumption that the proportion of overexpressed miRNAs incorpo-
rated in the Ago2-RISC complex is enhanced, the comparison of RNA-sequencing data from
non silencing control cells (ns ctrl) to miR-23a or miR-27a overexpressing cells should provide
an enrichment of a) the miRNA of interest and b) a set of mRNA sequences that are bound to
and therefore targeted by the respective miRNA. In detail, mRNA sequencing was performed
for Ago2-RIP input and output samples (fig. 3.18). Additionally, small RNAs of the input sam-
ples were sequenced, to check whether the global miRNA expression is affected by lentiviral
miRNA overexpression. In total, three independent experiments were performed resulting in
triplicates for each cell line (U2932 R1 pGIPZ ns ctrl1, miR-23a1 and miR-27a1) and each
sample (Ago2-RIP input and output).
In order to identify the mRNAs that are targeted by the respective miRNA, first the enriched
transcripts of Ago2-RIP output vs. input were compared. This comparision identifies all tran-
scripts that are incorporated within the RISC complex and bound to Ago2. In a next step,
these Ago2-bound transcripts were compared between miRNA overexpressing cell line to ns
ctrl cell line. The differentially expressed mRNAs of this comparison are identified as targets
of the respective miRNA (enrichment higher than two-fold, p-value less than 0.05; see section
3.2.7).
This approach will give insight into the yet unknown DLBCL specific MIR23A targetome and
may predict in which cellular processes the MIR23A cluster is involved in DLBCL.
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Figure 3.17.: Experimental design of miR-23a/27a targetome identification via Ago2-RIP
Scheme of Ago2-RIP approach for identification of the miRNA targetome of a DLBCL cell line. 1,5x108 cells of
control or miRNA overexpressing (miR OE) cell line are lysed and cell lysates are used for Ago2-RNA immunopre-
cipitation (Ago2-RIP) with an Ago2-specific antibody that is coupled to magnetic beads. The RNA from Ago2-RIP
input and output samples is isolated and used for cDNA library preparation, which is subsequently analyzed by
Next Generation Sequencing.
Figure 3.18.: Bioinformatical comparisons for miRNA targetome identification
Scheme of bioinformatical comparisons of Ago2-RIP sequencing data performed for miRNA target identification.
Compared are Ago2-RIP samples of miR-23a or miR-27a overexpressing cell lines to non silencing control. First
the enrichment of Ago2-bound mRNAs are analyzed by comparison of Ago2-RIP input and output samples for
each cell line. Next, these enriched transcripts from miRNA overexpressing cell line are compared to non silencing
ctrl. These transcripts are identified as miR-23a or miR-27a bound targets within the Ago2-RISC complex.
Since a large cell number is needed for such an experiment, a DLBCL cell line stably overex-
pressing the miRNA of interest (miR-23a or miR-27a) or a non silencing control (ns ctrl), was
generated. For this purpose, the cell line U2932 R1 was chosen as a DLBCL model cell line,
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because it is on the one hand well characterized (Quentmeier et al., 2013) and shows on the
other hand relatively low levels of MIR23A, making it favorable for induction and overexpres-
sion experiments. Therefore, lentiviral expression vectors for stable miR-23a, miR-27a and
ns ctrl overexpression were cloned. MiR-24 was not cloned, because it is not expressed in B
cells and it did not respond to B-cell receptor activation (fig. 3.5 d). In parallel, also vectors for
transient miRNA overexpression were cloned in order to validate the identified MIR23A targets
in transient overexpression experiments.
3.2.2. Cloning of pre-miR-23a and pre-miR-27a into the transient expression vector pSG5
for miRNA overexpression
The pSG5 expression vector coding for miR-23a~miR-27a was kindly provided by Friedrich
Grässer. Using PCR the restriction sites for XhoI and MluI were added 74 bp in 5’ direction
and 62 bp in 3’ direction of the pre-miR-23a sequence. The flanking sequences ensure that
the miRNA processing machinery is able to bind correctly to the stem loop sequence. The
PCR product was subcloned into the TopoTA cloning vector pCR2.1, excised by EcoRI and
ligated into the pSG5 expression vector (section 2.9).
The same cloning strategy was applied for miR-27a. In this case the XhoI and MluI restric-
tion sites were added 81 bp 5’ direction and 98 bp in 3’ direction of miR-27a stem loop se-
quence.
The restriction sites XhoI and MluI were used for subcloning into a lentiviral expression vec-
tor.
3.2.3. Cloning of pre-miR-23a and pre-miR-27a into the lentiviral vector pGIPZ
The lentiviral transduction vector pGIPZ ns ctrl (coding for a non silencing control, GFP and a
puromycin resistance) was chosen to generate lentiviral particles that transduce miR-23a and
miR-27a into U2932 R1 (section 2.9). The non-silencing sequence is flanked by a XhoI and
a MluI restriction site. These were used to excise the ns ctrl sequence and replace it by the
pre-miR23a or pre-miR-27a sequences described in section 3.2.2.
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3.2.4. Generation of stable miR-23a and miR-27a overexpressing clones
HEK293T cells were used to produce lentiviral particles harboring the ns ctrl, miR-23a or
miR-27a sequences. These lentiviral particles were harvested from HEK293T supernatant,
the virus titer was determined and the virus solution was used for transduction of the target
cell line U2932 R1. Successfully transduced clones were selected by Puromycin resistance
and GFP expression (strategy see fig. 2.8). Next, the miRNA expression of each selected
clone was verified by qRT-PCR (figure 3.19).
By this approach, many clones overexpressing ns ctrl, miR-23a and miR-27a were generated.
Selection criteria for new generated cell lines were: homogeneous and constant GFP expres-
sion over several generations, functional mature miRNA expression and unchanged c-MYC,
BCL-6 and Ago2 expression. U2932 R1 pGIPZ ns ctrl1, ns ctrl2, miR-23a1, miR-23a2 and
miR-27a1 fulfilled this criteria, whereas the miR-27a10 clone was found to be a double clone,
showing two distinct GFP populations. Since only two miR-27a clones were obtained, both
were used for further experiments (fig. 3.19, supplementals A.1 and A.2).
Figure 3.19.: MIR23A expression of stable ns ctrl/miR-23a/miR-27a overexpressing U2932 R1
pGIPZ clones
QRT-PCR results of mature miR-23a and miR-27a expression in lentiviral transduced U2932 R1 clones compared
to U2932 R1 qnd R2. (Mean with 95% CI, endogenous control: SNORD48.) These cell lines fulfilled all selection
criteria (for details refere to main text) and were used for all further experiments. Note that U2932 R1 pGIPZ
miR-27a10 is a GFP-double clone.
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3.2.5. Characterization of stable miR-23a and miR-27a overexpressing clones
Since miR-23a and miR-27a were previously described to be associated with proliferation and
growth (Liu et al., 2013; Jahid et al., 2012; Jiang and Melnick, 2015; Pan et al., 2014), cell num-
bers of the parental cell line U2932 R1 and the ns ctrl, miR-23a and miR-27a overexpressing
U2932 R1 pGIPZ clones were assessed to identify differences in proliferation rates. In detail,
equal cell numbers were seeded and cell number as well as cell viability were determined after
24, 48, 72 and 96 hours.
Figure 3.20.: Proliferation of U2932 R1 pGIPZ clones
U2932 R1 pGIPZ clones and U2932 R1 were seeded at a density of 5x105 cells/mL in RPMI1640 +20% FCS. After
24, 48 and 72 hours cell were manually counted using a Neubauer counting chamber. Viability was determined by
trypanblue exclusion. One representative experiment of two is shown.
Neither the overexpression of ns ctrl, nor miR-23a or miR-27a altered the proliferation rate
of U2932 R1 (fig. 3.20 a). The cell numbers of all clones increase with time, doubling after
around 30 hours and stagnate between 48 and 72 hours. Cell viability of all clones stays
constant between 90 to 95% for 48 hours before slightly decreasing between 48 and 72 hours
(fig. 3.20 b). The miR-23a and ns ctrl overexpressing cell lines did not differ from the parental
clone in cell viability, while the miR-27a overexpressing clones showed a slight worse viability
by ca. 5%. Stagnation of cell growth and reduction of viability is possibly due to starvation,
because the cells were not feeded during this time span.
3.2.6. Establishment of an Ago2-RNA immunoprecipitation assay for miRNA targetome
identification in DLBCL
In order to identify the miR-23a and miR-27a mRNA targets in DLBCL, an Ago2-RNA im-
munoprecipitation assay (Ago2-RIP) was established for the DLBCL cell line U2932 R1. The
protocol used in this thesis was based on the paper “Systematic Analysis of Viral and Cellular
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MicroRNA Targets in Cells Latently Infected with Human g-Herpesvirus by RISC Immunopre-
cipitation Assay” (Dölken et al., 2010). It was optimized for the use with the suspension cells
U2932 R1. Most important was to obtain enough high quality RNA for mRNA Sequencing,
therefore cell number, lysis volume, number of freeze and thaw cycles and antibody to bead
ratio were systematically tested and adjusted.
Figure 3.21.: Ago2 protein is enriched by immunoprecipitation
ControlWestern blot of Ago2-RIP fromU2932R1 pGIPZmiR-23a1. The 100 kDa band represents Ago2. 40 μg total
protein per lane. Output 1/40 (v/v) of input. Iso ctrl = isotype control, depl. ctrl = depletion control. Housekeeper:
GAPDH. One representative blot from more than three is shown.
As could be seen on the Western blot in fig. 3.21 the Ago2 protein (ca. 100 kDa) could
successfully be enriched upon immunoprecipitation in the output fraction, especially because
only 1/40 of input volume was loaded on the lanes. The depletion controls (or flow through)
show a depletion of Ago2 protein when Ago2-antibody was used, but not when an isotype
control was used. Additionally, no Ago2 protein was enriched in the output fraction of isotype
control, showing that the immunoprecipitation was specific for Ago2 protein.
Figure 3.22.: MiRNAs are enriched in Ago2-RIP output
(a) Bioanalyzer small RNA chip data of small RNA fractions of U2932 R1 Ago2 RIP. The 4 nt peak resembles
the marker nucleotide. (b) Ago2-RNA immunoprecipitation in U2932 R1. qRT-PCR analyzes show an 40-fold
enrichment of mature miRNAs and only 6-fold enrichment of pre-miR-24-2 compared to input fractions. Mean with
95% CI, endogenous control: SNORD48.
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To check whether the Ago2 immunoprecipitation also includes an enrichment of miRNAs,
the output RNA was fractionated into small and large RNAs and analyzed using Bioanalyzer
agarose chips (fig. 3.22 a). Input as well as output RNA fractions show a peak between 40
and 80 nt, which represent small RNAs, such as 5S and 5.8S rRNA, tRNAs and other small
RNA species. As expected, the Ago2 output shows an additional peak at 20 bp, which is not
present in the isotype control output. This peak represents the enrichment of mature miRNAs,
that bind within the RISC complex to Ago2 and have a size between 18-22 bp. The relative
abundance of miRNAs in the input fraction is low, so this 20 bp peak is not visible without en-
richment. Comparing the height of the small RNA peak (40-80 bp), one can clearly see that the
peak decreases upon immunoprecipitation, showing that the immunoprecipitation is specific,
but still there is a background of other RNA species. Over all, about 150 ng high quality total
RNA per sample was obtained upon Ago2-RNA immunoprecipitation from 1.5 x 108 cells (RIN
values > 8 , supplementary fig. A.4).
In a next step, it was validated by qRT-PCR analyses that these 20 nt long RNA sequences,
which were enriched in the Ago2-RIP output fractions, are mature miRNAs (fig. 3.22 b). In-
deed, the mature miR-23a and miR-27a transcripts were 40-fold enriched compared to input.
As a proof of principle, the precursor miRNA of miR-24 was only 6-fold enriched. Pre-miRNAs
were not expected to be bound to Ago2, because they are not incorporated into the RISC. No-
tably, the ratio of miR-23a to miR-27a did not change upon immunoprecipitation in unmodified
parental cell line U2932 R1, showing that the procedure per se did not alter the composition
of different miRNAs incorporated into the RISC complex.
Nevertheless, still other RNA species can be found after immunoprecipitation. Especially, ri-
bosomal RNA is still present in the output samples (supplementary fig. A.4). Therefore, and in
order to enrich mRNAs, poly A enrichment was applied before cDNA library generation for next
generation sequencing of mRNA transcripts. For small RNA sequencing (only of miR-23a1
and ns ctrl1 inputs) the 5’-phosphate and 3’-hydroxyl groups of mature miRNAs, that are gen-
erated by Drosha and Dicer processing, were used for adapter ligation before cDNA library
preparation.
In summary, the Ago2-RIP could successfully be established for DLBCL cell line U2932 R1.
The Ago2 protein together with its bound miRNAs could be specifically and highly enriched
upon immunoprecipitation. The RNA amount gained from Ago2-RIP output (~150 ng total
RNA per sample) was sufficient for RNA sequencing. Additionally, the RNA quality was still
high upon Ago2-RNA immunoprecipitation.
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3.2.7. RNA sequencing & analysis
In order to identify the MIR23A targetome in DLBCL an Ago2-RIP assay was established for
the DLBCL cell line U2932 R1 (section 3.2.6). Ago2-RIP assays were performed for U2932
R1 pGIPZ clones: miR-23a1, miR-27a1 and ns ctrl 1 (section 3.2.1, fig. 3.17 and 3.18). Total
RNA was isolated from Ago2-RIP input and output samples for each cell line in triplicates
(three independent experiments). Besides mRNA sequencing of Ago2-RIP input and output
samples, small RNA sequencing was performed for U2932 R1 miR-23a1 and ns ctrl1 inputs
to check whether global miRNA expression was affected by miR-23a overexpression.
cDNA library preparation and Next Generation Sequencing were performed at the GMAK, HZI
Brunswick. For mRNA sequencing, poly A enrichment was applied. For small RNA sequencing
no enrichment was performed. All Ago2-RIP samples were sequenced (50 bp single-end) on
the Illumina High Seq 2500.
Sequencing yield was 20-50 Mio reads per mRNA sample and 12-16 Mio reads per small RNA
sample. Reads were trimmed form adapter sequences and low quality bases, mapped to the
human genome (hg38) by STAR and counted by HTseq. Normalization was performed accord-
ing to total number of reads within a sample and between samples , followed by the comparison
of the sequences according to the scheme in fig. 3.18 (Claudia Pommerenke, unpublished).
Thresholds for differentially expressed genes were set to at least two-fold enrichment and a
Benjamini-Hochberg adjusted p-value lower than 0.05.
The mapping efficiency of ~83% of all reads to the human genome resulted in ~25 Mio uniquely
mapped reads per sample, which is suitable to analyze global gene expression profiles (fig.
3.23).
Principal Component Analyses (PCA) of all sequencing data showed that the input and output
samples formed as expected two different groups distinct from each other (fig. 3.24). The only
exception was input sample ns ctrl1 batch b (fig. 3.24 blue squares b), which differs from all
other samples.
In summary, the sequencing data obtained from the input and output samples of Ago2-RIP
were consistent and reliable. Hence, they could further be analyzed as depicted in fig. 3.18.
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Figure 3.23.: Alignment efficiency for all mRNA sequencing samples
Sequences gained by mRNA sequencing of Ago2-RIP samples were mapped to human genome (hg38). Percent
of uniquely mapped reads to annotated gene regions of Ago2-RIP samples are depicted in green. Light grey:
sequences, that are too short for uniquely mapping to annotated regions. Dark grey: sequences that could not
be uniquely aligned. (a) Ago2-RIP samples of U2932 R1 miR-23a1 and ns ctrl1. (b) Ago2-RIP samples of U2932
R1 miR-23a1 and ns ctrl 1. Note, that ns1 ctrl samples are identical in (a) and (b). a, b, c = different triplicates,
Ago_XXX_X = output sample, miR/ns_X = input sample.
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Figure 3.24.: Principal component analysis of Ago2-RIP RNA sequencing samples
PCA analyses of mRNA sequencing data gained from Ago2-RIP input and output samples: (a) miR-23a1 compared
to ns ctrl1 Ago2-RIP RNA sequencing samples. (b) miR-27a1 compared to ns ctrl1 Ago2-RIP RNA sequencing
samples. a, b, c = different triplicates of Ago2-RIP RNA samples, black squares = Ago2-RIP output RNA sequenc-
ing samples of U2932 R1 pGIPZ miR-23a1/miR-27a1, red squares = Ago2-RIP output RNA sequencing samples
of U2932 R1 pGIPZ ns ctrl1, green squares = Ago2-RIP input RNA sequencing samples of U2932 R1 pGIPZ
miR-23a1/miR-27a1, blue squares = Ago2-RIP input RNA sequencing samples of U2932 R1 pGIPZ ns ctrl 1.
3.2.8. MiR-23a and miR-27a targetome in DLBCL
In order to identify the miR-23a and miR-27a targetome, Ago2-RIPs were performed for the
miRNA overexpressing cell lines U2932 R1 pGIPZ miR-23a1, miR-27a1 and ns ctrl1 (detailed
description in section 3.2.1, fig. 3.17 and 3.18). Total RNA of input and output samples was
sequenced. Additionally, small RNA sequencing was performed for the inputs of U2932 R1
pGIPZ miR-23a1 and ns ctrl1.
As a proof of principle, small RNA sequencing revealed that only miR-23a was highly enriched
(190-fold) in the miR-23a overexpressing cell line compared to ns ctrl cell line (fig. 3.25 in-
ner circle). However, also seven other miRNAs (miR-3919, miR-4662B, miR-618, miR-129-1,
miR-199B, miR-99a and miR-150) were enriched, but the base mean values of these miR-
NAs lay between 11-300 reads compared to 29643 reads for miR-23a. It is therefore highly
probable, that the identified targets are only targeted by miR-23a and no other miRNA.
In total, the comparison of enriched RNA sequences from Ago2-RIP input to output of miR-23a
or miR-27a overexpressing cells to non silencing control cells lead to the identification of 26
miR-23a and 20 miR-27a targets in the DLBCL cell line U2932 R1 (fig. 3.25 and 3.26, table 3.1
and 3.2). The threshold of enrichment was set to a minimum of two-fold and the p-value was
set to less than 0.05 (see section 3.2.7). Many of the targets were already predicted by the
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algorithm the web tool “Target Scan” uses. Nearly all identified targets (see table 3.3 and 3.4)
harbor at least one miR-23a or miR-27a 7mer binding sites. Notably, most binding sites are
located in the 3’UTR, except for the identified Zinc finger proteins (ZNFs), which have more
miR-23a 7mer binding sites in their coding sequences (CDS).
Interestingly, this approach also detected two long non coding RNAs (lncRNA), one targeted
by miR-23a the other by miR-27a. Long non-coding RNAs are transcribed by Pol II and are
therefore also polyadenylated. Since the RNA samples were enriched over poly A tails at cDNA
synthesis, it is not surprising to find lncRNAs among the sequencing data. Nevertheless, this
study focused on the protein coding mRNAs that are targeted by the MIR23A cluster.
For miR-23a 25 novel protein coding target mRNAs were identified for DLBCL cell line U2932
R1. 12 of them were zinc finger proteins, that contain a DNA binding ZNF domain. All these
identified ZNFs belong to the same protein family: KRAB-C2H2-ZNFs. Members of this family
comprise a high sequence homology, which might be an explanation why so many are targeted
by miR-23a. Notably, many ZNFs as well as other miR-23a targets are encoded on chromo-
some 19, where also the MIR23A cluster itself is encoded. In fact, the identified ZNFs belong
to two separate ZNF clusters, that were generated due to gene duplication during evolution:
ZNF cluster 269 on chromosome 19 and ZNF cluster 114 on chromosome 7. For the other
miR-23a targets no such similarities could be identified. Those targets, that are already de-
scribed, function in a wide range of cellular processes (table 3.1). The same is true for the 19
newly identified protein coding mRNAs of miR-27a (table 3.2). Strikingly, many of the miR-27a
targets are encoded on chromosome 19, as already observed for the miR-23a targets.
Taken together, 37% of all identified miR-23a and miR-27a targets are encoded on chromo-
some 19, where also the MIR23A is encoded, indicating an unknown mechanism underlying
these observations (see section 3.2.8.1).
Comparing the identified miR-23a/27a targets with the differentially expressed genes between
miRNA overexpressing cell line compared to control (at least two-fold difference), 12 of 46
targets are differentially expressed (fig. 3.27). These targets are possibly targeted for RNA-
degradation by the respective miRNA (Braun et al., 2011). Technically, the miRNA effect on
these targets can be analyzed by qRT-PCR.
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Figure 3.25.: MiR-23a targetome and differentially expressed transcripts in U2932 R1 pGIPZ
miR-23a1 vs. ns ctrl1
Outer circle: differential expressed transcripts (log2FC) of miR-23a1 clone vs. non silencing control clone. blue:
downregulated, red: upregulated; middle circle: chromosomal localization of identifiedmiR-23a targets (enrichment
at least two-fold, p-value ≤ 0.05); inner circle: differential expressed miRNAs (log2FC) of miR-23a1 clone vs. non
silencing control clone. blue: downregulated, red: upregulated; DE: differential expression, FC: fold change.
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Figure 3.26.: MiR-27a targetome and differentially expressed transcripts in U2932 R1 pGIPZ
miR-27a1 vs. ns ctrl1
Outer circle: differentially expressed transcripts (log2FC) of miR-27a1 clone vs. non silencing control clone. blue:
downregulated, red: upregulated; middle circle: chromosomal localization of identifiedmiR-27a targets (enrichment
at least two-fold, p-value≤ 0.05); inner circle: differentially expressed miRNAs (log2FC) of miR-27a1 clone vs. non
silencing control clone. blue: downregulated, red: upregulated; DE: differential expression, FC: fold change.
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Table 3.1.: miR-23a targets in DLBCL cell line U2932 R1
gene description chromosome log2(fc) padj predicted
ZNF92 zinc finger protein 92 7 3.21 1.06E-04 yes
ZNF708 zinc finger protein 708 19 3.05 4.41E-04 yes
KIAA1467 KIAA1467 12 2.69 5.31E-13 yes
ZNF257 zinc finger protein 257 19 2.62 3.36E-03 yes
ZNF253 zinc finger protein 253 19 2.56 1.17E-02 yes
UQCR10 ubiquinol-cytochrome c re-
ductase, complex III subunit
X
22 2.49 3.20E-02 no
ZNF254 zinc finger protein 254 19 2.44 1.27E-02 yes
ZNF273 zinc finger protein 273 7 2.43 1.12E-02 yes
WBP2 WW domain binding protein
2
17 2.42 1.78E-03 yes
MALSU1 mitochondrial assembly of ri-
bosomal large subunit 1
7 2.32 3.88E-04 no
IGSF8 immunoglobulin superfamily,
member 8
1 2.22 3.90E-02 yes
ZNF43 zinc finger protein 43 19 2.19 2.79E-02 yes
NDUFA2 NADH dehydrogenase
(ubiquinone) 1 alpha sub-
complex, 2
5 2.17 4.11E-02 yes
RP11-1017G21.5 lncRNA RP11-1017G21.5 14 2.08 3.09E-02 no
ZNF430 zinc finger protein 430 19 1.95 3.77E-02 yes
CNN2 calponin 2 19 1.95 3.36E-03 yes
ZNF138 zinc finger protein 138 7 1.91 3.17E-02 yes
VRK3 vaccinia related kinase 3 19 1.75 1.25E-05 yes
SDHD succinate dehydrogenase
complex, subunit D, integral
membrane protein
11 1.72 3.17E-02 yes
ZNF85 zinc finger protein 85 19 1.62 6.56E-03 yes
PNRC2 proline-rich nuclear receptor
coactivator 2
1 1.61 3.88E-04 yes
CRIPT cysteine-rich PDZ-binding
protein
2 1.60 2.79E-02 no
ZNF93 zinc finger protein 93 19 1.50 8.97E-03 yes
DUSP5 dual specificity phosphatase
5
10 1.38 1.27E-02 yes
ZNF195 zinc finger protein 195 11 1.33 3.17E-02 yes
STK35 serine/threonine kinase 35 20 1.18 3.09E-02 yes
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Table 3.2.: miR-27a targets in DLBCL cell line U2932 R1
gene description chromosome log2(fc) p value predicted




6 3.26 1.45E-03 n.d.
PLEKHJ1 pleckstrin homology domain
containing, family J member
1
19 2.90 3.42E-03 no
TOR2A torsin family 2, member A 9 2.84 1.43E-02 no
C12orf73 chromosome 12 open read-
ing frame 73
12 2.50 8.63E-05 yes
CLECL1 C-type lectin-like 1 12 2.15 1.03E-03 yes
LIMK1 LIM domain kinase 1 7 1.90 1.23E-02 yes
EEF1A1P16 eukaryotic translation elon-
gation factor 1 alpha 1 pseu-
dogene 16
12 1.83 2.63E-03 n.d.
DPF1 D4, zinc and double PHD fin-
gers family 1
19 1.80 1.40E-02 no
BBC3 BCL2 binding component 3 19 1.77 3.92E-03 yes
FBXO46 F-box protein 46 19 1.68 4.99E-02 yes
CALM3 calmodulin 3 (phosphorylase
kinase, delta)
19 1.68 1.68E-03 yes
C2orf44 chromosome 2 open reading
frame 44
2 1.68 3.55E-08 no
FAM193B family with sequence similar-
ity 193, member B
5 1.51 3.20E-05 yes
WDYHV1 WDYHV motif containing 1 8 1.50 1.36E-03 no
CEBPG CCAAT/enhancer binding
protein (C/EBP), gamma
19 1.33 1.36E-03 no
TSPYL1 TSPY-like 1 6 1.30 1.27E-03 no
FAM206A family with sequence similar-
ity 206, member A
9 1.23 1.28E-02 yes
FAM98A family with sequence similar-
ity 98, member A
2 1.22 1.91E-02 yes
PRCP prolylcarboxypeptidase (an-
giotensinase C)
11 1.14 1.27E-03 no
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Table 3.3.: Number and location of 7 mer miR-23a binding sites in identified miR-23a targets
target 3’UTR CDS 5’UTR
CNN2 1 0 0
CRIPT 3 1 0
DUSP5 1 0 0
IGSF8 2 1 0
KIAA1467 3 1 0
MALSU1 0 1 0
NDUFA2 2 0 0
PNRC2 4 0 0
SDHD 3 0 0
STK35 5 3 0
UQCR10 2 0 0
VRK3 2 5 0
WBP2 2 0 0
ZNF138 34 27 1
ZNF195 10 77 2
ZNF253 3 21 0
ZNF254 5 45 0
ZNF257 5 28 1
ZNF273 4 19 0
ZNF43 6 89 4
ZNF430 5 28 0
ZNF708 4 20 0
ZNF85 6 158 0
ZNF92 3 58 2
ZNF93 1 10 0
RP11-1017G21.5 n.d. 1 n.d
Table 3.4.: Number and location of 7 mer miR-27a binding sites in identified miR-27a targets
target 3’UTR CDS 5’UTR
BBC3 2 0 0
C12orf73 1 0 0
C2orf44 4 2 0
CALM3 1 0 0
CEBPG 1 1 1
CLECL1 5 0 0
DPF1 1 9 0
FAM193B 1 5 6
FAM206A 2 0 0
FAM98A 1 0 1
FBXO46 1 0 0
LIMK1 3 1 0
PLEKHJ1 3 0 0
PRCP 0 2 0
TOR2A 4 0 0
TSPYL1 1 1 0
WDYHV1 1 4 2
HNRNPLP1 n.d. 3 n.d.
EEF1A1P16 n.d. 0 n.d.
CTC-246B18.10 n.d. 1 n.d.
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Figure 3.27.: Differentially expressed miR-23a and miR-27a targets
Dark grey: number of differentially expressed genes between (a) miR-23a overexpressing cell line compared to non
silencing control (ns ctrl) and (b) miR-27a overexpressing cell line compared to ns ctrl. light grey: newly identified
miR-23a/-27a targets. overlap: differentially expressed miR-23a/-27a targets.
3.2.8.1. Clustering of miR-23a and miR-27a target genes on chromosome 19
When examining the lists of newly identified miR-23a and miR-27a targets in detail (table 3.1
and 3.2 ), one can observe that 17 of 46 identified targets (37%) are encoded on chromosome
19, where also the MIR23A cluster is encoded (fig. 3.28). Plotting the number of identified
miR-23a/27a targets against the number of expressed genes per chromosome, one can ob-
serve a linear positive correlation (fig. 3.29). The more genes are expressed from a certain
chromosome, the more targets are identified from it. However, chromosome 19 shows a clear
overrepresentation of miR-23a/27a target genes compared to other chromosomes. Moreover,
chromosome 7 also codes for slightly more miR-23a/27a targets than expected for a linear
correlation of miRNA targets and expressed genes per chromosome.
3.2. IDENTIFICATION OF THE MIR23A TARGETOME 89
Figure 3.28.: Clustering of targets on chromosome 19
Location of the MIR23A cluster compared to the identified miR-23a and miR-27a targets that are also encoded on
chromosome 19.
Figure 3.29.: MiR-23a and miR-27a targets are enriched on chromosome 19
Number of genes expressed per chromosome in ns ctrl 1 cell line plotted against the number of identified targets
per chromosome.
A possible explanation for this observation could be, that the model cell line expresses more
transcripts encoded on chromosome 19 than transcripts from other chromosomes, leading to
an increased probability of the miRNAs to target those transcripts. However, this was not the
case. As depicted in fig. 3.30 a) the most expressed transcripts are encoded by chromosome
1. The transcript expression of chromosome 19 was similar to that of chromosome 2,3,11,12
and 17, which showed no accumulation of targets.
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Figure 3.30.: Transcripts of chromosome 19 are not overrepresented
Transcript expression analyses of U2932 R1 pGIPZ non silencing control cell line 1 (a) Sum of reads per chromo-
some. (b) normalized gene expression for all genes (red), identifiedmiR-23a/-27a targets encoded on chromosome
19 (blue) and identified miR-23a/-27a targets encoded on other chromosomes (green).
Moreover, it was tested whether miR-23a/miR-27a targets are overexpressed compared to
other genes (fig. 3.30 b). Neither the expression of miR-23a/miR-27a targets on chromosome
19, nor the expression of miR-23a/miR-27a targets on the other chromosomes differed from
the mean expression of all genes. The transcripts of chromosome 19 are not overrepresented
in the cell.
One further reason, that could explain the observation of target clustering on chromosome 19,
could be that chromosome 19 codes for more miR-23a and miR-27a binding sites in the 3’UTR
of its expressed genes. Plotting the number of miR-23a/27a binding sites against the number of
3’UTRs per Mb per chromosome, one can observe the exact opposite: the miR-23a/-27a bind-
ing sites are underrepresented in the 3’UTR of chromosome 19 transcripts (fig. 3.31).
Taken together, the observation that the miR-23a/27a targets cluster on chromosome 19 is not
due to overrepresentation of transcripts encoded on chromosome 19, nor due to accumulation
of miRNA binding sites in transcripts encoded by chromosome 19.
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Figure 3.31.: MiR-23a/-27a binding sites are underrepresented on chromosome 19 transcripts
Percentage of 7mer binding sites for miR-23a (a) and miR-27a (b) in 3’UTRs of genes expressed in ns ctrl1 cell
line in respect to chromosomal gene density.
3.2.9. Validation of Ago2-RIP targets
The Ago2-RIP approach led to a list of 26 miR-23a and 20 miR-27a newly identified mRNA
targets in U2932 R1, from which three were chosen for in vitro validation. Selection criteria
were: transcript expression, high enrichment in Ago2-RIP samples, p-value, possible contribu-
tion in tumorigenesis, availability of an specific antibody and previous description as a MIR23A
target in literature. Since miRNAs inhibit protein biosynthesis, the protein levels of the target
candidates were investigated in miR-23a/miR-27a overexpressing cells compared to control
cells.
3.2.9.1. VRK3 protein is not regulated by miR-23a
The newly identified miR-23a target vaccina related kinase 3 (VRK3) was chosen for validation
on protein level. VRK3 is a serine/threonine kinase, localized to the endoplasmatic reticulum
(ER) and the nucleus. It was 3.3-fold enrichedwith a very low p-value of 1.25x10−5 in miR-23a1
Ago2-RIP samples compared to control (table 3.1). VRK3 was shown to play an important role
in negative feedback loop of MAPK/ERK signaling by targeting a phosphatase of ERK (Kang
and Kim, 2006). Because MEK/ERK signaling was identified to activate the MIR23A cluster
(section 3.1.3), VRK3 might therefore be involved in a negative feedback loop of MIR23A
activation upon BCR stimulation.
To test whether VRK3 protein level is indeed downregulated by miR-23a, total cell lysates of
stable miR-23a overexpressing clones were analyzed by Western blotting using an antibody
specific against VRK3 (fig. 3.32). Comparing the intensity of the VRK3 protein band on West-
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Figure 3.32.: VRK3 protein levels are not changed by miR-23a overexpression
Western blot of VRK3 in total cell lysates of U2932 R1 pGIPZ miR-23a/27a or non silencing control overexpressing
clones. Loading control: GAPDH, one representative result of three is shown.
ern blot membrane, no difference between miR-23a overexpressing U2932 R1 pGIPZ clones
vs. ns ctrls or miR-27a overexpressing clones could be observed. Consequently, VRK3 protein
levels are, at least under default conditions, not downregulated by miR-23a.
3.2.9.2. LIMK1 protein is downregulated by miR-27a
The novel identified miR-27a target, LIM domain kinase 1 (LIMK1) was chosen for validation
on protein level. It was enriched 3.7-fold in miR-27a1 Ago2-RIP samples compared to con-
trols with a p-value of 1.23x10−2 (table 3.2). The LIMK1 is a serine/threonine kinase, that is
implicated in migration by inhibition of Cofilin (Arber et al., 1998) and in mitosis by inhibition of
p25/TPPP (Acevedo et al., 2007) (for details see discussion). Additionally, LIMK1 was already
shown to be a target of the paralogous miR-27b in non small cell lung cancer (NSCLC), where
it regulates invasion and proliferation (Wan et al., 2014).
To validate LIMK1 as a miR-27a target in DLBCL, LIMK1 protein levels from total cell lysates of
miR-27a stable overexpressing U2932 R1 pGIPZ clones and ns ctrl clones were compared by
Western blotting (fig. 3.33 a). The LIMK1 protein levels are downregulated to 38% in miR-27a1
and to 28% in miR-27a10 stable overexpressing U2932 R1 pGIPZ clones. The sister clone
U2932 R2, which expresses higher miR23A levels than the U2932 R1 clone (fig. 3.11) shows
also considerable low LIMK1 levels. Surprisingly, the U2932 R1 pGIPZ miR-23a1 clone shows
also a slight downregulation of LIMK1 to 76%. However, the miR-23a2 clone showed no such
effect. The ns ctrl 3 clone is different from the other two control clones, hence LIMK1 level
are downregulated by 17%. This observation may be due to other reasons, but not a direct
miR-27a effect.
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Figure 3.33.: LIMK1 is a miR-27a and miR-23a target
(a) Total cell lysates of U2932 R1 pGIPZ non silencing control, miR-23a or miR-27a stable overexpressing clones.
(Loading control: GAPDH, one representative result of three is shown). b) Total cell lysates of parental U2932 R1
48 h post transient transfection with miR-23a, miR-27a or miR-23a~27a expression vector (pSG5). 5 μg plasmid
DNA per 5x106 cells, one representative result of three is shown. (c) corresponding relative expression of miR-23a
and miR-27a upon transfection in U2932 R1. Endogenous control: GAPDH.
To validate these results and to clarify whether miR-23a also targets LIMK1, transient over-
expression experiments were performed. Therefore, the parental cell line U2932 R1 was
transfected with pSG5_miR-23a, pSG5_miR-27a or pSG5_miR-23a~27a expression vector
(section 3.2.2). Mature miR-23a and miR-27a expression levels were detected by qRT-PCR
(fig. 3.33 c) and LIMK1 protein levels were analyzed by Western blotting 48 hours after trans-
fection (3.33 b). Indeed, the LIMK1 protein levels decreased by 25%, when miR-27a was
overexpressed only 5-fold compared to empty vector pSG5. Furthermore, the double trans-
fection with miR-23a and miR-27a, which led to higher levels of miR-27a (ca. 9-fold) than the
single-miR-27a transfection, decreased LIMK1 levels to a higher degree (down to 47%). To
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test whether this effect was due to higher miR-27a level or due to an additive effect of miR-23a,
the same cells were transfected with miR-23a alone. Surprisingly, the same effect (downreg-
ulation to 47%) could also be obtained when overexpressing miR-23a 20-fold higher than the
empty vector control.
Taken together, LIMK1 protein levels are downregulated bymiR-23a andmiR-27a in stable and
transient miRNA overexpressing experiments for DLBCL cell line U2932 R1, although LIMK1
mRNAwas only 3.7-fold enriched in miR-23a Ago2-RIP samples compared to ns control.
3.2.9.3. PUMA protein can not be induced in miR-27a overexpressing cells
BCL-2 binding component 3 (BBC3) or P53 upregulated modulator of apoptosis (PUMA) is
a pro-apoptotic protein and was described as a tumor suppressor in different cancer entities.
It was chosen as a target candidate for validation on protein level, because it was enriched
3.4-fold, had a good p-value of 3.92x10−3 (see table 3.2) and is implicated in apoptosis, which
plays an important role during B cell maturation process (section 1.1). Moreover, it was shown
in mice, that PUMA is targeted by mmu-miR-23a and mmu-miR-27a in a traumatic brain injury
model (Sabirzhanov et al., 2014).
Because of low PUMA levels, it was difficult to detect PUMA by Western blotting. Conse-
quently, PUMA levels were induced by etoposide treatment of miR-27a or ns ctrl overexpress-
ing U2932 R1 pGIPZ clones. Etoposide induces DNA double strand breaks, that activate p53,
which subsequently induces PUMA. Although p53 was induced in all samples upon etoposide
treatment, only the β-isoform, but not the α-isoform, of PUMA was induced in the parental
cell line U2932 R1 and the ns ctrl clones (fig. 3.34). Notably, PUMA-β was not induced in the
miR-27a overexpressing clone miR-27a1. It seems as if it is only slightly induced in miR-27a10
clone, but this is due to unequal loading as indicated by the endogenous control GAPDH.
When comparing the basal PUMA levels in DMSO treated controls of the stable overexpress-
ing clones to ns ctrl clones, unexpectedly no regulatory pattern could be observed. Obviously,
PUMA has to be induced in order to monitor the inhibitory miR-27a effect.
In summary, the expression of PUMA-β isoform is inhibited bymiR-27a upon etoposide-induced
DNA damage in DLBCL cell line U2932 R1.
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Figure 3.34.: PUMA is a miR-27a target
U2932 R1 pGIPZ miR-27a and non silencing control (ns ctrl) overexpressing cells were treated for 7 hours with 100
μM etoposide (+) or 1:500 DMSO (-). Loading control: GAPDH, one representative experiment of three is shown.
3.3. MIR23A function
3.3.1. Global affected processes by miR-23a or miR-27a overexpression
The identification of the direct miR-23a and miR-27a targets in DLBCL cell line U2932 R1 by
Ago2-RIP resulted in two different gene sets with no overlap. Thus, miR-23a andmiR-27a have
distinct direct targets. However, it is likely that miRNAs of the same cluster act in the same
cellular processes. Because miRNA overexpression resulted in differential gene expression
profiles, these genes can be considered as indirect miRNA targets. Their expression is not
altered by direct binding of the miRNA and subsequently inhibition of proteinbiosynthesis, but
by indirect means, such as downregulation of a transcriptional repressor or activator, etc..
To analyze in which biological processes these indirect targets are involved, gene ontology
analyses for differentially expressed genes were performed.
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Figure 3.35.: Top 20 GO terms enriched in U2932 R1 pGIPZ miR-23a1 vs. ns ctrl1
Hypergeometrical test for overrepresentation of gene ontology terms (GO) of differentially expressed genes be-
tween U2932 R1 pGIPZ miR-23a1 and ns ctrl1 cell lines. FDR = false discover rate. Shown are GO terms with
p-value ≤0.05. FDR = false discovery rate, FDR q-value is the correction of the p-value for multiple testing using
the Benjamini and Hochberg method.
Gene ontology analyses of differentially expressed genes (DEG) upon miR-23a overexpres-
sion in U2932 R1 show that genes are affected, which are involved in many different cellu-
lar processes (fig. 3.35). Notably, processes involved in ribosomal protein biosynthesis are
enriched. Additionally, processes that direct proteins to membranes emerge, indicating that
protein trafficking or secretion might be affected by miR-23a overexpression. Gene ontology
terms related to a virus might be explained by the lentivirus, that was introduced to gain miRNA
overexpression in these cells.
Figure 3.36.: GO terms enriched in U2932 R1 pGIPZ miR-27a1 vs. ns ctrl1
Hypergeometrical test for overrepresentation of gene ontology terms (GO) of differentially expressed genes be-
tween U2932 R1 pGIPZ miR-27a1 and ns ctrl1 cell lines. FDR = false discover rate. Shown are GO terms with
p-value ≤0.05. FDR = false discovery rate, FDR q-value is the correction of the p-value for multiple testing using
the Benjamini and Hochberg method.
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Gene ontology analyses of differentially expressed genes upon miR-27a overexpression in
U2932 R1 revealed interestingly only two significantly enriched GO terms: “regulation of apop-
totic process” and “regulation of programmed cell death” (fig. 3.36). This was one reason to
test the rate of apoptosis in U2932 R1 miR23a/27a overexpressing cells (fig. 3.38).
To assess a possible cooperative effect of miR-23a andmiR-27a the overlap of differentially ex-
pressed genes upon miR-23a and miR-27a overexpression in U2932 R1 was analyzed. These
overlap generated a list of 104 genes that are affected by overexpression of both, miR-23a and
miR-27a (fig. 3.37 and table A.1). Surprisingly, GO term analyses with these genes could not
identify significantly enriched cellular processes, indicating that miR-23a and miR-27a act sep-
arately to regulate different cellular processes.
Figure 3.37.: Venn diagram of DEG of miR-23a1 vs. ns ctrl1 compared to ns ctrl1 vs. miR-27a1
Differentially expressed genes (DEG) of U2932 R1 pGIPZ miR-23a1 vs. ns ctrl1 compared to ns ctrl1 vs. miR-27a1
identifies 104 genes affected by both, miR-23a and miR-27a overexpression.
In conclusion, miR-23a and miR-27a might act separately regulating different cellular pro-
cesses. Neither the overlap of direct nor indirect miR-23a with miR-27a targets leads to a
significant enrichment of GO terms using a hypergeometrical test.
3.3.2. miR-27a attenuates the sensitivity of DLBCL cells to undergo apoptosis
The pro apoptotic protein PUMA could be validated in U2932 R1 as amiR-27a target on protein
level (section 3.2.9.3), favouring together with theGO term analyses of indirect miR-27a targets
(fig. 3.36) apoptosis as a possible cellular function in which theMIR23A cluster is involved. The
introduction of DNA double strand breaks led to the induction of p53, which in turn activated
the β-isoform of PUMA in the control cells (parental cell line U2932 R1 and U2932 R1 pGIPZ
ns ctrl1 and 2), but not in the miR-27a overexpressing cells (fig. 3.34). Furthermore, also
LIMK1, which could also be validated as an miR-27a target on protein level (section 3.2.9.2),
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was shown to be implicated in apoptosis (Tomiyoshi et al., 2004). It is therefore probable that
overexpression of miR-27a attenuates apoptosis by targeting PUMA-β and LIMK1.
To test this hypothesis, apoptosis was induced for 16h in the parental cell line U2932R1 and the
stable miR-23a, miR-27a and ns ctrl overexpressing U2932 R1 pGIPZ clones using etoposide.
The apoptosis rate was determined by AnnexinV/7AAD staining following FACS analyses.
Percent of positive cells were normalized to DMSO control (fig. 3.38, for FACS profiles see
supplementals).
Figure 3.38.: Overexpression of miR-27a reduces sensitivity to etoposide induced apoptosis in
DLBCL cell line U2932 R1
Parental cell line U2932 R1, U2932 R1 non silencing control (ns1, ns2), miR-23a (miR-23a1, miR-23a2) and
miR-27a (miR-27a1, miR27a10) overexpressing cell lines were treated for 16h with 100 μM etoposide to induce
apoptosis. Cells were double stained with Annexin V-PE and 7AAD prior to FACS analysis. Mean +/- SD, n=3,
students t-test, *p≤0.05
Comparing the induction of Annexin V positive cells from parental cell line U2932 R1 to U2932
R1 pGIPZ non silencing control cell lines ns ctrl1 and ns ctrl2, one can observe an higher
apoptosis rate for the control clones. The parental clone showed an induction rate of 7-fold
compared to DMSO treated control, while ns ctrl cell lines showed an induction rate of approx-
imately 11-fold. It may be speculated that the genetical modification of the cells by insertion of
the lentivirus, overexpression of eGFP as well as overexpression of an hairpin sequence might
induce cellular stress leading to an enhanced disposition to undergo apoptosis. Therefore, the
correct controls to compare the miRNA overexpressing clones to, are the non silencing control
cell lines. While U2932 R1 pGIPZ ns ctrl cells have an induction rate of early apoptotic cells
(Annexin V positive) of 11-fold, the miR-23a overexpressing clones show decreased apoptotic
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rates of 7-fold. Notably, the miR-27a overexpressing clones show a significant reduction of
apoptosis rate (5-fold) compared to controls. The rate of double positive (Annexin V/7AAD)
late apoptotic or dead cells is not affected by miRNA overexpression.
In conclusion, the overexpression of miR-23a and miR-27a reduces the ability of etoposide
treated cells to undergo apoptosis.
3.4. The MIR23A cluster in BL and DLBCL patients
The role of the MIR23A cluster is discussed controversially in literature. Although intensively
investigated in many different human diseases and cancers, the miRNAs encoded in this clus-
ter can have diverse functions. MiR-23a was reported to act as a tumor suppressor or as an
onco-miR, depending on the cellular context (Cao et al., 2012; He et al., 2014). Nevertheless,
several studies have shown altered expression of MIR23A cluster in different cancers, among
these also some hematopoietic malignancies (APL (Saumet et al., 2009), ALL and AML (Mi
et al., 2007)). For B-NHL it was shown by Lenze et al. that miR-23a is differentially expressed
between BL vs. DLBCL (Lenze et al., 2011). Wang et al. already indicated that miR-23a is
aberrantly expressed in DLBCL compared to healthy controls (Wang et al., 2014). However,
the expression status of the whole MIR23A cluster in DLBCL compared to germinal center
cells, which are the healthy progenitor cells from which DLBCL develops, was unknown so
far.
Therefore, the publicly available data base of the International Cancer Genome Consortium
(ICGC) Project “Determining Molecular Mechanisms in Malignant Lymphoma by Sequencing”
(ICGC-MMML, release v22, published in (Hezaveh et al., 2016)) was retrieved to compare the
MIR23A expression of BL and DLBCL patients to healthy GCBs (fig. 3.39). The differential
expression of miR-23a in BL vs. DLBCL described by Lenze et al. in 2011 could be verified.
Additionally, the comparison of the MIR23A cluster expression of BL and DLBCL patients to
healthy GCBs reveals a significant overexpression of miR-23a, miR-27a and miR-24 in the
patient samples (fig. 3.39).
Taken together, the patient sequencing data show that the whole MIR23A cluster is aberrantly
activated in BL and in DLBCL compared to healthy controls (GCBs).
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Figure 3.39.: MIR23A cluster expression in B-NHL patients
MicroRNA sequencing data of 14 BL and 16 DLBCL patients compared to GCB isolated from three healthy controls
(ICGC v22 published in Hezaveh et al. 2016). Mann-Whitney U-test *p≤ 0.05.
3.4.1. Expression of newly identified and validated miR-23a and miR-27a targets in BL and
DLBCL patients
The observation that MIR23A levels are aberrantly high in BL and DLBCL compared to controls
raises the question which consequences arise from this aberrant high expression of MIR23A
cluster for the DLBCL patients. Wang et al. showed already in 2014 that high miR-23a lev-
els were correlated with a worse overall survival rate of DLBCL patients. Thus, the MIR23A
cluster might have an onco-miR function in DLBCL. Although a miRNA does not necessarily
downregulate their targets on RNA level, the expression of the direct miR-23a/27a targets,
identified in this study, were analyzed for BL and DLBCL patients on RNA sequencing data
provided by the ICGC data base.
Although VRK3 protein could not be validated to be downregulated by miR-23a overexpres-
sion under normal conditions in DLBCL cell line U2932 R1 (fig. 3.32), its mRNA levels are
decreased in BL and DLBCL patients compared to healthy GCBs (fig. 3.40 a).
In the case of LIMK1, a validated target gene of miR-27a in this study (fig. 3.2.9.2), BL and
DLBCL patients show a decrease in LIMK1 mRNA levels (fig. 3.40 b).
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Figure 3.40.: MiR-23a and miR-27a target expression in BL and DLBCL patients
Expression of selected targets in BL and DLBCL patients and normal GCBs (ICGC v22 published in Hezaveh et
al. 2016). (a) Expression of possible miR-23a target VRK3. (b) Expression of validated miR-27a target LIMK1. (c)
Expression of validated miR-27a target PUMA. (d) Expression of ZNFs that are targeted by miR-23a. BL = Burkitt
lymphoma, DLBCL = diffuse large B cell lymphoma, GCB = germinal center B cells, VRK3 = Vaccina related
kinase 3, LIMK1 = LIM domain kinase 1, PUMA = p53 upregulated modulator of apoptosis, ZNF = zinc finger.
Mann-Whitney U-test *p≤ 0.05.
In contrast, the mRNA levels of validated miR-27a target PUMA (fig. 3.34) are downregulated
in BL, whereas the mean expression of DLBCL patients is higher compared to controls (fig.
3.40 c).
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Interestingly, most ZNFs, that were identified as possible miR-23a targets in DLBCL model cell
line U2932R1, are downregulated in BL andDLBCL patients compared to healthyGCBs.
In general, miRNA regulation in mammalia must not result in downregulation of target mRNA
levels. However, the mRNA transcripts of VRK3, LIMK1 and most ZNFs are decreased in
B-NHL compared to healthy GCBs.
4. Discussion
This study had two major aims: the first one was to identify signaling pathways that regulate
the expression of MIR23A cluster in DLBCL, in order to enlighten the processes that lead
to aberrant high MIR23A cluster expression in DLBCL. The second aim was to identify the
targetomes of miR-23a and miR-27a in DLBCL in order to predict the cellular functions in
which miR-23a and miR-27a are involved and to test the onco-miR hypothesis for the MIR23A
cluster.
DLBCL and BL patients show increased miR-23a levels compared to healthy controls (Wang
et al., 2014) (fig. 3.39), indicating that the MIR23A cluster is de-regulated in aggressive B cell
lymphoma. Furthermore, DLBCL patients with higher miR-23a levels show a worse overall
survival rate than patients with low miR-23a levels, suggesting the MIR23A cluster to have a
onco-miR function in DLBCL (Wang et al., 2014).
This thesis shows that the MIR23A cluster is activated by BCR signaling in BL and DLBCL cell
lines. In detail, the BCR downstream MEK/ERK signaling cascade was identified to mediate
the activation of MIR23A cluster in DLBCL cell lines. Furthermore the onco-miR hypothesis
for the MIR23A cluster in DLBCL could be supported by identification and validation of the
miR-23a and miR-27a specific targetome in a DLBCL model cell line.
4.1. Regulation of the MIR23A cluster
4.1.1. BCR signaling activates the MIR23A cluster
This study identified MEK/ERK dependent BCR signaling in DLBCL cell lines as a general
mechanism responsible for the activation of the MIR23A cluster.
The MIR23A cluster is activated during normal GC reaction: while naive B cells and centro-
blasts show low MIR23A cluster expression, memory B cells have high MIR23A cluster ex-
pression (Malumbres et al., 2009; Tan et al., 2009; Zhang et al., 2009; Iqbal et al., 2015). DL-
BCL develops from GCB cells, thus DLBCL cells still harbor GC characteristics and a related
gene expression profile (Küppers, 2005). However, tumor samples of DLBCL patients express
aberrant high MIR23A levels compared to healthy controls ((Wang et al., 2014) and fig. 3.39).
Notably, the healthy controls used in both studies were different. Wang et al. used paraffin em-
bedded reactive lymph nodes, while primary tonsillar GCBs were sorted in the ICGC-MMML
project to get a normal control, which represents the precursor cells from BL and DLBCL. How-
ever, the results were similar. This indicates that a deregulated process during GC reaction
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might lead to aberrant high MIR23A cluster expression in GC derived lymphoma. The BCR
signaling, which plays a key role in GC reaction (section 1.2.1), was identified in this study to be
responsible for MIR23A cluster activation. This might be a general mechanism for GC derived
lymphoma, since BCR dependent activation of the MIR23A cluster was observed in several
DLBCL and one BL cell line (section 3.1.3). The observation, that CD77 positive GCBs isolated
from human pediatric tonsils, which represent centroblasts (Pascual et al., 1994; Klein et al.,
2003), did not respond to BCR stimulation with an upregulation of MIR23A cluster expression
(fig. 3.6), supports the hypothesis of aberrant BCR signaling in BL and DLBCL. However,
these experiments were only performed twice. Although widely accepted, the CD77 marker
was questioned as an appropriate marker for centroblasts (Högerkorp and Borrebaeck, 2006).
Thus, it was shown, that CD77 positive and negative populations are both actively cycling and
that gene expression profiles of both populations did not fit to functional characteristics of cen-
troblasts or centrocytes (Högerkorp and Borrebaeck, 2006). Additionally, GCBs used in this
study were isolated from pediatric tonsils due to frequent infections and abnormal growth, ask-
ing whether these cells are an appropriate normal control. The MIR23A cluster levels might
not be further increased by BCR stimulation, because the GCB cells are already fully activated
due to antigen response and inflammation.
During GC reaction SHM and CSR lead to affinity maturation of the BCR. These processes
include genetic modifications, such as chromosomal translocations and somatic mutations.
Errors that occur during these processes can lead to malignant transformation of these cells,
as observed in BL, DLBCL and FL. Indeed, many activating mutations within BCR signaling
components were reported occurring in aggressive B cell lymphoma (Seda and Mraz, 2015).
Importantly, B cell lymphoma are dependent on the survival signals provided by BCR signal-
ing, as shown by their sensitivity to chemical inhibitors that specifically target effectors of the
BCR signaling network (Young and Staudt, 2013; Blachly and Baiocchi, 2014; Gaudio et al.,
2016). E.g. for ABC DLBCL a chronic BCR signaling due to different mutations was reported:
many ABC DLBCL patients carry CARD11 mutations that cause the spontaneous formation of
aggregates, which recruit all downstream signaling components of the NFκB pathway (Lenz
et al., 2008). Additionally, the ITAMs of CD79 are frequently mutated preventing endocytosis
of the BCR and inhibit the activity of LYN to deliver negative feedback signals that attenu-
ate BCR activity (Davis et al., 2010). Another mechanism for chronic active BCR signaling is
the reactivity against self antigen (Young et al., 2015). The presence of BCR clusters on the
cell surface of ABC DLBCL, resembling the clusters that are formed after antigen encounter-
ing, support this observation (Rui et al., 2011). In contrast to chronic active BCR signaling in
ABC DLBCL, in GCB DLBCL and BL tonic BCR signaling was reported (Young and Staudt,
2013; Efremov, 2016). It predominantly activates the PI3K pathway in an antigen-independent
manner to provide the cell with survival signals. Responsible for tonic BCR signaling are al-
terations of signaling pathway components, such as SYK amplification (Monti et al., 2005) or
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tensin homolog (PTEN) deletion in GCB DLBCL (Pfeifer et al., 2013). Many BL cases harbor
transcription factor 3 (TCF3) mutations that prevent ID3 to inhibit TCF3 resulting in increased
activity of PI3K (Richter et al., 2012; Schmitz et al., 2013). However, inhibition of PI3K/AKT
signaling did not inhibit MIR23A cluster activation upon BCR stimulation in U2932 R1 (fig. 3.8),
indicating that it is not responsible for MIR23A cluster activation in this cell line. Furthermore,
when comparing differential expressed miRNAs from ABC DLBCL with GCB DLBCL cell lines,
the MIR23A cluster does not appear in these analyses (Malumbres et al., 2009), indicating,
that neither the NFκB pathway nor PI3K/AKT signaling are predominantly responsible for the
activation of the MIR23A cluster in DLBCL.
Indeed, this study could identify MEK/ERK signaling as the major BCR downstream signal-
ing cascade responsible for activation of the MIR23A cluster in DLBCL cell line U2932 R1.
Although mutations of Ras/Raf, which act upstream of MEK and ERK, were reported for differ-
ent cancers (Masliah-Planchon et al., 2015; Downward, 2003), including hairy cell leukemia,
where BRAF mutations were shown to result in constitutive active RAF/MEK/ERK signaling
(Vaqué et al., 2014), no such mutations are known for DLBCL. However, constitutive active
ERK signaling was found in DLBCL (Hollmann et al., 2006). ERK2 itself can bind to DNA
and act as a transcriptional repressor (Hu et al., 2009). Furthermore, ERK2 was reported to
promote a “poised” state of developmental genes by potentiating PRC2-mediated trimethy-
lation of H3K27 and phosphorylation of RNA Pol II in mice (Tee et al., 2014). Indeed, the
MIR23A promoter harbors six canonical ERK2 binding sites, but as the MIR23A cluster is in-
duced upon ERK1/2 activation, ERK2 itself might not be the transcription factor responsible
for the activation of the MIR23A cluster. Instead, a downstream factor of ERK1/2 might exert
this function. Many downstream factors were already described for the MAP kinase ERK1/2
(Yoon and Seger, 2006). Among these downstream ERK1/2 targets are many transcription
factors, including MYC and ELK1 (Gille et al., 1995; Yoon and Seger, 2006).
4.1.2. BCR downstream transcription factors
Proto-oncogene MYC was of special interest, because it is downstream of the BCR signal-
ing and many lymphomas harbor MYC translocations (Küppers, 2005). Furthermore, MYC is
considered to promote lymphomagenesis (Dalla-Favera et al., 1982). In regard to transcrip-
tional regulation of the MIR23A cluster, MYC was reported to bind to the paralogous MIR23B
promoter and suppress miR-23a and miR-23b levels in BL model cell line P493-6 (Gao et al.,
2009). This observation was validated in this study and extended to the whole MIR23A cluster
in P493-6 (fig. 3.12), indicating that MYC might also bind to the MIR23A promoter. Instead,
Li et al. showed that c-MYC induced the MIR23A cluster expression in mammary carcinoma
(Li et al., 2013a). However, in DLBCL model cell line U2932 R1 ectopic MYC overexpression
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and siRNA knockdown approaches revealed, that MYC does neither activate nor repress the
MIR23A cluster in DLBCL. Furthermore, the MIR23A cluster could still be activated by BCR
stimulation, when MYC protein levels were abolished by CHX treatment (fig. 3.7). These data
indicate, that MYC is not responsible for the regulation of the MIR23A cluster in DLBCL cell
line U2932 R1.
The first transcription factor described to be a substrate of ERK1/2 was ELK1 (Gille et al., 1995).
Indeed, this was validated in U2932 R1 (fig. 3.14). Upon BCR stimulation ERK and ELK1
were phosphorylated. Furthermore, the inhibition of ERK phosphorylation by trametinib also
inhibited ELK1 phosphorylation. ELK1 forms a ternary complex with serum response factor
(SRF) and serum response element (SRE) of c-Fos promoter (Gille et al., 1995). Induction
of c-Fos is important for cell proliferation and differentiation. Furthermore, phosphorylated
ELK1 induces the binding of c-Fos to c-Jun, which together form the transcriptionally active
AP-1 complex (Whitmarsh and Davis, 1996). AP-1 subsequently induces cyclin D1, which
is responsible for cell cycle progression (Shaulian and Karin, 2001). ELK1 was regarded as
candidate for MIR23A cluster activation, because Acunzo et al. showed by ChIP assay that
ELK1 binds to the promoter of MIR23A cluster in non-small cell lung cancer (NSCLC) and
activates it. However, systematical ELK1 overexpression and knockdown experiments could
not confirm this hypothesis for DLBCL cell line U2932 R1 (fig. 3.15).
Although both transcription factors MYC and ELK1 were described to regulate the miR-23a
levels in other cancer entities, neither did this in DLBCLmodel cell line U2932R1. One possible
explanation might be, that the binding sites of ELK1 and MYC within the MIR23A promoter
are not available due to chromatin modifications. Indeed, somatic mutations of epigenetic
modifier proteins are a hallmark of DLBCL (Morin et al., 2010, 2011) (Pasqualucci and Dalla-
Favera, 2014). One example is EZH2 in GCB DLBCL. It is upregulated during normal GC
reaction in centroblasts and induces bivalent chromatin at genes required for memory and
plasma cell differentiation (e.g. IRF4 and PRDM1) (Béguelin et al., 2013). Importantly, EZH2
mutation of the key tyrosine in catalytic site of SET domain enhances EZH2 activity (Sneeringer
et al., 2010) and subsequently leads to permanent silencing of target genes, resulting in a
differentiation block and accelerated lymphoid transformation (Béguelin et al., 2013).
Another possibility is that the co-factors, which bind to MYC or ELK1, are de-regulated or
mutated. One co-factor of ELK1 is cyclic AMP response element binging (CREB) protein
(CBP) (Janknecht and Nordheim, 1996). Indeed, CBP translocations were reported for several
hematopoietic diseases, such as acute myeloid leukemia (AML) (Borrow et al., 1996; Giles
et al., 1997; Panagopoulos et al., 2001), but not for aggressive B cell lymphoma. Interestingly,
CBP loss was shown to induce T cell lymphomagenesis in mice (Kang-Decker et al., 2004).
For cofactors of MYC, such as MIZ1, ATAD2, Mad or MAX, no alterations were described in
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lymphoma. However, mutations for PIM1, a serine/threonine kinase, which strongly synergizes
with MYC, were reported for ABC DLBCL (Peters et al., 2016).
ERK was described to phosphorylate various different proteins, including transcription factors
(Yoon and Seger, 2006). It would therefore be necessary to analyze whether binding sites
of these ERK downstream transcription factors can be found within the MIR23A promoter re-
gion.
Other transcription factors regulating the MIR23A cluster are described in literature, such as
PU.1, NFAT and NFκB family members. PU.1 was reported to activate the MIR23A cluster in
early stages of B cell development in the bone marrow, where the MIR23A cluster inhibits the
development of the lympoid line (Kong et al., 2010), an observation that was recently validated
in a MIR23A knockout mice (Kurkewich et al., 2016). Indeed, PU.1 is also expressed in GCB
cells (centroblasts) (Torlakovic et al., 2005; Cattoretti et al., 2006) and might therefore be an
interesting candidate for further analyses.
Another interesting candidate is NFAT, because it can be activated upon BCR signaling by
PLCγ-Ca2+-Calcineurin signaling (Gachet and Ghysdael, 2009). In detail, NFATc3 was shown
to activate theMIR23A cluster in cardiomyocytes (Lin et al., 2009). Indeed, it was reported, that
another NFAT family member, NFATc1 was localized in the nucleus of BL and DLBCL samples
(Marafiot et al., 2005) and constitutively activated together with NFκB in DLBCL (Fu et al.,
2006). Bioinformatical analyses of the MIR23A cluster promoter for transcription factor binding
sites revealed ETS1 as a promising candidate, since ETS1 deregulation was reported in BL
and DLBCL (Testoni et al., 2015). Furthermore, ETS1 deregulation was shown to contribute
to pathogenesis in DLBCL (Bonetti et al., 2013). Moreover, ETS1 is a substrate of ERK (Yoon
and Seger, 2006; Plotnik et al., 2014).
Although the NFκBmembers cRel and p65 were already shown to activate the MIR23A cluster
in a T cell leukemic cell line (Rathore et al., 2012), initial stimulation experiments did not support
these findings for DLBCL cell line U2932 R1. In detail, the activation of CD40 signaling and
LPS stimulation, which predominantly activate NFκB signaling, did not result in an activation
of the MIR23A cluster in U2932 R1 and BL-2 (fig. 3.1 and 3.3). However, the CD77 positive
GCBs responded to CD40L stimulation with an increase of MIR23A expression, showing that
NFκB signaling might activate the MIR23A cluster in healthy GCBs, but not in the DLBCL cell
line U2932 R1.
In summary, this study shows for the first time, that BCR dependent MEK/ERK signaling ac-
tivates the MIR23A cluster in DLBCL cell lines. The activation of MIR23A cluster in DLBCL
is aberrant compared to healthy GCB cells, suggesting that aberrant BCR signaling might be
responsible for the high MIR23A cluster expression in BL and DLBCL patients.
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4.2. MiR-23a & miR-27a targetome identification in DLBCL
In order to identify the cellular processes in which miR-23a and miR-27a are involved, their
mRNA targets in DLBCL cell line U2932 R1 were analyzed using Ago2-RIP approach. This
led to the identification of 26 novel direct miR-23a and 20 novel direct miR-27a targets for the
DLBCL model cell line U2932 R1. Both, direct (miRNA bound mRNAs) and indirect targets
(differentially expressed genes) identified in this study indicate, that the MIR23A cluster acts
as an onco-miR in DLBCL.
4.2.1. Ago2-RIP assay
Many different methods for the identification of miRNA targets are available, such as in silico
predictions, expression profiling or ribosome profiling, proteomic approaches (stable isotope
labeling with amino acids in cell culture (SILAC)), immunoprecipitation of miRISC proteins
with/without cross-linking and pull-down experiments (Thomson et al., 2011; Martinez-Sanchez
and Murphy, 2013). Each of these methods has its own advantages and disadvantages. No
matter by which means the targets were identified, for each target the downregulation of a
protein by a miRNA has to be validated experimentally.
The Ago2-RIP approach, applied in this study, identifies genome wide direct miRNA-mRNA
interactions mediated within the RISC complex. Furthermore, targets that are targeted by
non-canonical binding of the miRNA can be identified, a great benefit compared to in silico
predictions. Moreover, miRNAs that do not alter the target mRNA levels can be identified. This
is of importance in mammalia, because many miRNAs are thought to mediate mild changes in
mRNA levels, since they are supposed to work as fine tuners, which generate thresholds for
their target mRNAs (Mukherji et al., 2011; Hadjimichael et al., 2016).
A major disadvantage of an Ago2-RIP, as well as for other experimental approaches, is the
ectopic overexpression of the miRNA (miRNA mimics, stable or transient expression vectors).
Unphysiological overexpression might overload the miRNA biogenesis machinery and alter
the composition of different miRNAs incorporated into the RISC complex. This might disturb
other cellular processes not related to the specific miRNA, leading to undesired secondary
effects and false interpretations. Furthermore, low affinity targets might be overrepresented.
Therefore, inhibition of miRNA by an anti-sense miRNAs or miRNA-sponges can help to avoid
these problems. However, it is difficult to determine effective miRNA inhibition, because the
miRNA is sequestered by anti-sense miRNAs or miRNA-sponges, leaving miRNA levels con-
stant.
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In this study, stable overexpression of pre-miR-23a and pre-miR-27a was used. Small RNA
sequencing revealed an overexpression rate of miR-23a of 190-fold compared to control. This
high miRNA levels did not significantly alter the global miRNA expression profile, as shown
by small RNA sequencing of miR-23a overexpressing U2932 R1 pGIPZ clones compared to
control (fig. 3.25 inner ring). However, the composition of miRNAs in Ago2-RIP output samples
could not be analyzed because the RNA amount was not enough for mRNA and small RNA
sequencing.
To gain most reliable results, Ago2-RIP assay was optimized and performed in three inde-
pendent experiments. Most challenging was the aim to obtain enough RNA amounts of high
quality for RNA sequencing. The immunoprecipitation was shown to specifically pull down
Ago2 protein and enrich mature miRNAs (fig. 3.21 and 3.22). Furthermore, the RNA qual-
ity was high after immunoprecipitation (fig. A.4) and sequencing reads could successfully be
mapped against the human genome (fig. 3.23). Three independent experiments were per-
formed to identify possible outliers. Only targets that were at least 2 times enriched compared
to control and had a p-value lower than 0.05 were considered as possible miR-23a or miR-27a
targets, thereby lowering the chance to get unspecific results.
4.2.2. Direct miR-23a and miR-27a targets in DLBCL
The majority of identified targets of miR-23a and miR-27a in DLBCL cell line U2932 R1 harbor
canonical miRNA binding sites for the respective miRNA, showing that the applied Ago2-RIP
approach successfully enriched mRNAs that directly bind to the respective miRNA. All targets,
except of one, harbor at least one canonical 7 mer binding site (table 3.3 and 3.4). The pseu-
dogene EEF1A1P16, which has no canonical binding site, might be targeted by non-canonical
binding of miR-27a. However, since it is not coding for a protein, it was excluded from further
analyses. Interestingly, most identified miR-23a and miR-27a targets were novel in human
cells, indicating that indeed the targetome of a miRNA is context and cell type specific.
4.2.2.1. PUMA and apoptosis
Apoptosis was the only GO term, that was significantly enriched in differential gene expression
analyses of miR-27a overexpressing U2932 R1 pGIPZ clones to controls. Therefore PUMA
(or BBC3) was chosen as a miR-27a candidate for validation on protein level. Furthermore, it
was already described as a miR-23a and miR-27a target in mice upon traumatic brain injury
(Sabirzhanov et al., 2014).
PUMA is a pro-apoptotic protein belonging to the family of BCL-2 homology (BH) domain 3-
only proteins, which mediate canonical mitochondrial apoptosis in response to intrinsic stress,
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such as DNA damage (Lomonosova and Chinnadurai, 2008). In response to cellular stress
p53 is activated, which in turn induces PUMA. In a next step PUMA activates pro-apoptotic
BH domain proteins, such as Bax and Bak, which subsequently cause permeabilization of
mitochondrial outer membrane and the release of pro-apoptotic molecules from mitochondria
(Cytochrome c and apoptosis inducing factor (AIF)) resulting in controlled cell death (Shamas-
Din et al., 2011; Ashkenazi, 2008).
The basal level of PUMA is low in U2932 R1 cell line, as expected in a viable and proliferating
cell line. It was therefore not expected, that miR-27a overexpression will not further reduce
miR-27a levels under normal conditions. Indeed, it was reported, that PUMA expression is
silenced as a consequence of DNA methylation in human BL and loss of PUMA induces lym-
phomagenesis in mouse (Garrison et al., 2008; Michalak et al., 2009), supporting the onco-miR
hypothesis for the MIR23A cluster. Furthermore, PUMA levels are lower in BL compared to
healthy controls, while DLBCL patients show similar or higher levels compared to control (fig.
3.40). In order to induce PUMA protein levels, DNA double strand breaks were introduced
by etoposide treatment. This led to the induction of p53, which activates PUMA. Only under
these stress conditions, the miR-27a effect on PUMA-β could be observed. MiR-27a inhib-
ited the induction of PUMA-β in stable overexpressing clones upon etoposide treatment (fig.
3.34). Interestingly, the alpha isoform of PUMA was neither induced by p53, nor inhibited by
miR-27a. Previously, both isoforms were reported to be induced upon p53 in p53-inducible
NSCLC cells (Nakano and Vousden, 2001). The 3’UTRs of both isoforms are identical and
harbor the same canonical miR-27a 8mer binding site and could therefore both be targeted by
miR-27a. PUMA-α is encoded by exon 1a, 2, 3 and 4 while PUMA-β is encoded by exon 1b,
3 and 4. However, no additional canonical 7mer or 8mer miR-27a binding sites can be found
in exons coding for PUMA-β, but not for PUMA-α. This indicates, that miR-27a might target
PUMA-β by a non-canonical binding site within exon 1b, which could be missing in PUMA-α.
Another possibility is, that in principle all PUMA isoforms are targeted by the common binding
site in their 3’UTR, but the PUMA-α isoform is specifically stabilized, e.g. by RNA editing in the
3’UTR. Thus, it can no longer be targeted by miR-27a (Liang and Landweber, 2007; Zhang
et al., 2016).
NOXA is another BH3-only protein, which is induced by p53 and promotes apoptosis in the
same way as PUMA (Ashkenazi, 2008). Previously, Roufayel and colleagues demonstrated
that NOXA is a miR-23a target under heat-stress conditions (Roufayel et al., 2014). This
indicates, that the whole cluster might regulate apoptosis. Furthermore, this might explain
why miR-23a and miR-27a attenuated the ability of U2932 R1 cells to undergo apoptosis upon
etoposide treatment (fig. 3.38). This aspect has to be addressed in further experiments. First
it has to be shown that this effect can be reversed by miRNA inhibition. Secondly, it has to
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be proven whether PUMA-β or NOXA can rescue the attenuated apoptosis of miR-23a and
miR-27a overexpressing cells.
4.2.2.2. LIMK1 and migration
Another newly identified miR-27a target in DLBCL cell line U2932 R1 was LIMK1. It is a
serine/threonine kinase, activated by p21-activated kinase 6 (PAK6). PAKs are kinases, that
are frequently upregulated or hyperactivated in various human cancers (Kumar et al., 2006).
Moreover, it was already shown that PAK6 is a miR-23a target in prostate cancer (Cai et al.,
2014), leading to the hypothesis, that the whole MIR23A cluster might act in the PAK/LIMK
signaling pathway. Indeed LIMK1 levels are lower in BL and DLBCL patients compared to
GCBs, showing a negative correlation to MIR23A cluster expression (fig. 3.39 and 3.40).
LIMK1 could be validated as a miR-27a target in stable and transient overexpressing cells (fig.
3.33). Notably, alsomiR-23a was able to decrease LIMK1 protein levels. This can be explained
due to three 7mer1A binding sites for miR-23a in the CDS of LIMK1 mRNA. However, this
raises the question, why LIMK1 was not found in the miR-23a-Ago2-RIP. Indeed, LIMK1 was
shown to be a target for the paralogous miR-27b in non-small cell lung cancer (NSCLC) (Wan
et al., 2014). MiR-27b has the identical seed region to miR-27a, thus targeting presumably the
same mRNAs.
LIMK1 phosphorylates and thereby inactivates actin depolymerizing factor (ADF)/Cofilin (Ar-
ber et al., 1998), which regulates actin dynamics to modulate cell polarity and motility. LIMK1
is therefore involved in cancer cell invasion and metastasis. Unphosphorylated Cofilin binds
to actin filaments (f-actin) and induces fragmentation of the filament and depolymerisation of
the pointed end of the filament (Bailly and Jones, 2003). This increases the actin filament
turnover resulting in the generation of barbed ends that subsequently form lamellipodial pro-
trusions, which are required for directed cell migration (Bailly and Jones, 2003; Nishita et al.,
2005). Phosphorylation of Cofilin inhibits the ability of Cofilin to bind to f-actin and to generate
barbed ends (Zebda et al., 2000). It was shown that overexpression of LIMK1 or constitutive
active LIMK1 led to high levels of P-Cofilin, which inhibited cell polarity and the formation of
lamellipodia (Zebda et al., 2000; Dawe et al., 2003). Therefore, the downregulation of LIMK1
by miR-27a might lead to unphosphorylated Cofilin, which increases cell polarity and migra-
tory potential. Enhanced cell migration might result in dissemination of the primary tumor and
the formation of distant secondary tumors. Although, very hypothetical, this might support the
onco-miR hypothesis for the MIR23A cluster.
However, there are also studies showing that miR-23a inhibits migration and invasion by tar-
geting PAK6 in prostate cancer (Cai et al., 2014). Downregulation of PAK6 led to low P-LIMK1
and consequently low P-Cofilin levels (Cai et al., 2014). In contrast to other studies, were phos-
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phorylated Cofilin abolished cell migration (Zebda et al., 2000; Dawe et al., 2003; Nishita et al.,
2005), in this study unphosphorylated Cofilin also abolished migration and invasion (Cai et al.,
2014). This paradoxon was not addressed by the authors. Moreover, another study reported
similar findings: the inhibition of LIMK1 by a cell-permeable peptide led to unphosphorylated
Cofilin and to impairedmigration of Jurkat cells (Nishita et al., 2002). These observations show,
that actin dynamics are very sensitive to perturbations in protein concentration. Possibly the
balance of P-Cofilin to Cofilin or the correct distribution of Cofilin within the cell determines
whether a cell responds to a stimulus with cell polarity and consequently directed migration or
not.
LIMK1 does not only regulate actin dynamics, but also microtubule dynamics during mitosis.
In detail, it was shown to mediate microtubule disassembly by phosphorylation of p25 (also
known as tubulin polymerization promoting protein (TPPP)) (Acevedo et al., 2007). TPPP/p25
is responsible for correct spindle formation during mitosis (Tirián et al., 2003). Moreover, it
was shown that LIMK1 mediated phosphorylation of Cofilin was also implicated in accurate
spindle orientation during mitosis (Chakrabarti et al., 2007; Kaji et al., 2008). Incorrect spindle
formation might lead to unequal distribution of chromosomes to the daughter cells
(Bakhoum and Compton, 2012). However, chromosomal instability is not a common feature
of lymphomas.
SinceWan et al. showed, that high miR-27b levels downregulated LIMK1 and thereby inhibited
cell invasion as well as cell growth (Wan et al., 2014), it would be interesting to check in future
studies whether miR-27a has the same effect in DLBCL.
4.2.2.3. VRK3 and MEK/ERK signaling
ThemiR-23a target candidate VRK3 was of special interest in this study, because it is known to
be involved in negative regulation of ERK (Kang and Kim, 2006). Because MEK/ERK signaling
was identified in this study to activate the MIR23A cluster, VRK3 might therefore be involved
in a feedback loop of MIR23A activation upon BCR stimulation.
VRK3 is a serine/threonine kinase, mainly located in the ER and the nucleus (Nichols and
Traktman, 2004), which binds and activates vaccinia H1-related (VHR) (Kang and Kim, 2006),
also known as dual-specificity phosphatase 3 (DUSP3). DUSP3 is a nuclear phosphatase
that specifically de-phosphorylates and thereby inactivates ERK (Kang and Kim, 2006). In-
terestingly, another dual-specificity phosphatase DUSP5, which was previously reported to
de-phosphorylate ERK1 (Ishibashi et al., 1994) (Ueda et al., 2003), was found to be enriched
in the miR-23a Ago2-RIP, indicating that miR-23a might regulate several levels of ERK feed-
back loop. Targeting ERK dephosphorylating enzymes might lead to enhanced ERK signaling,
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which would reinforce the MIR23A cluster expression, creating a positive feedback loop for the
MIR23A cluster.
Strikingly, miR-23a did not decrease VRK3 protein levels in stable overexpressing U2932 R1
cell lines under normal conditions. Although VRK3 harbors two miR-23a binding sites in the
3’UTR and five in the CDS, the VRK3 protein levels were not affected in stable overexpressing
cells. Indeed, VRK3 protein levels are already very low and may not be further decreased
by miRNA action. Maybe miR-23a is responsible to hold VRK3 protein levels on a constant
low level. Increased VRK3 levels would lead to decreased survival signals by BCR signaling,
being a disadvantage for the tumor cell. Indeed, patient samples show, that VRK3 levels in
BL and DLBCL patients are lower compared to GCB controls. This supports the onco-miR
hypothesis for the MIR23A cluster. It is possible, that the inhibitory function of the miRNA can
not be observed until VRK3 levels are induced in response to a certain stimulus. The same
was observed for the miR-27a target PUMA. A reasonable stimulus might be the activation
of the BCR, which activates ERK, that subsequently should be dephosphorylated by VRK3
activated DUSP3 activity.
However, it can not be excluded, that VRK3might be a false positive miR-23a target candidate,
identified by secondary interactions during immunoprecipitation. Direct physical interaction of
miR-23a to VRK3 mRNA can be analyzed by Luciferase reporter gene assays and mutation
of miRNA binding sites in future studies.
4.2.2.4. Zinc finger proteins
12 of 25 novel identified miR-23a targets were zinc finger proteins (ZNF), that contain a DNA
binding ZNF domain and therefore potentially act as transcription factors. All these identified
ZNFs belong to the same protein family: KRAB-C2H2-ZNFs. Members of this family com-
prise a high sequence homology, which might be an explanation why so many are targeted
by miR-23a. This sequence homology makes it difficult to analyze ZNF expression by qRT-
PCR or Western Blot. The identified ZNFs belong to two separate ZNF clusters, that were
generated due to gene duplication during evolution: ZNF cluster 269 on chromosome 19 and
ZNF cluster 114 on chromosome 7. Notably, many ZNFs as well as other miR-23a targets are
encoded on chromosome 19, where also the MIR23A cluster itself is encoded (see section
4.2.3). Interestingly, all identified ZNFs were downregulated in BL and DLBCL patients com-
pared to healthy controls (fig. 3.40d), indicating that they might have cooperative or redundant
functions. Indeed, ZNFs belonging to the KRAB ZNF family were reported to be highly ex-
pressed in T-lymphoid cells (Bellefroid et al., 1993). Since the MIR23A cluster was reported to
suppress the B cell development (Kong et al., 2010) one might speculate, that this inhibition is
mediated through the downregulation of these ZNFs.
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4.2.3. Enrichment of targets on chromosome 19
More than one third (37%), namely 17 out of 46 newly identified miR-23a and miR-27a tar-
gets in the DLBCL model cell line U2932 R1, are encoded on chromosome 19, where also
the MIR23A cluster is encoded (fig. 3.28). A closer look at the location of the targets on chro-
mosome 19 reveals that they are encoded on both arms of the chromosome, although this
finding is referred to as “clustering of targets”. This study could show, that it is not due to an
overrepresentation of expressed transcripts from chromosome 19 in the used cell line or due
to a higher percentage of potential miR-23a or miR-27a binding sites on transcripts from chro-
mosome 19. This indicates, that it might not just be a coincidence, but that there might be a
biological mechanism underlying this observation.
It is well known that during interphase the chromosomes are arranged in a highly defined
manner within the nucleus (Marshall et al., 1997). Furthermore, fluorescent in situ hybridiza-
tion (FISH) analyses and chromosome conformation capture (C3) assays revealed, that there
is a correlation between chromatin topology and gene activity (Sexton and Cavalli, 2015). It
would therefore be of interest to find out whether the MIR23A cluster is in near proximity of its
targets. Chen et al. addressed this question on a global scale by Chromatin Interaction Analy-
sis by Paired-End Tag Sequencing (ChIA-PET) analyses, where they identified the interactions
of miRNA genes with target genes (Chen et al., 2014). They could show that miRNA genes
and protein coding genes were organized in functionally compartmentalized chromatin com-
munities that are expressed together when they are spatially co-located (Chen et al., 2014).
Furthermore, miRNA-target interactions were enriched between communities with functional
homogeneity (Chen et al., 2014). Instead, no miRNA-target interactions were detected when
miRNA and target originated from the same community (Chen et al., 2014). These chromatin
communities were related to topologically associated domain (TAD) structures of the genome
(Chen et al., 2014; Pombo and Dillon, 2015). This might represent a mechanism by which a
miRNA is co-expressed with its targets.
Another mechanism which could explain the co-expression would be a coordinated activation
of the MIR23A cluster together with its targets by the same transcription factor, as suggested in
other studies (Wang et al., 2011; Le et al., 2014). Indeed, the MIR23A cluster and most of the
identified miR-23a and miR-27a target harbor putative myeloid zinc finger 1 (MZF1) binding
sites in their promoter regions. MZF1 was already implicated to play a role in various cancer
entities (Mudduluru et al., 2010).
Furthermore, miRNAs as well as the miRNA processing machinery and Ago2 protein are
present in the nucleus (Hwang et al., 2007; Park et al., 2010). It was shown, that a long
non coding RNA (lncRNA) silences gene expression at certain loci by the recruitment of tran-
scriptional repressors, such as the polycomb repressive complex 2 (PRC2) (Roberts, 2014).
4.3. BIOLOGICAL FUNCTION & GLOBAL EFFECTS OF MIR23A CLUSTER IN DLBCL 115
Silencing of the lncRNA by a miRNA disrupts this complex, leading to the activation of the tar-
get gene (Roberts, 2014). Since the Ago2-RIP identified several lncRNAs (RP11-1017G21.5,
CTC-246B18.10 and KIAA1467), this might be an interesting aspect for further investigations,
especially because CTC-246B18.10 is also expressed on chromosome 19.
4.3. Biological function & global effects of MIR23A cluster in DLBCL
Targetome identification via Ago2-RIP assay in DLBCL cell line U2932 R1 revealedmany novel
and direct targets for miR-23a and miR-27a, from which two (LIMK1 and PUMA) were verified
on protein level by miRNA overexpression experiments.
Furthermore, this study showed, that miR-23a and miR-27a are both implicated in the regu-
lation of apoptosis. In detail, miR-23a and miR-27a attenuated the ability of DLBCL cell line
U2932 R1 to undergo apoptosis when DNA damage was induced (fig. 3.38). This strongly
supports the onco-miR hypothesis for the MIR23A cluster, which was tested in this study. In
addition, this observation could contribute to an explanation for the worse overall survival rate
of patients with higher miR-23a levels. Cells that have a lower ability to undergo apoptosis,
might not respond to chemotherapy. Future experiments have to address, whether PUMA is
indeed the key player mediating this observation. Indications that this cluster is involved in
multidrug resistance came also from Zhang et al., who showed that miR-27a downregulation
increased the sensitivity of eosphageal cancer to undergo apoptosis (Zhang et al., 2010).
Interestingly, identified miR-27a target LIMK1, which is mainly known to function in migration,
was also shown to be cleaved by caspase-3 like proteases, generating an N-terminally trun-
cated, constitutively active fragment, that induces membrane blebbing, a common feature of
apoptotic cells (Tomiyoshi et al., 2004).
Besides these direct targets, miR-23a and miR-27a overexpression also affected global gene
expression profiles of U2932 R1. 904 genes were differentially expressed between miR-27a
overexpressing and ns ctrl cell line. These genes are referred to as indirect miRNA targets.
GO-term enrichment analyses of these indirect target genes revealed a significant enrichment
for gene sets associated with apoptosis (fig. 3.36). This indicates that the direct miR-27a
target PUMA is definitely not the only player mediating apoptosis in the context of miR-27a
overexpressing DLBCL cells, as expected for amiRNA that can have several direct and indirect
targets. Furthermore, the onco-miR hypothesis is supported by this results.
GO-term enrichment analyses of the 651 differentially expressed genes of miR-23a overex-
pressing vs. ns ctrl U2932 R1 cells revealed an enrichment of many different cellular processes
(fig. 3.35). The majority is associated with the ribosome and proteinbiosynthesis, because
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many ribosomal proteins are differentially regulated. Indeed, cancer cells frequently exhibit
increased ribosome biogenesis (Takada and Kurisaki, 2015).
Strikingly, GO-term enrichment analyses of the overlap of indirect targets of miR-23a with indi-
rect targets of miR-27a did not show any significant enriched cellular process. This indicates,
that both miRNAs might function in different cellular processes and do not have any coopera-
tive effect. However, this is contradictory to the observation, that both, miR-23a and miR-27a,
attenuate the ability of U2932 R1 cells to undergo apoptosis. GO-term enrichment analyses
using the hypergeometrical test has some limitations. It does not include the direction and
fold change of gene expression changes. If a certain process is e.g. targeted by the miRNA
directly, one might expect, that the differentially expressed genes involved in this process are
downregulated. This is not covered by GO-term analyses. Moreover, this analyses strongly
depend on the information listed in the provided gene sets. Thus, it is possible that many iden-
tified indirect targets are not functionally described yet and are therefore not found in these
GO-terms gene sets.
In summary, functional analyses showed that the MIR23A cluster is involved in the regulation
of apoptosis. High levels of miR-23a and miR-27a decreased the ability of the DLBCL model
cell line to undergo apoptosis. This supports the onco-miR hypothesis for the MIR23A cluster
and might be one possible explanation for the worse outcome of DLBCL patients with higher
miR-23a levels.
5. Summary and Conclusion
The MIR23A cluster, encoding miR-23a, miR-27a and miR-24 is aberrantly activated in BL and
DLBCL cells compared to their normal counterparts, the germinal center B cells. This study
identified the BCR signaling as a general mechanism in BL and DLBCL cell lines responsi-
ble for the induction of the MIR23A cluster. Since normal GCBs did not increase MIR23A
cluster levels in response to BCR signaling, it is hypothesized that aberrant BCR signaling to-
gether with factors of the microenvironment might cause high MIR23A cluster expression in BL
and DLBCL patients compared to healthy controls. As the main BCR-downstream signaling
cascade mediating MIR23A cluster activation the MEK/ERK signaling pathway was identified.
Downstream transcription factors ELK1 and c-MYC were not involved in the activation of the
MIR23A cluster in DLBCL cell lines.
Ago2-RIP assay followed by RNA-sequencing identified 46 novel direct miR-23a and miR-27a
targets in a DLBCL model cell line. Interestingly, 37% of the newly identified targets were en-
coded on chromosome 19. Moreover, LIMK1 and PUMA-β were validated as direct miR-27a
targets being downregulated on protein level upon miR-27a overexpression. Bioinformatical
prediction of MIR23A cluster function based on DEG upon miR-27a overexpression in DL-
BCL cell line U2932 R1 indicated, that the MIR23A cluster might regulate apoptosis. Indeed,
this could be verified in functional analyses. Hence, this study demonstrated that miR-23a
and miR-27a attenuate the ability of DLBCL cells to undergo apoptosis in response to DNA
damage. This might be one possible explanation why DLBCL patients with high miR-23a ex-
pression levels have a worse overall survival rate than patients with low levels, supporting the
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A.Supplementals
Figure A.1.: GFP expression profile of U2932 R1 pGIPZ clones
FACS analyses of GFP expression profile of stable transduced U2932 R1 pGIPZ clones. 10000 counts were
measured. Cells were gated to the living, PI negative population. Percentage of living green M1 population cells
are depicted.
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Figure A.2.: Western blot characterization of U2932 R1 pGIPZ clones
Expression of Ago2, c-MYC and Bcl-6 in U2932 R1 pGIPZ miR-23a/-27a and ns ctrl overexpressing clones com-
pared to the parental clone U2932 R1 and sister clone U2932 R2. (20 μg total protein per well, one representative
blot of three is shown)
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Figure A.3.: MTT Assay for U2932 R1 upon Ibrutinib and Trametinib treatment
U2932 R1 was treated with inhibitor dilution series for 24h and 48h and cell viability was assesed using MTT assay.
Trametinib: 12800 - 50 nM; Ibrutinib 1280 - 5 nM; 0 nM = DMSO ctrl
Figure A.4.: High quality of total RNA after Ago-RIP
Bioanalyzer total RNA Chip analyzes for quality control of Ago2-RIP input and output samples of U2932 R1
miR-23a1. The 25 nt peak represents the marker. In both samples the 18S and 28S RNA peaks are clear and
distinct. No RNA degradation could be observed. The RNA Integrity Numbers (RIN) indicate high RNA quality.
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Table A.1.: Differentially expressed genes of miR-23a1/ns crtl1 vs. miR-27a1/ns ctrl1
Gene ID Gene name Description
ENSG00000207980 MIR23A microRNA 23a
ENSG00000111052 LIN7A lin-7 homolog A (C. elegans)
ENSG00000163618 CADPS Ca++-dependent secretion activator
ENSG00000166503 HDGFRP3 Hepatoma-derived growth factor-related protein 3
ENSG00000146938 NLGN4X neuroligin 4, X-linked
ENSG00000196482 ESRRG estrogen-related receptor gamma
ENSG00000113140 SPARC secreted protein, acidic, cysteine-rich (osteonectin)
ENSG00000253941 IGHVII-51-2 immunoglobulin heavy variable (II)-51-2 (pseudogene)
ENSG00000128641 MYO1B myosin IB
ENSG00000179455 MKRN3 makorin ring finger protein 3
ENSG00000169862 CTNND2 catenin (cadherin-associated protein), delta 2
ENSG00000254167 IGHVIII-51-1 immunoglobulin heavy variable (III)-51-1 (pseudogene)
ENSG00000151623 NR3C2 nuclear receptor subfamily 3, group C, member 2
ENSG00000164362 TERT telomerase reverse transcriptase
ENSG00000100385 IL2RB interleukin 2 receptor, beta
ENSG00000168672 FAM84B family with sequence similarity 84, member B
ENSG00000057657 PRDM1 PR domain containing 1, with ZNF domain
ENSG00000184635 ZNF93 zinc finger protein 93
ENSG00000111249 CUX2 cut-like homeobox 2
ENSG00000203706 SERTAD4-AS1 SERTAD4 antisense RNA 1
ENSG00000185668 POU3F1 POU class 3 homeobox 1
ENSG00000124491 F13A1 coagulation factor XIII, A1 polypeptide
ENSG00000048740 CELF2 CUGBP, Elav-like family member 2
ENSG00000213967 ZNF726 zinc finger protein 726
ENSG00000126353 CCR7 chemokine (C-C motif) receptor 7
ENSG00000076356 PLXNA2 plexin A2
ENSG00000188868 ZNF563 zinc finger protein 563
ENSG00000207827 MIR30A microRNA 30a
ENSG00000182253 SYNM synemin, intermediate filament protein
ENSG00000213626 LBH limb bud and heart development
ENSG00000105974 CAV1 caveolin 1, caveolae protein, 22kDa
ENSG00000171291 ZNF439 zinc finger protein 439
ENSG00000163590 PPM1L protein phosphatase, Mg2+/Mn2+ dependent, 1L
ENSG00000198369 SPRED2 sprouty-related, EVH1 domain containing 2
ENSG00000156535 CD109 CD109 molecule
ENSG00000137285 TUBB2B tubulin, beta 2B class IIb
ENSG00000114790 ARHGEF26 Rho guanine nucleotide exchange factor (GEF) 26
ENSG00000173083 HPSE heparanase
ENSG00000064692 SNCAIP synuclein, alpha interacting protein
ENSG00000148600 CDHR1 cadherin-related family member 1
ENSG00000124785 NRN1 neuritin 1
ENSG00000183813 CCR4 chemokine (C-C motif) receptor 4
ENSG00000173198 CYSLTR1 cysteinyl leukotriene receptor 1
ENSG00000118985 ELL2 elongation factor, RNA polymerase II, 2
ENSG00000119138 KLF9 Kruppel-like factor 9
ENSG00000163518 FCRL4 Fc receptor-like 4
ENSG00000105997 HOXA3 homeobox A3
ENSG00000249679 RP11-279O9.4
ENSG00000106004 HOXA5 homeobox A5
ENSG00000081818 PCDHB4 protocadherin beta 4
ENSG00000150593 PDCD4 programmed cell death 4 (neoplastic transformation inhibitor)
ENSG00000005513 SOX8 SRY (sex determining region Y)-box 8
ENSG00000248905 FMN1 formin 1
ENSG00000160050 CCDC28B coiled-coil domain containing 28B
ENSG00000235159 RP6-109B7.4
Continued on next page
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Gene ID Gene name Description
ENSG00000159618 GPR114 G protein-coupled receptor 114
ENSG00000186026 ZNF284 zinc finger protein 284
ENSG00000196664 TLR7 toll-like receptor 7
ENSG00000142178 SIK1 salt-inducible kinase 1
ENSG00000072694 FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32)
ENSG00000121742 GJB6 gap junction protein, beta 6, 30kDa
ENSG00000164484 TMEM200A transmembrane protein 200A
ENSG00000072110 ACTN1 actinin, alpha 1
ENSG00000188596 CFAP54 cilia and flagella associated 54
ENSG00000158715 SLC45A3 solute carrier family 45, member 3
ENSG00000124942 AHNAK AHNAK nucleoprotein
ENSG00000078900 TP73 tumor protein p73
ENSG00000164695 CHMP4C charged multivesicular body protein 4C
ENSG00000179431 FJX1 four jointed box 1 (Drosophila)
ENSG00000187676 B3GALTL beta 1,3-galactosyltransferase-like
ENSG00000224565 RP1-148H17.1
ENSG00000184702 SEPT5 septin 5
ENSG00000177628 GBA glucosidase, beta, acid
ENSG00000115297 TLX2 T-cell leukemia homeobox 2
ENSG00000135631 RAB11FIP5 RAB11 family interacting protein 5 (class I)
ENSG00000082497 SERTAD4 SERTA domain containing 4
ENSG00000138760 SCARB2 scavenger receptor class B, member 2
ENSG00000260022 LA16c-306A4.1
ENSG00000124813 RUNX2 runt-related transcription factor 2
ENSG00000238287 RP11-656D10.3
ENSG00000134986 NREP neuronal regeneration related protein
ENSG00000249004 PRMT5P1 protein arginine methyltransferase 5 pseudogene 1
ENSG00000118515 SGK1 serum/glucocorticoid regulated kinase 1
ENSG00000121753 BAI2 brain-specific angiogenesis inhibitor 2
ENSG00000204954 C12orf73 chromosome 12 open reading frame 73
ENSG00000158792 SPATA2L spermatogenesis associated 2-like
ENSG00000189171 S100A13 S100 calcium binding protein A13
ENSG00000075420 FNDC3B fibronectin type III domain containing 3B
ENSG00000151150 ANK3 ankyrin 3, node of Ranvier (ankyrin G)
ENSG00000176771 NCKAP5 NCK-associated protein 5
ENSG00000003147 ICA1 islet cell autoantigen 1, 69kDa
ENSG00000225724 LL22NC03-80A10.11
ENSG00000273619 RP5-908M14.9
ENSG00000069702 TGFBR3 transforming growth factor, beta receptor III
ENSG00000071051 NCK2 NCK adaptor protein 2
ENSG00000136929 HEMGN hemogen
ENSG00000246095 LINC01096 long intergenic non-protein coding RNA 1096
ENSG00000140931 CMTM3 CKLF-like MARVEL transmembrane domain containing 3
ENSG00000182175 RGMA repulsive guidance molecule family member a
ENSG00000185792 NLRP9 NLR family, pyrin domain containing 9
ENSG00000137266 SLC22A23 solute carrier family 22, member 23
ENSG00000064393 HIPK2 homeodomain interacting protein kinase 2
ENSG00000175741 RWDD4P2 RWD domain containing 4 pseudogene 2
ENSG00000177494 ZBED2 zinc finger, BED-type containing 2
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Figure A.5.: FACS analysis of AnnexinV/7AAD staining of U2932 R1 clones upon etoposide treat-
ment
U2932 R1 pGIPZ cell lines overexprssing a non silencing control, miR-23a or miR-27a were treated for 16h with
100 μM etoposide to induce apoptosis. Cells were double stained with AnnexinV-PE and 7AAD prior to FACS
analysis. (one representative experiment of three is shown)
Curriculum Vitae
Natalie Veronika Freytag née Klytta
born on February 28th 1986 in Zabrze, Poland
Leibniz-Institut DSMZ




2014 -2017 Doctoral Thesis (continued)
”Characterization of the MIR23A Cluster in Diffuse Large B Cell Lymphoma -
Regulation and Targetome Identification”
Leibniz-Institut Deutsche Sammlung für Mikroorganismen und
Zellkulturen DSMZ, Braunschweig
Molecular Cancer Research
Supervisor: Prof. Dieter Kube (University Medical Center Göttingen)
Co-Supervisor: Dr. Sonja Eberth (Leibniz-Institut DSMZ Braunschweig)
2013-2014 Doctoral thesis
”Characterization of the MIR23A Cluster in Diffuse Large B Cell Lymphoma -
Regulation and Targetome Identification”
University Medical Center of the Georg-August University Göttingen
Haematology and Oncology, Supervisor: Prof. Dieter Kube
Co-Supervisor: Dr. Sonja Eberth
2013 - 2017 PhD program Molecular Medicine of the Georg-August University Göttingen
2010 - 2012 Master of Science, Developmental, Neural and Behavioral Biology
Georg-August-Universität Göttingen
Major: Cell and Developmental Biology
Master Thesis: ”Establishment of an Auxin Inducible Protein Degradation
System to Analyze the Function of Chk2 Kinase during Mitosis”
Supervisor: Prof. Holger Bastians
2007 - 2010 Bachelor of Science, Biology
Georg-August-Universität, Göttingen, Germany
Bachelor Thesis: ”Untersuchung der Funktion der Spermatogonien-spezifischen
Gene Nanos2, Dazl, Pou5f1 und Zfp145 in der Maus.”
Supervisor: Prof. Sigrid Hoyer-Fender
2005 - 2007 Staatlich-anerkannte biologisch technische Assistentin
Hans-Böckler-Berufskolleg Marl
2005 Abitur (A-level)
Städtisches Gymnasium Herten
147
